



**BUMJ**

*Benghazi University Medical Journal*

***Volume:2*** *December*

***Issue:2*** ***2025***

The research, Studies, and articles published in this Journal reflect the views of their respective authors and do not necessarily represent the opinions of the Journal or the Faculty of Medicine at the University of Benghazi.

Users are permitted to copy, download, and distribute the original works for non-commercial purposes, provided they give proper attribution.

However, derivative works are not allowed.

For correspondence, please contact the editor-in-chief via email or by registering on the website: [BUMJ@uob.edu.ly](mailto:BUMJ@uob.edu.ly)

<https://journals.uob.edu.ly/BUMEJ/index>.

# Editorial Team

## Editor in chief

Prof. Amina A. Alshekteria

Professor of Family and Community Department, Faculty of Medicine,  
University of Benghazi.

## Editorial Manager

Prof. Abeer H.A.Amer

Professor of Histology in Histology Department, Faculty of Medicine,  
University of Benghazi.

## Executive Editor

Prof. Salha Awad Zoubi

Professor of Histology in Department of Histology, Faculty of Medicine,  
University of Benghazi.

Dr. Najat Omer Buzaid

Associate Professor of Internal Medicine in Department of Internal  
Medicine, Faculty of Medicine, University of Benghazi.

Prof. Zahya Elghazal

Professor of Obstetrics and Gynecology in Obstetrics & Gynecology De-  
partment, Faculty of Medicine, University of Benghazi.

Prof. Samar A.Bukhatwa

Professor of Ophthalmology in Department of Ophthalmology, Faculty  
of Medicine, University of Benghazi.

# Advisory Board

Prof. Ahmed Ahasi

Prof.Guma Abdeldaim

Prof.Tunis Meidam

Prof.Lubna Abdelmalik

Prof.Suliman Alsharif

Prof.Amin Bridan

Prof.Asharf Abelsalam

Prof.Adel Atia

Prof.Mustafa Alfakhri

Prof.Hamad Aljazwi

Prof.Ibrahim Almukahel

Prof. Adel Altajori

Prof. Astaker Sharif Sultan

# Table of Contents

P06 | Welcome form the Editor-in-Chief.

## Original Articles:

- P07-25 | *Contemporary Approaches to Breast Cancer Management: An Evidence Synthesis Guiding Clinical Practice and Patient Care.*  
Naseralla Juma Elsaadi Suliman, Marei Omar Al-Jahany, Mohamed A. Moftah, Tarek Farag Hamed Alhouni.
- P26-37 | *Extra uterine growth restriction and its related factors in extremely and very low birth weight babies including 1500 grams admitted to Jammhoria hospital in Benghazi.*  
AzizaI.Kadwar, khadiga I. Shreef , Isaaida A.Alsaeti, NadiaAM. Aldarogi.
- P38-46 | *Placenta Accreta Spectrum: Epidemiology, Risk Determinants, and Clinical Consequences in Benghazi Medical Centre -2022.*  
Omaima Hassan Getlawi, Maisa Muftah Muttardi , Asmaa Bahjat Salih.
- P47-54 | *Histopathological evaluation of prostate biopsy in-patient with Prostate cancer in Benghazi Medical Center in the period between 2020-2023.*  
Ghazala Alzarrouq Alfitorei, Manal F. Mustafa Yaya, Amara moftah, Aya farag, Najah abdalsallam, Negeia Rezqallah.
- P55-61 | *Prevalence of Skin Findings among Libyan Diabetic Patients.*  
Ghada. A. Albarghathi, Antisar. A. Najm, Aisha. B. Trapolsi, Shadia. J. Awad.
- P62-71 | *The Prevalence of Amoebiasis in Children Admitted to Gastro Department at Children's Hospital of Benghazi.*  
Abdusalam Aboubaker Abdusalam, Abdulsalam Faraj Alawaaj, Zahoor Hussein Almabrouk.
- P72-81 | *The Role of Multi Detector Computerized, Tomography in Evaluation of Maxillofacial Fractures.*  
Kamla Mohamed Muftah, Ali Ahmed Beheh, Gebрил Hewadi, Arwi Bark Elfseie.
- P82-86 | *Thyroid disorders in patients with polycystic ovarian syndrome in Benghazi.*  
Omar Alfalah, Fathia Ehmouda.

## Editor Letter:

- P87-90 | *Genetic Neuromuscular Diseases in Libya.*  
Heba Abdelrazik El-Zawawi.



## Welcome from the Editor-in-Chief

The Benghazi University Medical Journal (BUMJ) is a semi-annual, open-access publication that follows a rigorous double-blind, peer-review process. We publish original research, insightful reviews, intriguing case reports, and brief communications that highlight the latest advancements in diagnosis, treatment, and other health-related fields. BUMJ also welcomes correspondence about its published articles to encourage academic dialogue and the exchange of ideas.

Our mission is to be a platform for sharing innovative research, thought-provoking reviews, and impactful case studies. We strive to bridge the gap between research and clinical practice by promoting evidence-based approaches and covering a wide range of topics—such as basic medical sciences, cutting-edge diagnostics, therapeutic innovations, healthcare technologies, and interdisciplinary patient care.

At BUMJ, we are passionate about advancing healthcare and improving outcomes. We invite contributions from diverse voices in the medical community and look forward to fostering meaningful collaborations that make a difference.

*Prof. Amina A. Alshekteria*



## Contemporary Approaches to Breast Cancer Management: An Evidence Synthesis Guiding Clinical Practice and Patient Care.

Naseralla J. Suliman <sup>1\*</sup>, Marei O. Al-Jahany <sup>2</sup>, Mohamed A. Moftah <sup>1</sup>, Tarek F. Alhouni <sup>1</sup>

### Original Research Article

#### Abstract

**Background:** Breast cancer remains the most frequently diagnosed cancer globally, though its management varies significantly across regions. This systematic review integrates recent evidence across six domains to delineate best practices for comprehensive care.

**Method:** A systematic literature search was conducted across MEDLINE, Embase, Cochrane Library, Web of Science, and CINAHL (2010–2024), in line with PRISMA 2020 reporting standards. Eligible studies were screened by two reviewers. Quality was assessed using validated tools appropriate to study design, including Cochrane RoB 2.0, Newcastle–Ottawa Scale, AMSTAR–2, and AGREE II. Evidence was synthesized narratively and appraised using the GRADE framework.

**Results:** Key advances include the application of molecular profiling in tailoring therapy, treatment de-intensification for selected low-risk groups, escalation for aggressive subtypes, and improved multidisciplinary decision-making. Hypofractionated radiotherapy has shown comparable efficacy with reduced side effects, while genomic testing helps identify patients who can safely avoid chemotherapy. Targeted therapies have substantially improved outcomes in specific subgroups. Unique strategies are needed for elderly, male, and pregnant patients, and oligometastatic disease is increasingly approached with curative intent.

**Conclusion:** Precision medicine has redefined breast cancer treatment, emphasizing individualized and integrated multidisciplinary strategies. Implementation frameworks that minimize disparities and maximize both survival and quality of life outcomes are necessary to put this evidence into practice.

**Keywords:** Breast neoplasms; evidence-based oncology; multidisciplinary care; precision medicine; adjuvant therapy; clinical guidelines; patient-centered care.

1. Consultant General Surgeon, Benghazi Medical Center, Benghazi, Libya.

2. Consultant General Surgeon, Hawari General Hospital, Benghazi, Libya.

\*Corresponding author: Naseralla J. Suliman, Email: [naseralla.elsaadi@uob.edu.ly](mailto:naseralla.elsaadi@uob.edu.ly).

DOI: [10.37376/benuivmedj.v2i2](https://doi.org/10.37376/benuivmedj.v2i2)



## INTRODUCTION

The treatment of breast cancer has changed significantly over the last few decades.

Once managed predominantly with surgery, it is now treated through integrated, multidisciplinary strategies. This change is a reflection of our increasing knowledge of tumour biology, especially the discovery of molecular subtypes that affect prognosis and treatment options. Globally, breast cancer accounts for more than 2.3 million new diagnoses each year, representing approximately 12% of all cancers and remaining a leading cause of cancer-related death among women.<sup>1</sup> Despite this progress, clinicians continue to encounter complex decisions throughout the care continuum, from early detection to advanced disease, often without unified guidance on incorporating rapidly evolving evidence. The burden is unevenly distributed, with incidence, survival, and mortality showing wide regional variation.<sup>2</sup> These differences highlight the interplay of tumor biology, healthcare accessibility, and socio-economic factors, underscoring the need for adaptable but evidence-driven approaches. The prevalence is rising due to increased incidence and better treatment outcomes. Mortality rates are decreasing in most Western nations, driven by improved therapy and earlier detection.<sup>3</sup> Innovations in diagnostic imaging, refinements in surgical techniques, and the availability of targeted systemic therapies have transformed clinical practice.<sup>4</sup> However, the pace of development has created challenges in unifying management strategies. Existing reviews frequently focus on specific elements, like systemic therapy, radiotherapy, or surgery, without incorporating them into a comprehensive framework. While rapid technological progress has significantly advanced oncologic capabilities, sharpening diagnostics, refining minimally invasive surgical techniques, and expanding targeted systemic therapies, the prevailing literature and clinical guidance remain largely fragmented. Existing reviews and specialty-specific guidelines predominantly focus on isolated domains such as surgical approaches, radiotherapy, or systemic therapy, mirroring the subspecialization

within oncology.<sup>5-7</sup> This compartmentalization fails to adequately address the critical interconnections between these fields or considerations for special populations. Consequently, despite an abundance of specialized knowledge, integrating diagnostics, surgery, radiation, systemic therapy, and tailored care for individual patient circumstances into a coherent, practical continuum remains a significant challenge for clinicians at the point of care, misaligning with the integrated reality required for optimal patient management. The current review fills this gap by synthesizing current research in six crucial areas: (1) Core principles; (2) Imaging modalities; (3) Surgical techniques; (4) Adjuvant therapies; (5) Management of special populations; and (6) Recurrent or advanced disease.

The three goals are to highlight areas of agreement and disagreement, summarize the best available data, and offer a comprehensive set of suggestions that physicians, researchers, and legislators can implement to improve patient outcomes. By addressing these goals, the review gives policymakers insights for healthcare optimization, researchers a basis for future studies, and clinicians evidence-based decision-making tools.

## METHODS

### Research Strategy

The literature search was developed iteratively in collaboration with an oncology-trained medical librarian. Five databases, PubMed/MEDLINE, Embase, Cochrane Library, Web of Science, and CINAHL, were searched for English-language studies published between January 2010 and December 2024. Search terms combined controlled vocabulary (MeSH/Emtree) with free-text keywords, covering domains such as diagnosis, imaging, surgery, radiotherapy, systemic therapy, special populations, and advanced disease.

The review adhered to PRISMA 2020 reporting standards.<sup>8</sup> Additional references were identified by scanning the bibliographies of included papers and consulting field experts. Grey literature was also explored using OpenGrey, ClinicalTrials.gov, and recent proceedings of major oncology societies



(ASCO, ESMO, ASTRO, SSO) to mitigate publication bias.

#### Eligibility Criteria

Study selection was guided by the

#### PICOS framework:

-Population: Adult patients ( $\geq 18$  years) diagnosed with breast cancer at any stage, including special groups (elderly, men, pregnant women).

-Intervention/Exposure: Any diagnostic, therapeutic, or management intervention across the six pre-specified domains.

-Comparator: Any comparison group or none.

-Outcomes: Primary outcomes were overall survival, disease-free/progression-free survival, local control, quality of life, and treatment-related toxicity. Secondary outcomes included diagnostic accuracy, surgical complications, and patient-reported outcomes.

-Study design: We considered randomized trials, prospective/retrospective cohorts, systematic reviews/meta-analyses, and clinical guidelines.

We established exclusion criteria to focus on clinically relevant evidence with sufficient methodological rigor. Studies were excluded if they:

- (1) Focused solely on basic science or preclinical research without direct clinical applications;
- (2) Addressed only screening or prevention in healthy populations;
- (3) Reported outcomes for fewer than 50 patients (except for rare conditions or special populations);
- (4) Were published only as conference abstracts without full-text publication; or
- (5) Focused exclusively on quality of life or psychosocial aspects without addressing clinical management.

#### Study Selection and Data Extraction

Two reviewers independently screened titles, abstracts, and full texts using Covidence software, with discrepancies resolved by consensus. A standardized form was used to extract study design, patient characteristics, interventions, and outcomes. For systematic reviews and guidelines, we extracted summary effect estimates and key recommendations with their evidence grading, respectively.

#### Quality Assessment

Methodological quality was evaluated using design-specific instruments:

-RCTs: Cochrane Risk of Bias Tool 2.0 (randomization, adherence to interventions, outcome completeness, measurement reliability, and reporting bias).

-Observational studies: Newcastle-Ottawa Scale (selection, comparability, outcome/exposure assessment).

-Systematic reviews/meta-analyses: AMSTAR-2 tool (protocol registration, literature search, study selection, data synthesis, and bias assessment).

-Clinical guidelines: AGREE II instrument (scope, development rigor, clarity, applicability, independence).

Quality ratings were not used as exclusion criteria but were considered in interpreting the strength of evidence and recommendations.

#### Data Synthesis and Analysis

We performed a structured narrative synthesis organized by topic, prioritizing recent, methodologically robust evidence (e.g., high AMSTAR-2 ratings).

Using the GRADE approach, we assessed the certainty of evidence (high to very low) and the strength of the recommendation (strong/conditional). This is considered a risk of bias, inconsistency, and imprecision, while balancing benefits against harms, patient values, and equity. We also explored heterogeneity and conducted subgroup analyses where feasible.

#### Ethical Considerations

As this was a secondary analysis of published data, ethical approval was not required. We adhered to principles of transparency and integrity in conduct and reporting. Contributions of the authors were assigned using the CRediT taxonomy.


## RESULTS

### Study Selection and Characteristics

The selection process is illustrated in PRISMA flow diagram (Figure 1). The 312 studies included in the qualitative synthesis consisted of randomised, con-

trolled trials

(n = 87, 27.9%), observational studies (n = 124, 39.7%), systematic reviews/meta-analyses (n = 58, 18.6%), and guidelines/consensus (n = 43, 13.8%).



**Figure 1:** PRISMA Flow Diagram showing the study selection process.

**Notes:** With 4,827 records identified through database searching, 138 additional records sourced from other avenues, 3,245 records remaining after the removal of duplicates, 2,503 records excluded following the screening process, 742 full-text articles evaluated for eligibility, 430 full-text articles excluded with specified reasons, and 312 studies incorporated into the qualitative synthesis.

The included publications spanned January 2010 to December 2024, with 68.3% published within the last five years. Studies originated from 38 countries, primarily North America (42.3%), Europe (35.9%), and Asia (16.7%). Primary study sample sizes

ranged from 52 to 25,432 participants (median: 487), collectively representing 1,245,876 distinct patients. Follow-up in longitudinal studies varied from 6 months to 20 years (median: 5.3 years). Detailed characteristics of included studies are presented in Table 1.



**Table 1:** Characteristics of studies included in the systematic review

| Study Design                        | Study Size (%) | Publications Dates | Median Follow-up |
|-------------------------------------|----------------|--------------------|------------------|
| Observational Studies               | 124 (39.7%)    | 2010-2024          | 5.5 years        |
| Randomized Controlled Trials (RCTs) | 87 (27.9%)     | 2010-2024          | 4.0 years        |
| Systematic Reviews/Meta-analyses    | 58 (18.6%)     | 2012-2024          | N/A              |
| Guidelines/Consensus Statements     | 43 (13.8%)     | 2010-2024          | N/A              |
| Total                               | 312 (100%)     | 2010-2024          | 5.3              |

**Notes:** Systematic Reviews/Meta-analyses aggregate across studies, so their median follow-up often mirrors the overall median. Guidelines/consensus statements are not primary data but often cite long-term evidence, so their “median follow-up” tends to be on the higher side of the range. Systematic reviews on breast cancer management identified several key themes (Table 2): dense breast tissue was associated with increased cancer risk; multidisciplinary care correlated with improved

guideline adherence and patient survival; and digital breast tomosynthesis demonstrated superior diagnostic accuracy over traditional mammography. In surgical oncology, breast-conserving surgery plus radiotherapy yielded long-term outcomes comparable to mastectomy. The rapid evolution of systemic treatments was reflected by agents like CDK4/6 inhibitors, which showed substantial benefits in disease-free survival.<sup>9</sup>

**Table 2:** Systematic review studies reveal insights across various domains of breast cancer research.

| Domain              | Study Design       | Sample Size | Key Findings  | Level of Evidence |
|---------------------|--------------------|-------------|---|-------------------|
| Basic Principles    | Meta-analysis      | 18,432      | Women with extremely dense breasts had 4.64-fold higher risk of breast cancer                       | High              |
|                     | Systematic review  | 12,578      | MDT discussion associated with improved guideline adherence (OR 2.15) and better survival (HR 0.82) | High              |
| Imaging Techniques  | Meta-analysis      | 52,412      | DBT had pooled sensitivity of 86% and specificity of 88% for breast cancer detection                | High              |
|                     | Prospective cohort | 3,231       | Ultrasonography increased cancer detection by 3.7 per 1,000 screens in women with dense breasts     | Moderate          |
|                     | Comparative study  | 1,457       | CESM showed comparable diagnostic performance to MRI (sensitivity: 95% vs.97%)                      | Moderate          |
| Surgical Techniques | Meta-analysis      | 9,426       | BCS with radiotherapy showed equivalent 10-year survival to mastectomy (82% vs. 81%)                | High              |
|                     | Multicenter cohort | 1,177       | Comparable local recurrence rates between oncoplastic BCS and conventional BCS (5.2% vs. 4.7%)      | Moderate          |
|                     | Meta-analysis      | 8,560       | SLNB non-inferior to ALND for regional recurrence with reduced lymphedema risk (RR 0.35)            | High              |

| Domain              | Study Design         | Sample Size | Key Findings   | Level of Evidence |
|---------------------|----------------------|-------------|--|-------------------|
| Adjuvant Treatment  | RCT                  | 4,096       | 26 Gy in 5 fractions is non-inferior to 40 Gy in 15 fractions for local recurrence                           | High              |
|                     | Meta-analysis        | 5,101       | CDK4/6 inhibitors improved invasive disease-free survival (HR 0.70)  | High              |
|                     | RCT                  | 1,486       | Dual HER2 blockade improved invasive disease-free survival (HR 0.81)   | High              |
|                     | Meta-analysis        | 3,453       | Adjuvant bisphosphonates reduced bone recurrence (RR 0.83) in postmenopausal women                           | High              |
| Special Populations | Prospective cohort   | 1,284       | Geriatric assessment-guided treatment reduced morbidity without compromising survival                        | Moderate          |
|                     | Retrospective cohort | 2,170       | Surgery plus endocrine therapy superior to primary endocrine therapy alone in fit elderly patients (HR 0.70) | Moderate          |
|                     | Multicenter cohort   | 447         | No significant differences in congenital abnormalities with in-utero chemotherapy after first trimester      | Moderate          |
| Recurrent/Advanced  | Meta-analysis        | 4,580       | CDK4/6 inhibitors improved PFS (HR 0.55) and OS (HR 0.75) in HR+/HER2-metastatic disease                     | High              |
|                     | RCT                  | 557         | Trastuzumab deruxtecan showed 60.9% response rate in heavily pretreated HER2+ disease                        | High              |
|                     | Meta-analysis        | 1,102       | Early palliative care integration improved quality of life (SMD: 0.28)                                       | Moderate          |

**Abbreviations:** BCS, breast-conserving surgery; CESM, contrast-enhanced spectral mammography; DBT, digital breast tomosynthesis; HR, hazard ratio; MDT, multidisciplinary team; MRI, magnetic resonance imaging; OR, odds ratio; PFS, progression-free survival; OS, overall survival; RCT, randomized controlled trial; RR, risk ratio; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; SMD, standardized mean difference.

### Quality Assessment

-RCTs: Using the Cochrane RoB 2.0 tool on 87 randomized controlled trials, 32 trials (36.8%) were rated as low risk of bias, 41 (47.1%) showed some concerns, and 14 (16.1%) were judged high risk.

-Observational studies: Newcastle-Ottawa scores

ranged from 4 to 9 (median: 7). Approximately two-thirds (62.9%) were classified as high quality ( $\geq 7$  points).

-Systematic reviews/meta-analyses: AMSTAR-2 ratings showed 12 reviews (20.7%) were high quality, 26 (44.8%) moderate, 15 (25.9%) low, and 5 (8.6%) critically low.

-Guidelines: AGREE II domain scores ranged from 42% to 96%. Highest scores were observed for scope/purpose (median 85%) and clarity (82%), while applicability (58%) and editorial independence (65%) were comparatively weaker.

A summary of quality assessment results is presented in Table 3.



**Table 3:** Quality assessment of the 312 studies included in the qualitative synthesis.

| Study Type                                | Quality Category                    | (%) Number |
|---|-------------------------------------|------------|
| (RCTs (n = 87                             | (Low Risk of Bias (Most reliable    | (36.8%) 32 |
|   | (Some Concerns (Moderately reliable | (47.1%) 41 |
|   | (High Risk of Bias (Unreliable      | (16.1%) 14 |
| (Observational Studies (n = 124           | (High Quality (NOS $\geq 7$         | (62.9%) 78 |
|   | (Medium Quality (NOS 5-6            | (28.2%) 35 |
|   | (Low Quality (NOS $< 5$             | (8.9%) 11  |
| (Systematic Reviews/Meta-analyses (n = 58 | High Quality                        | (20.7%) 12 |
|   | Moderate Quality                    | (44.8%) 26 |
|   | Low Quality                         | (25.9%) 15 |
|   | Critically Low Quality              | (8.6%) 5   |
| (Clinical Practice Guidelines (n = 43     | (High Quality (AGREE II $\geq 80\%$ | (41.9%) 18 |
|   | (Moderate Quality (AGREE II 60-79%  | (46.5%) 20 |
|   | (Low Quality (AGREE II $< 60\%$     | (11.6%) 5  |

**Notes:** Quality assessment of included studies using domain-specific tools. For RCTs, the Cochrane Risk of Bias Tool 2.0 was used; for observational studies, the Newcastle-Ottawa Scale (NOS); for systematic reviews, AMSTAR-2; and for guidelines, the AGREE II instrument. The majority of studies were of moderate to high quality across all study types.

#### Basic Principles of Breast Cancer Management

High-quality evidence supports the use of validated risk assessment models (Table 4). Risk stratification

tools such as the Gail and Tyrer-Cuzick models were validated for identifying women who may benefit from enhanced surveillance. In a large validation study of 132,139 women, the Tyrer-Cuzick model,<sup>10</sup> achieved an Area Under the Curve (AUC) of 0.70 (95% CI: 0.68–0.72).<sup>11,12</sup> Chemoprevention with selective estrogen receptor modulators (SERMs) demonstrated a 38% risk reduction in incidence (RR 0.62, 95% CI 0.56–0.69) across nine randomized trials.<sup>13</sup>

**Table 4:** Evidence Synthesis by Domain with GRADE Ratings.

| Domain              | Key Finding   | GRADE Rating | Key References         |
|---------------------|---|--------------|------------------------|
| Basic Principles    | Risk assessment models identify high-risk individuals         | Moderate     | Tyrer et al. 2020      |
|                     | Chemoprevention reduces breast cancer incidence               | High         | Manna et al. 2023      |
|                     | Digital breast tomosynthesis improves cancer detection        | Moderate     | Marinovich et al. 2018 |
|                     | Triple assessment approach has high diagnostic accuracy       | High         | Chintamani et al. 2022 |
| Imaging Techniques  | MRI has highest sensitivity for breast cancer detection       | High         | Lee et al. 2023        |
|                     | Abbreviated MRI protocols maintain diagnostic accuracy        | Moderate     | Kim et al. 2025        |
|                     | Contrast-enhanced mammography approaches MRI performance      | Moderate     | Xiang et al. 2020      |
| Surgical Approaches | BCS+RT is equivalent to mastectomy for early-stage disease    | High         | Litière et al. 2012    |
|                     | “No ink on tumor” adequate margin for invasive cancer         | High         | Morrow et al. 2016     |
|                     | SLNB accurate with lower morbidity than ALND                  | High         | Krag et al. 2010       |
|                     | Omission of completion ALND is safe for limited nodal disease | Moderate     | Giuliano et al. 2017   |

**Notes:** The strength of evidence was rated as high, moderate, low, or very low using the GRADE approach, which considers study design, risk of bias, inconsistency, indirectness, imprecision, and other factors. Key references for each finding are provided. BCS = breast-conserving surgery; RT = radiotherapy; SLNB = sentinel lymph node biopsy; ALND = axillary lymph node dissection.

The concordant triple diagnostic approach (clinical exam, imaging, biopsy) yields >99% sensitivity and specificity, with core needle biopsy as the standard for obtaining biological data.<sup>14</sup> Incorporating biological factors into the 8th edition American Joint Committee on Cancer (AJCC) staging system (2021) improved prognostic accuracy (C-index 0.71→0.79) over anatomical staging.<sup>15</sup>

#### Imaging Techniques in Breast Cancer

For screening, digital breast tomosynthesis (DBT) improved detection rates by 27–53% and reduced recall rates by 15–37% compared with conventional mammography.<sup>11</sup> The imaging benefit is especially noticeable in women with thick breasts. Breast MRI

offers the highest sensitivity (>90%) but variable specificity (72–90%). Abbreviated MRI protocols achieve sensitivity (86–95%) and specificity (81–89%) with reduced time and cost.<sup>16</sup> Contrast-enhanced mammography (CEM) provides a sensitivity of 89–100% and specificity of 80–87%, nearing MRI performance at a lower cost, making MRI unsuitable for patients.<sup>17,18</sup> Artificial intelligence in mammography shows strong promise, with deep learning algorithms achieving an AUC of approximately 0.92 (95% CI 0.90–0.94) in a large cohort.<sup>19</sup> In the neoadjuvant setting, MRI predicts pathological complete response with 74–90% accuracy. Molecular imaging, such as 18F-FDG PET/CT, demonstrates high sensitivity (96%) and specificity (89%) for distant metastases, and emerging radiotracers facilitate non-invasive tumor biology assessment.<sup>20</sup>


#### Surgical Approaches to Breast Cancer

Evidence confirmed the oncological equivalence of breast-conserving surgery (BCS) followed by radiotherapy compared to mastectomy for early disease, with no survival difference at 20 years (HR 0.88,



95% CI 0.75–1.05).<sup>21</sup> Figure 2 displays a forest plot illustrating hazard ratios with 95% confidence intervals for 12 key breast cancer trials, categorized by

type of intervention (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy).



**Figure 2:** Forest plot displaying hazard ratios with 95% confidence intervals for 12 key breast cancer trials

**Notes:** The trials are categorized by intervention type (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy). The plot includes a vertical line at HR=1.0, with points to the left favoring intervention and points to the right favoring control. As described by Morrow et al. (2016), margin assessment of ‘no ink on tumour’ is deemed sufficient for invasive cancer based on a meta-analysis of 33 studies showing no significant reduction in local recurrence with wider margins.<sup>5</sup> For ductal carcinoma in situ (DCIS), margins of at least 2 mm reduced recurrence rates (OR 0.72, 95% CI 0.47–0.97), although the optimal margin width remains debated.<sup>22</sup> Sentinel lymph node biopsy (SLNB) demonstrated false-negative rates of 5–10% and significantly lower morbidity compared to axillary dissection. For patients with limited sentinel node involvement,

### Special Population Considerations

Evidence for elderly patients ( $\geq 70$  years) supports the use of comprehensive geriatric assessment, utilizing validated tools (G8, VES-13) to identify those requiring full evaluation.<sup>36</sup> The PRIME II trial showed that omitting radiotherapy after breast-conserving surgery in women  $\geq 65$  years with low-risk, ER-positive tumors on endocrine therapy increased local recurrence (4.1% vs. 1.3% at 5 years) but did

not increase the risk of distant recurrence or overall survival.<sup>37</sup> The PRIME II trial also showed that omitting radiotherapy after breast-conserving surgery in women  $\geq 65$  years with low-risk, ER-positive tumors on endocrine therapy increased local recurrence (4.1% vs. 1.3% at 5 years) but did

not increase the risk of distant recurrence or overall survival.<sup>37</sup> The PRIME II trial also showed that omitting radiotherapy after breast-conserving surgery in women  $\geq 65$  years with low-risk, ER-positive tumors on endocrine therapy increased local recurrence (4.1% vs. 1.3% at 5 years) but did not increase the risk of distant recurrence or overall survival.<sup>37</sup>

omission of completion axillary dissection does not compromise survival in appropriately selected patients based on the Z0011 trial (10-year overall survival 86.3% vs. 83.6%,  $p=0.24$ ).<sup>23,24</sup> Oncoplastic procedures allowed BCS for larger or complex tumors, achieving good-to-excellent cosmetic results in 90–94% of patients with recurrence rates of 0–7% based on a systematic review of 474 studies.<sup>25</sup> Nipple-sparing mastectomy was safe in carefully chosen patients, showing 1–2% recurrence at five years with high patient satisfaction.<sup>26</sup>

#### Adjuvant Treatment Strategies

Radiotherapy with fewer, larger daily fractions (40–42.5 Gy over 15–16 sessions) shows non-inferior tumor control and diminished treatment-related morbidity.<sup>27</sup>

Ultra-hypofractionation (26–28 Gy in 5 fractions), shown in the FAST-Forward trial, offers non-inferior local control with acceptable toxicity. Partial breast irradiation in selected low-risk patients yields local recurrence rates comparable to whole breast irradiation (difference <1% at 5 years) with reduced toxicity and improved convenience.<sup>28</sup>

Genomic assays provide critical prognostic and predictive information, particularly for ER-positive, HER2-negative disease. The TAILORx trial demonstrated that patients with node-negative disease and intermediate recurrence scores (11–25) can safely omit chemotherapy if over 50 years of age or with scores <16 if 50 years or younger (Sparano et al., 2018).<sup>29</sup> The RxPONDER trial extended these findings to patients with limited nodal involvement, showing no chemotherapy benefit for postmenopausal women with 1–3 positive nodes and recurrence scores  $\leq 25$  (Kalinsky et al., 2021).<sup>30</sup>

Targeted therapies markedly improved outcomes:

-Dual HER2 blockade (trastuzumab + pertuzumab) enhanced disease-free survival in high-risk HER2-positive disease based on the APHINITY trial.<sup>31</sup>

-Immunotherapy (pembrolizumab) improved pCR and event-free survival in triple-negative disease (KEYNOTE-522 trial).<sup>32</sup>

-Extended endocrine therapy reduced late recur-

not affect distant recurrence or overall survival, supporting shared decision-making.<sup>37</sup>

For male breast cancer, modified radical mastectomy remains the standard due to limited breast tissue and central tumor location, with tamoxifen as the preferred adjuvant endocrine therapy. Evidence is largely extrapolated from female breast cancer studies, though international registries are beginning to address this significant knowledge gap.<sup>38</sup> In pregnancy-associated breast cancer, surgery is safe during any trimester, but chemotherapy is contraindicated during the first trimester (Loibl et al., 2015).<sup>39</sup> Prognosis is similar to non-pregnancy-associated cancer when matched for stage and biology. For hereditary breast cancer syndromes, prophylactic mastectomy reduced risk by over 90% in BRCA carriers. Furthermore, salpingo-oophorectomy reduced ovarian cancer risk by approximately 80% and breast cancer risk by about 50% in premenopausal women.<sup>40</sup>

#### Management of Locally Recurrent and Advanced Breast Cancer

They emphasize aggressive local and systemic approaches. For locoregional recurrence following breast-conserving surgery (BCS), mastectomy offers a high control rate of 85–95%. Furthermore, a meta-analysis of eight randomized controlled trials (RCTs) established that incorporating local therapy into systemic treatment significantly improves survival (HR 0.69, 95% CI 0.58–0.83) 2.<sup>41</sup>

In the setting of metastatic disease, treatment is tailored to the subtype. For hormone receptor-positive, HER2-negative disease, adding CDK4/6 inhibitors to endocrine therapy approximately doubles progression-free survival across various trials, with the MONALEESA-2 trial also demonstrating improved overall survival (HR 0.76, 95% CI 0.61–0.95).<sup>42</sup> HER2-positive metastatic disease benefits from a sequence of effective targeted agents, notably trastuzumab deruxtecan, which has shown impressive efficacy in heavily pretreated patients (objective response rate 60.9%, median progression-free survival 16.4 months).<sup>43</sup> For metastatic triple-negative breast cancer, sacituzumab govitecan improves



overall survival compared to chemotherapy (HR 0.51, 95% CI 0.41-0.62) in previously treated individuals.<sup>44,47</sup> Additionally, immunotherapy with pembrolizumab plus chemotherapy improves progression-free survival (HR 0.65, 95% CI 0.49-0.86) in PD-L1-positive disease, though better biomarkers are needed for patient selection.<sup>36</sup>

Oligometastatic breast cancer is a distinct category where aggressive local therapy, such as stereotactic body radiotherapy (SBRT), can offer long-term disease control, achieving local control rates of 80-90% in prospective studies. The SABR-COMET trial suggested improved overall survival with SBRT for patients with 1-5 metastases (HR 0.57, 95% CI 0.30-1.10), although breast cancer-specific data remain limited.<sup>45</sup> Brain metastases pose a significant challenge, with emerging strategies including HER2-targeted tyrosine kinase inhibitors with CNS penetration (tucatinib, neratinib), antibody-drug conjugates (trastuzumab deruxtecan), and immunotherapy showing promise.<sup>43</sup>

## DISCUSSION


### Interpretation of Findings

The evolution toward precision medicine is a key advancement, integrating molecular characteristics, genomic profiles, and patient preferences into treatment decisions. Incorporating biological factors improved prognostic accuracy over anatomical staging. This prognostic stage integrates grade, oestrogen receptor, progesterone receptor, and HER2 status, underscoring the shift toward biologically driven management.<sup>15</sup> This represents a paradigm shift from historical approaches requiring 1-2 cm margins, reducing re-excision rates and improving cosmetic outcomes without compromising oncological safety. This shift, which affects staging, chemotherapy use, and targeted therapies, facilitates both treatment de-escalation in low-risk cases and intensification for biologically aggressive disease.<sup>46</sup> The goal is to minimize unnecessary toxicity while ensuring optimal oncologic outcomes, shortening treatment, and reducing patient visits. Practical examples include omitting axillary dissection in limited nodal disease, utilizing partial-breast irra-

diation, and employing genomic assays to guide the need for chemotherapy. This approach reflects a sophisticated understanding of breast cancer as a heterogeneous disease requiring tailored strategies. High-quality evidence supports the use of validated risk assessment models to identify individuals who may benefit from enhanced surveillance or risk-reducing interventions (Table 4).

Specialized, team-based care is fundamental to high-quality management (Figure 3). Evidence shows that coordinated input from surgeons, oncologists, radiologists, and other specialists improves decision-making, adherence to evidence-based guidelines, and ultimately, survival outcomes.<sup>36</sup> While consistent with prior reviews, this current analysis offers a more comprehensive integration across the entire continuum of care. Earlier reports often focused narrowly on specific areas,<sup>5</sup> such as surgical margins or adjuvant chemotherapy selection (Denduluri et al., 2018).<sup>7</sup> This review, however, contextualizes individual treatment choices within the broader therapeutic landscape, highlighting the interactions among imaging, surgery, radiotherapy, and systemic options. In a substantial validation study involving 132,139 women, the Tyrer-Cuzick model achieved an Area Under the Curve (AUC) of 0.70 (95% CI: 0.68–0.72). This result is regarded as acceptable in the context of medical modelling, suggesting that the model demonstrates a fairly good capacity to distinguish between high-risk and low-risk women, and possesses statistical power.<sup>11,12</sup>

## Multidisciplinary Breast Cancer Management Framework




**Figure 3:** Conceptual framework diagram showing the patient at the center, surrounded by six disciplines (Surgical Oncology, Medical Oncology, Radiation Oncology, Radiology, Pathology, Supportive Care) with connecting lines.

Notable findings include the rapid emergence of evidence supporting novel approaches such as abbreviated MRI protocols, ultra-hypofractionated radiotherapy, and the use of immunotherapy in early triple-negative disease. These developments underscore the dynamic nature of the field and the necessity for regular evidence updates. The approach of using comprehensive geriatric assessment, utilizing validated tools (G8, VES-13) detects vulnerabilities impacting treatment tolerance, enabling tailored interventions. The decision algorithm presented in Figure 4 provides a practical framework for integrating these advances into clinical practice, recog-

nizing that optimal management must consider both disease and patient-specific factors.

## Breast Cancer Treatment Decision Algorithm



**Figure 4:** Flowchart showing treatment decision pathways based on stage (I-III vs. IV) and molecular subtype (HR+/HER2-, HER2+, TNBC). The algorithm includes decision points, treatment steps, and connections between pathways, with a legend explaining the symbols used.

### Review's Limitations

While comprehensive, the review has some limitations:


1. Study identification: Although multiple databases and grey literature sources were searched, relevant studies in non-English languages may have been missed.
2. Heterogeneity: Considerable variability across included studies (in design, populations, and end-points) limited the feasibility of formal meta-analysis for most outcomes.
3. Evidence quality: The strength of evidence varied widely, with relatively robust data for surgical and radiotherapy interventions but limited high-quality evidence for special populations and emerging therapies. Quality assessment revealed notable variation across study types, which has implications for the strength of evidence within different domains.

4. Scope: Our focus was primarily on clinical management. Broader issues such as survivorship, psychosocial support, and healthcare implementation strategies were outside the review's remit. Quality assessment revealed notable variation across study types, which has implications for the strength of evidence within different domains.

5. Evolving field: Advances in systemic therapy and molecular diagnostics are rapid, meaning that certain conclusions may become outdated relatively quickly.

Despite these constraints, the review provides a comprehensive synthesis of evidence-based strategies relevant to current clinical practice. The following seven key findings infographic, presented in Figure 5, highlights both the advances and remaining challenges identified in this synthesis.

### Key Findings: Breast Cancer Management Systematic Review



**Figure 5:** Infographic displaying seven key findings in hexagonal shapes with connecting lines.



### Implications for Practice and Policy

For clinicians, treatment plans must integrate tumor biology, anatomical extent, comorbidity, and patient values, with MDT discussion as standard. De-escalation is appropriate for selected low-risk patients (e.g., omitting axillary surgery or radiotherapy), while intensification is warranted for high-risk disease (e.g., targeted therapies in HER2-positive or BRCA-mutated cancers). Chemoprevention with selective estrogen receptor modulators (SERMs) revealed a 38% risk reduction in incidence with a sustained benefit up to five years post-treatment, albeit with limited uptake due to concerns about toxicity.<sup>13</sup> Comprehensive geriatric evaluation optimizes decisions for older adults. The practice-changing finding applies to women with T1-2 tumors, 1-2 positive sentinel nodes, undergoing breast-conserving surgery with whole-breast radiotherapy and adjuvant systemic therapy. For patient with nipple-sparing mastectomy, patient selection remains critical, with contraindications including tumors <2 cm from nipple, inflammatory breast cancer, and extensive DCIS with nipple involvement.<sup>26</sup> For policy-makers, the review highlights the need for equitable access to genomic testing, advanced imaging, and multidisciplinary care, requiring resource-stratified guidelines and implementation science to bridge evidence to real-world practice.

### Future Research Directions

There are still several topics that need more research:

- Risk prediction models that integrate biomarkers, imaging, and artificial intelligence to enhance stratification. The advantage is obvious in women with dense breasts, though cost-effectiveness is still being investigated.
- Management of ductal carcinoma in situ (DCIS), where overtreatment remains a concern and risk-adapted strategies are needed. The advantage of wider margins must be weighed against cosmetic considerations and the small absolute risk reduction, given the effectiveness of adjuvant therapies.<sup>22</sup>
- Novel predictive biomarkers for therapy selection, especially in metastatic disease with multiple avail-

able options.

-The potential of the emerging technology is comparable to or exceeding human readers, pending further clinical validation.<sup>19</sup>

-Liquid biopsies to monitor disease evolution and treatment response in real time.

-Optimal strategies for brain metastases, including agents with central nervous system penetration.

-Implementation research to close the evidence-to-practice gap, particularly in resource-constrained environments.

### CONCLUSION

Contemporary breast cancer care demonstrates the potential of precision medicine and multidisciplinary collaboration to improve survival and quality of life. Our synthesis confirms strong evidence for practices such as breast-conserving surgery with radiotherapy, sentinel lymph node biopsy, endocrine therapy, and HER2-targeted therapy. Moderate-level support exists for approaches including hypofractionated radiotherapy, selective omission of axillary dissection, and the use of genomic assays to avoid unnecessary chemotherapy.

Significant challenges remain, particularly in refining risk stratification, optimizing the management of pre-invasive disease, developing predictive biomarkers, and ensuring equitable implementation of advances across all health systems.

Future progress will depend on ongoing cross-disciplinary collaboration, continued innovation in diagnostics and therapeutics, and health policy measures that prioritize both access and quality. By integrating current best evidence while identifying knowledge gaps, this review provides a framework to guide clinicians, researchers, and decision-makers in the ongoing effort to improve outcomes for patients with breast cancer worldwide.

### ACKNOWLEDGEMENTS

The authors gratefully acknowledge the contribution of Abdulmoula Amaari (Medical Librarian) for his assistance in designing and refining the literature search. We also thank Abdulmonim Obacid (Statistical Consultant) for guidance on methodological and analytical approaches. Special appreciation is

extended to the multidisciplinary breast cancer team at Benghazi Medical Center, whose expertise provided valuable input during the protocol development and preliminary findings discussion. Administrative and technical support from Eng. Naserdein Azouz is also acknowledged.

## DECLARATIONS

### Funding:

This work did not receive financial support from public, commercial, or not-for-profit funding bodies.

### Conflicts of Interest:

The authors declare no conflicts of interest related to the content of this review.

### Author Contributions:

Contributions were documented in line with the **CRedit taxonomy**:

-Conceptualization & methodology: N.J.S. Elsaadi, T.F. Houni, A.M. Amaari

-Data acquisition & validation: M.O. Al-Jahany, M.A. Moftah

-Analysis & interpretation: All authors, N. E. Azouz

-Manuscript drafting: N.J.S. Elsaadi, T.F. Houni, A.M. Obaeid

-Critical revisions & final approval: All authors

## REFERENCES

1. Harbeck N, Gnant M. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet*. 2017;389(10074):1134-50.
2. Waks AG, Winer EP. Breast cancer treatment: a review. *Jama*. 2019 Jan 22;321(3):288-300.
3. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology*. 2019 Aug 1;30(8):1194-220.
4. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*. 2020 Apr 1;18(4):452-78.
5. Morrow, M., Van Zee, K.J., Solin, L.J., Houssa-

mi, N., Chavez-MacGregor, M., Harris, J.R., Horton, J., Hwang, S., Johnson, P.L., Marinovich, M.L. and Schnitt, S.J., 2016. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. *Journal of Clinical Oncology*, 34(33), pp.4040-4046.

6. Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, White J, Harris JR. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. *Practical radiation oncology*. 2017 Mar 1;7(2):73-9.

7. Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update. *Journal of Clinical Oncology*. 2018 Aug 10;36(23):2433-43.

8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *bmj*. 2021 Mar 29;372.

9. Chen X, Xu D, Li X, Zhang J, Xu W, Hou J, Zhang W, Tang J. Latest overview of the cyclin-dependent kinases 4/6 inhibitors in breast cancer: the past, the present and the future. *Journal of Cancer*. 2019 Oct 21;10(26):6608.

10. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. *Stat Med*. 2020;39(30):4720-4732.

11. Marinovich ML, Hunter KE, Macaskill P, Housami N. Breast cancer screening using tomosynthesis or mammography: a meta-analysis of cancer detection and recall. *JNCI: Journal of the National Cancer Institute*. 2018 Sep 1;110(9):942-9.

12. Lee K, et al. Abbreviated versus full-protocol MRI for breast cancer screening: a systematic review and meta-analysis. *Clin Breast Cancer*. 2023;23(1):e1-e10.



13. Manna ED, Serrano D, Aurilio G, Bonanni B, Lazzeroni M. Chemoprevention and lifestyle modifications for risk reduction in sporadic and hereditary breast cancer. *Healthcare*. 2023;11(16):2360.
14. Chintamani. Approach to a Suspected Case of Breast Cancer. In *Breast Cancer: Comprehensive Management 2022* Jan 31 (pp. 87-101). Singapore: Springer Nature Singapore.
15. Weiss A, King TA, Hunt KK, et al. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence. *Surg Clin North Am*. 2018;98(4):687-702.
16. Kim KM, et al. Accuracy of abbreviated breast magnetic resonance imaging for breast cancer detection: a systematic review and meta-analysis. *Eur J Radiol*. 2025;182:110779.
17. Xiang W, Rao H, Zhou L. A meta-analysis of contrast-enhanced spectral mammography versus MRI in the diagnosis of breast cancer. *Thorac Cancer*. 2020;11(6):1423-1432.
18. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*. 2020;382(9):810-821.
19. Panceri SS, Mutz F, Cardoso VB, Carneiro RV, Oliveira-Santos T, Badue C, De Souza AF. Detecting cancerous tissue in mammograms using deep neural networks. In *2021 International Joint Conference on Neural Networks (IJCNN) 2021* Jul 18 (pp. 1-8). IEEE.
20. Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, Glanville J, McIntosh H, Renahan A, Weller D, Dunlop M. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. *Health Technology Assessment (Winchester, England)*. 2011 Sep;15(35):1.
21. Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. *The lancet oncology*. 2012 Apr 1;13(4):412-9.
22. Morrow, M., Van Zee, K.J., Solin, L.J., Houssami, N., Chavez-MacGregor, M., Harris, J.R., Horton, J., Hwang, S., Johnson, P.L., Marinovich, M.L. and Schnitt, S.J., 2016. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. *Journal of Clinical Oncology*, 34(33), pp.4040-4046.
23. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. *Jama*. 2017 Sep 12;318(10):918-26.
24. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol*. 2010;11(10):927-933.
25. De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, Tchou J, Fisher CS. Outcomes after oncoplastic breast-conserving surgery in breast cancer patients: a systematic literature review. *Annals of surgical oncology*. 2016 Oct;23(10):3247-58.
26. Song Y, Wang L, Huang W, Guo S, Wu X, Zheng H. Comparison of nipple sparing and skin sparing mastectomy with immediate reconstruction based on patient reported outcomes. *Scientific Reports*. 2025 Apr 29;15(1):14989.
27. Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. *The Lancet*. 2020 May 23;395(10237):1613-26.



28. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Cirlionis L, Chan C, Donovan EM. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. *The Lancet*. 2017 Sep 9;390(10099):1048-60.
29. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer Jr CE, Dees EC, Goetz MP, Olson Jr JA, Lively T. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *New England Journal of Medicine*. 2018 Jul 12;379(2):111-21.
30. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. *New England Journal of Medicine*. 2021 Dec 16;385(25):2336-47.
31. Von Minckwitz G, Procter M, De Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *New England Journal of Medicine*. 2017 Jul 13;377(2):122-31.
32. Pusztaï L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, Harbeck N. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. *Annals of Oncology*. 2024 May 1;35(5):429-36.
33. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *New England Journal of Medicine*. 2017 Nov 9;377(19):1836-46.
34. Tutt AN, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *New England Journal of Medicine*. 2021 Jun 24;384(25):2394-405.
35. Johnston SR, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). *Journal of Clinical Oncology*. 2020 Dec 1;38(34):3987-98.
36. Biganzoli L, Battisti NM, Wildiers H, McCartney A, Colloca G, Kunkler IH, Cardoso MJ, Cheung KL, De Glas NA, Trimboli RM, Kore-Grodzicki B. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). *The Lancet Oncology*. 2021 Jul 1;22(7):e327-40.
37. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *The lancet oncology*. 2015 Mar 1;16(3):266-73.
38. Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, Plichta JK, Ricker C, Roshal A, Ruddy KJ, Safer JD. Management of male breast cancer: ASCO guideline. *Journal of Clinical Oncology*. 2020 Jun 1;38(16):1849-63.
39. Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonaya A, Stensheim H, Thomssen C, Van Calsteren K. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. *JAMA oncology*. 2015 Nov 1;1(8):1145-53.
40. Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline☆. *Annals of Oncology*. 2023 Jan 1;34(1):33-47.
41. Boutros C, Tarabai M, El-Zaart A, et al. The impact of systemic therapy on survival of patients with isolated locoregional recurrence of breast cancer: A systematic review and meta-analysis. *Breast*.



2018;37:156-165.

42.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P. Overall survival with ribociclib plus letrozole in advanced breast cancer. *New England Journal of Medicine*. 2022 Mar 10;386(10):942-50.

43.Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, Krop IE, González Farré X, You B, Saura C, Kim SB. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis. *Cancer discovery*. 2022 Dec 2;12(12):2754-62.

44.Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R. Sacituzumab govitecan in metastatic triple-negative breast cancer. *New England journal of medicine*. 2021 Apr 22;384(16):1529-41.

45.Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. *The Lancet*. 2019 May 18;393(10185):2051-8.

46.Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Annals of Oncology*. 2017 Aug 1;28(8):1700-12.

47.Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *The Lancet*. 2020 Dec 5;396(10265):1817-28.

#### Supplementary Materials:

Primary search terms included:

“breast neoplasms” [MeSH] OR “breast cancer” OR “carcinoma of the breast” OR “mammary carcinoma” combined with domain-specific terms such as “diagnosis” OR “imaging” OR “mammography” OR “ultrasonography” OR “magnetic resonance imaging” OR “surgery” OR “mastectomy” OR “breast-conserving surgery” OR “axillary surgery” OR “sentinel lymph node biopsy” OR “radiotherapy” OR “chemotherapy” OR “endocrine therapy” OR “targeted therapy” OR “elderly” OR “male breast cancer” OR “pregnancy” OR “local recurrence” OR “metastatic” OR “advanced disease”.

Extra uterine growth restriction and its related factors in extremely and very low birth weight babies including 1500 grams admitted to Jammhoria hospital in Benghazi.

Aziza I.Kadwar <sup>1\*</sup>, khadiga I. Shreef <sup>1</sup>, Isaaida A. Alsaeti <sup>2</sup>, Nadia AM. Aldarogi <sup>3</sup>

## Original Research Article

### Abstract

**Background:** Extra-uterine growth restriction (EUGR) in premature infants remains a major challenge for neonatologists worldwide. In the neonatal intensive care unit (NICU), suboptimal nutrition and the fear of advancing feeds are key contributors. Updated feeding protocols that support rapid but safe feeding advancement, breast milk fortification, and close monitoring of growth parameters are essential to achieving optimal nutritional outcomes and preventing long-term neurodevelopmental impairment.

**Objective:** To determine the frequency of extra-uterine growth restriction (EUGR) among premature infants in Benghazi and identify associated risk factors.

**Method:** This cross-sectional study was conducted in Benghazi. Medical records of 107 premature infants were obtained from the neonatal clinic. All preterm infants born at <34 weeks' gestation and weighing ≤1500 grams were included. Growth measurements at birth, discharge, and 40 weeks corrected age were plotted on Fenton growth charts. Weight <10th percentile was classified as EUGR. A p-value <0.05 was considered statistically significant.

**Results:** EUGR was identified in 85 infants (79%) at discharge and in 63 infants (58.8%) at 40 weeks corrected age. Significant risk factors for EUGR at discharge and at 40 weeks included lower birth weight (p = 0.01; p = 0.005), longer hospital stay (p = 0.007; p = 0.01), small for gestational age (SGA) (p = 0.000; p = 0.02), and sepsis (p = 0.03; p = 0.001). Additionally, gestational age 33–34 weeks (p = 0.001) and multiple births (p = 0.03) were significant risk factors for EUGR at discharge only.

**Conclusion:** Extra-uterine growth restriction is highly prevalent among Libyan premature infants. Lower birth weight, prolonged hospitalization, SGA status, gestational age of 33–34 weeks, and multiple births were significant associated risk factors.

**Recommendations:** Implementation of updated feeding protocols for premature infants in Libya—including rapid but safe advancement of enteral feeds, breast milk fortification, and close monitoring of growth parameters—is essential to improving nutritional outcomes and reducing the risk of EUGR.

**Keywords:** Benghazi, extra-uterine growth restriction, extremely low birth weight, very low birth weight, premature infants.

1. Department of Pediatrics, Faculty of Medicine, University of Benghazi, and Benghazi Medical Centre.

2. Department of Pediatrics, Faculty of Medicine, University of Benghazi, and Children Hospital.

3. Department of Family and community medicine, Faculty of Medicine, University of Benghazi, Libya.

\*Corresponding author: Aziza I. Kadwar, Email: [Aziza.gadwar@uob.edu.ly](mailto:Aziza.gadwar@uob.edu.ly).

DOI: [10.37376/benuunivmedj.v2i2](https://doi.org/10.37376/benuunivmedj.v2i2)



## INTRODUCTION

The survival rate of extremely and very low birth weight infants has improved significantly in recent years, largely due to advances in neonatal medical care, including enhanced respiratory and nutritional support (1,2). However, suboptimal nutrition remains a major challenge in many Neonatal Intensive Care Units (NICUs) worldwide, often leading to extra-uterine growth restriction (EUGR) among premature infants.

EUGR is defined as weight, head circumference, or length  $\leq 10$ th percentile of intrauterine growth expectations, assessed at discharge, 36 weeks, or 40 weeks corrected age (3). Major neonatal societies—including the American Academy of Pediatrics, the Canadian Pediatric Society, and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)—recommend that postnatal growth in preterm infants should approximate intrauterine growth rates, ensuring that growth at corrected age is comparable to that of term infants.

A number of factors contribute to this largely irreversible condition. Suboptimal early nutrition, particularly inadequate protein intake in the first weeks of life, is considered one of the most important contributors (4). Other independent risk factors associated with EUGR include intrauterine growth restriction (IUGR), need for assisted ventilation on the first day of life, prolonged respiratory support for more than 28 days, male sex, extended hospitalization, development of bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), sepsis, exposure to steroids during hospitalization, delayed return to birth weight, and delayed achievement of full enteral feeds (3,5–7).

Over the last 10–15 years, nutritional guidelines have been refined to reduce the risk of EUGR, and these updates have shown promising outcomes. Current recommendations support early and aggressive initiation of both parenteral and enteral nutrition, with progressive advancement to full enteral feeds (8–11). These approaches have been associated with earlier recovery of birth weight, improved weight at discharge, shorter duration of parenteral nutrition,

earlier attainment of full feeds (8,11), lower rates of late-onset sepsis, and reduced incidence of NEC (9,12). Furthermore, milk fortification—whether human milk fortifiers or preterm formulas—along with post-discharge nutritional support provides an opportunity for catch-up growth (13).

Recent findings demonstrate that fortification of breast milk, close monitoring of growth parameters, and adherence to consensus guidelines from major neonatal societies can enable preterm infants to achieve growth trajectories that align with their birth percentiles. ESPGHAN has also introduced updated recommendations for targeted nutrition during critical illness, emphasizing optimal protein and energy delivery to support appropriate growth (14). In Japan, breast milk fortification standards were enhanced in the 2010s, and updated enteral feeding guidelines were introduced in 2017 (15).

EUGR is associated with poor neurodevelopmental outcomes, with long-term and often irreversible consequences (16,17). With the advancement of digital technologies, machine learning (ML) and artificial intelligence (AI) have been applied to better understand factors influencing EUGR. For example, Bozzetti et al. used ML to identify clinical and nutritional predictors of EUGR among infants born before 33 weeks and demonstrated the strong predictive value of early clinical and nutritional variables (18).

In Libya, the absence of standardized feeding guidelines—combined with reluctance among some clinicians to initiate early and aggressive feeding in extremely low and very low birth weight or critically ill infants—contributes to a higher risk of EUGR. Although national nutritional strategies were launched in 2020, implementation remains challenging, particularly in the care of sick premature infants. This study aims to highlight the magnitude of this problem in Benghazi and to raise awareness of the need for urgent improvements in nutritional practices for premature infants.

## AIM of THE STUDY

-To estimate the frequency of extra-uterine growth restriction (EUGR) at discharge and at 40 weeks corrected age among extremely and very low birth weight premature infants ( $\leq 1500$  grams).

-To identify the clinical characteristics and postnatal factors significantly associated with EUGR in premature infants  $\leq 1500$  grams.

## METHODOLOGY

It is a cross-sectional study that included 107 premature babies who were discharged from the NICU (neonatal intensive care unit) in Jammhoria Hospital in Benghazi. It is a public maternity hospital where extremely low, very low, and low birth weights ( $\leq 1500$  grams) were born in Benghazi. We selected 107 premature babies who were attending the neonatal clinic for follow-up and for their growth assessment, with inclusion criteria that included premature babies  $\leq 34$  weeks gestation with birth weight  $\leq 1500$  grams, and excluded premature babies with congenital anomalies and those babies without recorded data for weight and head circumference at both discharge and corrected age. We collected their files selectively from the neonatal clinic according to inclusion criteria during the period from 2004 until 2015. We collected the data from the files, which include their weight and head circumference at birth, weight at discharge, and at 40 weeks corrected age; their gestational age; sex; duration of hospital stay; and type of pregnancy (single or multiple births). The related factors that may predispose to EUGR were also registered, including the use of a ventilator or bubble non-invasive continuous positive pressure (CPAP), a history of hyaline membrane disease (HMD), necrotizing enterocolitis, a history of apnea, sepsis, bronchopulmonary dysplasia (BPD), and a maternal history of hypertension or preeclampsia. The measurements of birth weight were plotted on the Fenton chart; according to that, we divided them into 2 groups: group of average gestational age (AGA) for those with birth weight  $> 10$ th centile, another group of small for gestational age (SGA) with birth weight  $\leq 10$ th centile, and then the weight at discharge and

at 40 weeks corrected age were again plotted on charts. Those babies with weight at discharge and 40 weeks corrected age  $\leq 10$ th were defined as babies with extra-uterine growth restriction (EUGR). The two groups of AGA and SGA were compared for the frequency of EUGR, and both groups of EUGR and non-EUGR at discharge and 40 weeks were compared with certain factors that may predispose to EUGR that involved:

Clinical characteristics included sex, birth weight, gestational age, weight for gestational age (either SGA or AGA), duration of hospital stay, and type of pregnancy. Postnatal factors included use of a ventilator or CPAP, a history of hyaline membrane disease (HMD), necrotizing enterocolitis (NEC), a history of apnea, sepsis, BPD, and a history of maternal hypertension or preeclampsia.

## DATA ANALYSIS

The preterm infants were categorized into two groups: extra-uterine growth restriction (EUGR) and non-extra uterine growth restriction (non-EUGR). Quantitative data were summarized using descriptive statistics, including mean (M), median (Mdn), and standard deviation (SD). To assess the associations between variables and EUGR status at discharge and 40 weeks corrected age, inferential statistical tests were employed. Categorical variables were analyzed using the chi-square test ( $\chi^2$ ) or Fisher's exact test, as appropriate, while continuous variables were evaluated using the independent samples t-test. A two-sided significance level of  $\alpha = 0.05$  was adopted, with p-values  $< 0.05$  deemed statistically significant. All statistical analyses were performed using IBM SPSS Statistics, Version 23 (19).

## ETHICAL CONSIDERATIONS

Verbal approval to conduct the study was obtained under the supervision of the Neonatal Department and the neonatal follow-up clinic

## RESULTS

In the study, 107 premature babies between the period of 2004 and 2015 whose gestational age was 34 weeks or less with a birth weight of  $\leq 1500$  grams. Out of them, 73 (68.2%) were female, and the ges-




tational age between 28 and 32 weeks was estimated in 67.2%; the minimum gestational age was 28 weeks. The mean head circumferences at birth, at discharge, and at 40 weeks were 27.8±1.7, 28±1.39, and 33.59±2, respectively. The birth weight for

most of them (63.6%) was between 1200 and 1500 grams; the minimum birth weight was 0.635 kg; the mean birth weight was 1250 grams. (Table 1) (Figure. 1).


**Table (1):** Descriptive statistics of clinical characteristics for premature babies

| Characteristics of study participants     | Descriptive statistics |                    |        |         |         |
|---|------------------------|--------------------|--------|---------|---------|
|   | Mean                   | Standard deviation | Median | Minimum | Maximum |
| Gestational Age in weeks                  | 31.53                  | 1.61               | 31     | 28      | 34      |
| Duration of stay at hospital in days      | 14.4                   | 9.90               | 11     | 1       | 55      |
| Birth Weight in kg                        | 1.25                   | 0.168              | 1.28   | 0.635   | 1.5     |
| Weight at discharge in kg                 | 1.23                   | 0.885              | 1.24   | 0.885   | 1.600   |
| Weight at corrected age in kg             | 2.63                   | 0.682              | 2.6    | 1.070   | 4.100   |
| Head circumference at birth in cm         | 27.81                  | 1.71               | 28     | 21.8    | 33      |
| Head circumference at corrected age in cm | 33.59                  | 2.019              | 34     | 29      | 39      |



**Figure.1:** Distribution of premature babies by their birth weight.

The duration of stay at the hospital for 79.4% of premature babies was 1-20 days (Fig. 2). Almost all premature babies (59%) had a birth weight that was average for gestational age (AGA); it means that their birth weight was above the 10th centile. The pregnancy was single in 70.1% (Table 2).



**Figure 2:** Duration of hospital stay for premature babies

**Table (2):** Clinical characteristics of extremely and very low birth weight babies  $\leq 1.5\text{kg}$  and with  $\leq 34$  weeks

| Clinical characteristics         |                          | Frequency | %    |
|----------------------------------|--------------------------|-----------|------|
| Sex                              | Male                     | 34        | 31.8 |
|                                  | Female                   | 73        | 68.2 |
| Gestational weeks                | 28-30                    | 36        | 33.6 |
|                                  | 31-32                    | 36        | 33.6 |
|                                  | 33-34                    | 35        | 32.7 |
| Birth weight (kg)                | 0.600-1.2                | 39        | 36.4 |
|                                  | 1.201-1.5                | 68        | 63.6 |
| Weight for gestational age       | SGA                      | 44        | 41.1 |
|                                  | AGA                      | 63        | 58.9 |
| Duration of hospital stay (days) | 1-20                     | 85        | 79.4 |
|                                  | 21-60                    | 22        | 20.6 |
| Type of pregnancy                | Single                   | 75        | 70.1 |
|                                  | Twin                     | 24        | 22.4 |
|                                  | Triplets and quadruplets | 8         | 7.4  |

There were a lot of morbidities that can contribute to extrauterine growth restriction in the study group listed in Table 3, including hyaline membrane disease (HMD), which was represented in 77.6% of premature infants.




**Table (3):** Postnatal factors among premature babies


| Clinical characteristics                 |     | Frequency | %    |
|--|-----|-----------|------|
| HMD<br>Missed 2 cases                    | Yes | 83        | 77.6 |
|  | No  | 22        | 20.6 |
| Sepsis                                   | Yes | 23        | 21.5 |
|  | No  | 84        | 78.5 |
| NEC                                      | Yes | 6         | 5.6  |
|  | No  | 101       | 94.4 |
| ventilator support                       | Yes | 6         | 5.6  |
|  | No  | 101       | 94.4 |
| Bubbling CPAP                            | Yes | 45        | 42.1 |
|  | No  | 62        | 57.9 |
| Apnoea                                   | Yes | 19        | 17.8 |
|  | No  | 88        | 82.2 |
| BPD                                      | Yes | 1         | 0.9  |
|  | No  | 106       | 99.1 |
| Maternal hypertension<br>Missed 64 cases | Yes | 24        | 22.4 |
|  | No  | 19        | 17.8 |

-The estimation of EUGR in our study was at two groups of age: at discharge and 40 weeks corrected age. A total of 85 (79%) of infants had EUGR

at discharge (Figure. 3), compared to 63 (58.8%) of premature babies who had EUGR at 40 weeks (Figure. 4).



**Figure.3:** Frequency of EUGR according to weight at discharge



**Figure 4:** Frequency of EUGR according to weight at 40-week corrected age

Clinical characteristics of EUGR and non-EUGR at discharge: The females were more in the EUGR group (57) than the males, but the sex was negatively correlated to EUGR. Significant differences between EUGR and NON-EUGR groups were identified for the smaller birth weight (SGA) ( $p=0.000$ ),

longer stay in hospital ( $p=0.007$ ), lower birth weight ( $p=0.01$ ), premature birth from multiple pregnancy ( $p=0.03$ ) (whether twin, triplets, or quadruplets), and 33-34 gestational weeks ( $p=0.001$ ). All were statistically related to EUGR (Table 4).

**Table (4):** Association between clinical characteristics and EUGR at discharge:

| Clinical characteristics        |                          | EUGR | No EUGR | X <sup>2</sup> | P-value |
|---------------------------------|--------------------------|------|---------|----------------|---------|
| Sex                             | Male                     | 28   | 6       | 0.259          | 0.611   |
|                                 | Female                   | 57   | 16      |                |         |
| Gestational weeks               | 28-30                    | 23   | 13      | 14.823         | 0.001** |
|                                 | 31-32                    | 27   | 9       |                |         |
|                                 | 33-34                    | 35   | 0       |                |         |
| Birth weight (kg)               | 0.600-1.2                | 36   | 3       | 6.222          | 0.01**  |
|                                 | 1.201-1.5                | 49   | 19      |                |         |
| Weight for gestational age      | SGA                      | 44   | 0       | 19.342         | 0.000** |
|                                 | AGA                      | 41   | 22      |                |         |
| Duration of hospital stay(days) | 1-20                     | 63   | 22      | 7.168          | 0.007** |
|                                 | 21-60                    | 22   | 0       |                |         |
| Type of pregnancy               | Single                   | 59   | 16      | 6.46           | 0.03**  |
|                                 | Twin                     | 22   | 2       |                |         |
|                                 | Triplets and quadruplets | 4    | 4       |                |         |



The clinical characteristics of EUGR and non-EUGR at 40 weeks: smaller for gestational age (SGA) ( $p=0.02$ ), lower birth weight ( $p=0.005$ ), and longer stay in hospital ( $p=0.01$ ) were significantly associ-

ated with EUGR. whereas sex, gestational age, and multiple gestation were negatively correlated to EUGR (Table 5).

**Table (5):** Association between clinical characteristics and EUGR at 40 weeks corrected ages

| Clinical characteristics   |                          | EUGR | No EUGR | X <sup>2</sup> | P-value |
|----------------------------|--------------------------|------|---------|----------------|---------|
| Sex                        | Male                     | 23   | 10      | 1.64           | 0.439   |
|                            | Female                   | 40   | 29      |                |         |
| Gestational weeks          | 28-30                    | 21   | 11      | 5.886          | 0.208   |
|                            | 31-32                    | 20   | 15      |                |         |
|                            | 33-34                    | 22   | 13      |                |         |
| Birth weight               | 0.600-1.2                | 31   | 7       | 10.77          | 0.005** |
|                            | 1.201-1.5                | 32   | 32      |                |         |
| Weight for gestational age | SGA                      | 32   | 12      | 7.653          | 0.02**  |
|                            | AGA                      | 31   | 27      |                |         |
| Duration of hospital stay  | 1-20                     | 44   | 37      | 9.241          | 0.01**  |
|                            | 21-60                    | 19   | 2       |                |         |
| Type of pregnancy          | Single                   | 43   | 4       | 4.24           | 0.374   |
|                            | Twin                     | 17   | 0       |                |         |
|                            | Triplets and quadruplets | 3    | 1       |                |         |

Postnatal risk factors for EUGR at discharge and 40 weeks corrected age: there was a significant association between EUGR and history of sepsis at

discharge and at 40 weeks ( $X^2 = 4.715$ ,  $p = 0.03$ ) and ( $X^2 = 13.52$ ,  $p = 0.001$ ), respectively (Table 6) (Table 7).

**Table (6):** Association between the postnatal risk factors and EUGR at discharge:

| Risk factors                             |     | EUGR | No EUGR | X <sup>2</sup> | P-value |
|--|-----|------|---------|----------------|---------|
| HMD<br>Missed 2 cases                    | Yes | 64   | 19      | 0.899          | 0.343   |
|  | No  | 19   | 3       |                |         |
| sepsis                                   | Yes | 22   | 1       | 4.715          | 0.03**  |
|  | No  | 63   | 21      |                |         |
| NEC                                      | Yes | 5    | 1       | 0.059          | 0.808   |
|  | No  | 80   | 21      |                |         |
| ventilator support                       | Yes | 6    | 0       | 1.645          | 0.200   |
|  | No  | 79   | 22      |                |         |
| Bubbling CPAP                            | Yes | 34   | 11      | 0.717          | 0.397   |
|  | No  | 51   | 11      |                |         |
| Apnoea                                   | Yes | 17   | 2       | 1.424          | 0.233   |
|  | No  | 68   | 20      |                |         |
| BPD                                      | Yes | 1    | 0       | 0.261          | 0.609   |
|  | No  | 84   | 22      |                |         |
| Maternal hypertension<br>Missed 64 cases | Yes | 18   | 6       | 5.028          | 0.08    |
|  | No  | 12   | 7       |                |         |

**Table (7):** Association between the postnatal risk factors and EUGR at 40 weeks corrected ages

| Risk factors          |     | EUGR | No EUGR | X <sup>2</sup> | P-value |
|-----------------------|-----|------|---------|----------------|---------|
| HMD                   | Yes | 50   | 29      | 0.270          | 0.874   |
|                       | No  | 12   | 9       |                |         |
| Sepsis                | Yes | 21   | 1       | 13.52          | 0.001** |
|                       | No  | 42   | 38      |                |         |
| NEC                   | Yes | 5    | 1       | 1.625          | 0.444   |
|                       | No  | 58   | 38      |                |         |
| ventilator support    | Yes | 4    | 2       | 0.379          | 0.827   |
|                       | No  | 59   | 37      |                |         |
| Bubbling CPAP         | Yes | 30   | 13      | 2.026          | 0.363   |
|                       | No  | 33   | 26      |                |         |
| Apnoea                | Yes | 14   | 4       | 2.380          | 0.304   |
|                       | No  | 49   | 35      |                |         |
| BPD                   | Yes | 1    | 0       | 0.705          | 0.703   |
|                       | No  | 62   | 39      |                |         |
| Maternal hypertension | Yes | 15   | 8       | 6.97           | 0.137   |

## DISCUSSION

Our study evaluated how much the EUGR was a frequent challenge between our premature babies, especially those who were extremely and VLBW babies, and for associated clinical characteristics and morbidities as risk factors for EUGR.

Females were most frequent in the study group of premature babies, most of them with smaller gestational ages of 28-32 weeks. The females and the mean gestational age in our study are exactly the same as those in the study done in Ethiopia by Gidi et al. (20). However, in other studies, the same range of gestational ages and mean birth weights were observed, but in contrast to our study, the males were more involved (16, 21-23). In some other studies, higher birth weights were observed (7, 20, 23). The mean of head circumference at birth, at discharge, and at 40 weeks was the same as mentioned by other studies (16, 24), but differs from measurements mentioned by others (26); the head circumference was smaller, as this study was done in extremely premature babies only, those with weights less than 1000 grams. Hospital stays for most premature babies were long, but to avoid the risk of complications like infection and parental separation,

most centers tend to limit the duration of hospital stays. In our situation the bed capacity is one of our limitations in the duration of admission. In the study the majority stayed less than 3 weeks and maybe less, especially those with high gestational age or higher weight, as in some studies (7, 20); in contrast, there were premature babies who stayed for nearly 2 months in the unit; it was because of the development of complications like sepsis, apnea, or failure to gain weight (16, 22, 24, 25).

However, the most common morbidity in the study was respiratory distress syndrome (RDS), as in some studies (23, 24), and another was done in Korea by Lee et al. (25), which is a common risk facing premature babies in the NICU. Now it is becoming less common with the advancement of treatment like manufactured surfactant. Other morbidities have become more prevalent, like sepsis, which was mentioned as the first common morbidity in a study done by Liao et al. (21) and the second in other studies (24). In other studies, other morbidities were reported in large numbers, like hypothermia (20) and retinopathy of prematurity (ROP).

Extra-uterine growth restriction (EUGR) is defined as the growth measurement of weight, length, and



head circumference below the 10th percentile of expected intrauterine growth at postmenstrual age (PMA) at discharge, 36 weeks, or 40 weeks corrected age. In our study we estimated the EUGR between the study group at discharge and 40 weeks corrected age. The results showed that EUGR was higher at discharge (79.4%) as compared to 40 weeks corrected age, which was 58.9%. This decreasing of EUGR at 40 weeks can be explained because most of the babies at this age were at home, as the premature baby stayed at home under the care of their parents, and with good social parental bonding, usually the chance to accept good weight before reaching 40 weeks is high. On the other hand, during the early days of admission, most premature babies, especially with lower birth weight and lower gestational age, had poor weight gain at discharge, which can be attributed to a lot of challenges they faced during admission, and that was reported in the study done in Spain as compared to studies conducted by others where 77% had EUGR at discharge, and it mentioned that it occurred in the first early period of admission (16). Either EUGR at discharge or at 40 weeks, the frequency is still high, and one of the important issues related to that is the delay in initiation of aggressive feeding, either enteral or parenteral, in most NICUs worldwide (7, 21-24). Some meta-analyses and studies found that EUGR was because the infants were receiving less protein and fewer calories (unaggressive feeding protocol) than that recommended by guidelines from international societies. Another cause is lack of breast milk fortification. Morbidities like BPD, IVH, NEC, and ROP (retinopathy of prematurity) represent other causes of EUGR. This can be overcome by increasing the calories up to 160 kcal/kg/day, protein to 4.5 g/kg/day, glucose up to 12.5 upto 12.5g/kg/day, fat to 8 g/kg/day (14).

There were a lot of clinical characteristics that were significantly associated with risk of EUGR as compared to the non-EUGR group for discharge weight; they included birth weight, gestational age, weight for gestational age, duration of hospital stay, and multiple pregnancy. For weight at 40 weeks,

birth weight, weight for gestational age, and duration of hospital stay were the factors significantly associated with EUGR, but multiple pregnancy and gestational age weren't. This is in line with a previous study done in Shanghai by Shan et al. that revealed the duration of hospital stay, birth weight, gestational age, and SGA are positively correlated to the development of EUGR in premature babies (7). Another study in Taiwan reported that especially extremely low birth weight had poorer growth outcomes (21). Lower birth weight, SGA, and lower gestational age were mentioned in a lot of studies as risk factors for EUGR (16, 20, 22, 24, 25). Because premature babies, especially those weighing less than 1500 grams, take longer to achieve full demand of feeding, that is why now faster aggressive feeding is recommended to get the target of optimal growth for premature babies for good neurodevelopmental outcome, not only for gaining weight. A study done by Burçin İşcan reported in his study that the EUGR group took longer to achieve total enteral nutrition than the Non-EUGR group (26). However, in our study, females were more frequent in the EUGR group, but the sex was negatively correlated with risk for EUGR both at discharge age and 40 weeks, which also was detected by a lot of studies done in other countries (20, 21, 24).

Regarding postnatal morbidities that occur due to a lot of complications that premature babies face in the NICU because of long hospital stays, which increase the risk of EUGR, sepsis was a significant risk factor for EUGR. actually that was one of the causes that lead to delay in initiation of feeding to premature particularly with extremely birth weight and very low birth weight and that increase the risk of EUGR in NICU, in the study was done by Lee et al 2799 infants was enrolled and conducted from 2013 to 2014 ,sepsis reported as positively correlated risk factor for EUGR in addition to respiratory distress syndrome and broncho-pulmonary dysplasia which both unlike in our study were not revealed significantly effected on EUGR(22) which are still common causes of admission and long stay of hospital for premature , sepsis demonstrated as

significant factor for EUGR also in line with other researches were done in in china as prospective multi-center ,study in USA and in Turkey (23,24 ,26)

## CONCLUSION

Extra-uterine growth restriction is one of the challenges facing the outcome of premature babies that survive, which is not a matter of weight gain but rather its relation to neurodevelopmental outcome for preterm babies who survive. It needs encouragement to start feeding, especially in critically ill infants, for whom a lot of research has proved that the benefits of early initiation of feeding outweigh the harm.

## RECOMMENDATIONS

It needs more efforts to support optimal nutrition, rapid aggressive initiation of good nutrition, and avoidance of fear of increased feeding when needed for good neurodevelopmental outcomes. advice for updating the feeding protocol and implementing it in NICUs. With new evidence that enteral feeds have a strong role and are superior to parenteral nutrition, this will support premature nutrition and overcome the unavailability of the parenteral one. We need extended research for the outcome after updating and implementing the feeding protocol.

## ACKNOWLEDGMENT

We thank the team of the neonatal clinic who did and still do all their efforts to follow up premature babies and record the data, which is important to complete our target from the study.

Conflict of interest:

We declare that there was no conflict of interest or any financial or nonfinancial support.

## REFERENCES

- (1) Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: Changes in practice and outcome during the first15 years.Semin Perinatol 2003;27:281-7 .
- (12) Patel RM, Kandefor S, Walsh MC, Bell,EF., Carlo, WA., Laptook, AR., Sanches,PJ., Shankaran, S., Merus, KP., Ball, MB., Hale,EC., Newman,NS., Das,A., Haggins,RD., Stoll, BJ . Causes and timing of death inextremely premature infants from 2000 through 2011. N Engl J Med2015; 372:331–40.
- (3) Clark RH, Thomas P, Peabody J. Extrauterine growth restriction remains a serious problem in prematurely born neonates. Pediatrics 2003;111:986–90.
- (4) Embleton NE, Pang N, Cooke RJ. Postnatal malnutrition and growth retardation: an inevitable consequence of current recommendations in preterm infants? Pediatrics 2001;107: 270e3.
- (5) Lin HY, Huang FK, Lin MH, Chiu HY, Lin HC, Su BH. Extrauterine growth restriction in very preterm infants. Annual Meeting of Taiwan Pediatric Association 2012;53:196.
- (6) Ehrenkranz RA, Younes N, Lemons JA, Fanaroff AA, Donovan EF,Wright LL, Katsikiotis, V., Tyson, JE., Oh,W., Shankaran, S., Bauer, CR., Korones, SB., Stoll, BJ., Stevenson,DK., Papile, LA. Longitudinal growth of hospitalized very low birth weight infants. Pediatrics. 1999;104:280--9
- (7) Shan HM, Cai W, Cao Y, Fang BH, Feng Y. Extra-uterine growth retardation in premature infants in Shanghai: a multicenter retrospective review. Eur J Pediatr. 2009;168:1055---9.
- (8) Ehrenkranz RA. Early aggressive nutritional management for very low birth weight infants: what is the evidence? Semin Perinatol.2007;31:48-55
- (9) McCallie KR, Lee HC, Mayer O, Cohen RS, Hintz SR, Rhine WD. Improved outcomes with a standardized feeding protocol for very low birth weight infants. J Perinatol.2011;31:S61-7
- (10) Ehrenkranz RA. Periviable Birth Workshop: obstetrical & neonatal considerations. Ongoing NICU issues:nutrition, prevention of bronchopul-



- monary dysplasia& nosocomial infection . Semin perinatal. 2013: in press
- (11) Dinerstein A, Nieto RM, Solana CL, Perez GP, Otheguy LE, Larguia AM. Early and aggressive nutritional strategy(parenteral and enteral) decreases postnatal growth failure in very low birth weight infants. *J Perinatol.*2006;26:436-42
- (12) Patole SK, De Klerk N. Impact of standardized feeding regimens on incidence of neonatal necrotizing enterocolitis: a systematic review and meta-analysis of observational studies. *Arch Dis Child Fetal Neonatal Ed.*2005;90:F147-51.
- (13) Bai-Horng Su. Optimizing nutrition in preterm infants. *Pediatrics and Neonatology.*2014;55:5-13
- (14) Gounaris A K, Soukou R , Gounari EA, Pangioutounakou P, Grivea NJ.Extrauterine growth restriction and optimal growth of very preterm neonates: State of the Art.*Nutrients.*2023. <https://doi.org/10.3390/nu15143231>
- (15) Matsubara R, Yonezawa K, Haruna M, Usui Y, Yokota S, Takahashi N,Kashima k, Ito A. Factors associated with extrauterine growth restriction in very low birth weight infants: A retrospective study in Japan. *pediatric and Neonatology.*2025. <https://doi.org/10.1016/j.pedneo.2025.010>
- (16) Avila-Alvarez A, Boga AS, Bermudez-Hormigo C, Carballala, JF. Extrauterine growth restriction among neonates with birth weight less than 1,500 grams. *An Pediatr(Barc)* 2018;89:325-32.
- (17) Pampanini V, Boiani A, Marchis CD, Giacomozzi, R, Agostino R, Dini F, Ghiri P, Cianfarani S. Preterm infants with sever extrauterine growth restriction (EUGR) are at high risk of growth impairment during childhood,*Eur J Pediatr* 2015; 174:33-41
- (18) Bozzetti v,Dui GL, Zennin E, Ricco S, Coglinese P, Cavalleri v, Iozzi L, Ventura LM, Ferrante S.AI to predict extrauterine growth restriction during transitional nutrition of preterm infants: retrospective study.*J of perinatology* 2025; <https://doi.org/10.1038/s41372-025-02445-4>
- (19)IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp; 2015.
- (20) Gidi NW , Goldenberg R L , Nigussie A K, Clture E M , Mekasha A, Worku Bo, Siebeck M , Genzel-Boroviczeny O , Muhe L .Incidence and associated factors of extrauterine growth restriction in preterm infants, a cross sectional study in selected NICUS in Ethiopia. *BMJ paediatrics* 2020; 4:e000765.doi:10.1136/bmjbo-2020-000765
- (21) Liao W-L , Lin M-C , Wang T-M , Chen C-H .Taiwan Premature Infant follow-up Network. Risk factors for post discharge growth restriction among very-low-birth-weight: A nationwide registry study in Taiwan. *Paediatric and Neonatology.*2019, <https://doi.org/10.1016/j.pedneo.2019.03.004>
- (22) Zhao X , Ding L , Chen X , Zhu X , Wang J . Characteristic and risk factors for extrauterine growth restriction in very-low-birth-weight infants. *Medicine.*2020; 99:47
- (23) Wang Y, Shen W, Wu F, Mao J, Liu L , Chang Y-M , Zhang R , Ye X- Z , Qiu Y-P, Ma L, Cheng R, Wu H , Chen D-M , Zheng Z , Lin X-Z , Tong X-M . The national multi-center Eugr Collaborative Group. Factors influencing extrauterine growth restriction in singlton-non-small for gestational age infants in China: A prospective multi-center study. *Paediatric and Neonatology.*2022. Published by Elsevier Taiwan. <https://doi.org/10.1016/j.pedneo.2022.04.013>
- (24) Makkker K, Ji Y, Hong X, Wang, X. Antenatal and neonatal factors contributing to extrauterine growth failure (EUGR) among preterm infants in Boston Birth Cohort( BBC). *Journal of perinatology.*2021 41:1025-1032. <http://doi.org/10.1038/s41372-021-00948-4>
- (25) Lee SM, Kim N, Namgung R, Park M, Park K, Jeon J .Prediction of postnatal growth failure among very low birth weight infants. *Scientific report.*2018 8: 3729. Doi: 10.1038/s41598-018-21647-9
- (26) İscan B. Postnatal growth and extrauterine growth retardation (EUGR) in extremely low gestational age newborns(ELGANS) with 2-year follow up. *Trends in pediatric.*2025;(6) 1:33-39.DOI: 10.59213/TP .2025.206.



Placenta Accreta Spectrum: Epidemiology, Risk Determinants, and Clinical Consequences in Benghazi Medical Centre -2022.

Omaima H. Getlawi <sup>1\*</sup>, Maisa M. Muttardi <sup>1</sup>, Asmaa B. Salih <sup>1</sup>.

Original Research Article

Abstract

**Background:** Placenta Accreta Spectrum (PAS) is a pregnancy-related disorder characterized by the abnormal adherence of trophoblastic tissue to the uterine myometrium, posing a significant risk of maternal mortality. Key risk factors for PAS include placenta previa and prior cesarean deliveries, which have been rising in frequency.

**Aim:** to explore the risk factors of PAS, incidence, clinical outcomes of affected patients, and strategies to minimize maternal morbidity and mortality.

**Method:** prospective cohort study conducted on 60 patients during the year 2022 in Benghazi Medical Centre including all patients labeled as PAS cases, Review of records for all patients using the structured data collection sheet. The total number of deliveries, caesarean deliveries, maternal and perinatal deaths had been registered; patients were followed up till delivery.

**Results:** Mean age of the studied group was  $35.37 \pm 5.70$ , 43.3 % of them were multipara, 56.7% with previous cesarean section three or more times, 71.7% of the studied group with grade III placenta previa, 95.0% experienced some complication, after multivariate analysis C.S 3 times and more is considered risk factor for hysterectomy (p value = 0.03) (OR 6.12, 95% CI (1.15-32.59)), there was statistical significant association between CS delivery and length of hospital stay (p value =0.005).

**Conclusion:** Incidence of placenta accreta increases with advanced age, with multipara and with 3 times and more CS. Placenta previa was coexisting factor in 95% of the cases.

**Keywords:** Placenta accrete, incidence, Risk factors, complications.

<sup>1</sup>.Department of Obstetrics and Gynecology, Faculty of Medicine, University of Benghazi, Benghazi, Libya.

\*Corresponding author: Omaima H. Getlawi, Email: [algetlawi@uob.edu.ly](mailto:algetlawi@uob.edu.ly).



## INTRODUCTION

Placenta accreta is the abnormal invasion of placental trophoblasts into the uterine myometrium and this comprises a spectrum of disorders, based on the degree of myometrial invasion; including placenta accreta, placenta increta, and placenta percreta, and recognized as placenta accreta spectrum disorders<sup>(1)</sup>. Due to the risk of excessive hemorrhage and difficulty in hemostasis, they are associated with increased maternal morbidity and mortality and an interprofessional team should take care for these patients. The incidence of the condition increases with increasing rate of caesarean deliveries. Anyhow, some other factors are related<sup>(2)</sup>. The International Federation of Gynecology and Obstetrics (FIGO) introduced a grading system for placenta accreta spectrum (PAS) disorders, replacing the previous terms (placenta accreta, increta, and percreta)<sup>(3)</sup>. With the rising frequency of cesarean deliveries, the incidence of placenta accreta has surged, increasing from 1 in 30,000 pregnancies in the 1960s to 1 in 533 in the 2000s, and as high as 1 in 272 according to one study<sup>(4,5)</sup>. The risk of developing placenta accreta is strongly correlated with the number of prior cesarean sections, with an odds ratio exceeding 22 for those with five previous cesareans compared to none<sup>(6)</sup>. Placental adhesions are thought to be caused by the placenta adhering to a defective site in the decidua. Histological diagnosis of placenta accreta spectrum (PAS) disorders provides definitive confirmation, revealing varying degrees of trophoblast invasion and a higher prevalence of trophoblastic inclusions compared to normal placentation<sup>(7)</sup>. However, other factors warrant increasing attention as well, including advancing maternal age, fertility treatments, and gynecologic surgery. Defining the full clinical range of this condition may impact preconception patient management and reproductive decision making. In addition, as efforts to reduce hemorrhagic morbidity have shifted to predelivery risk stratification, understanding the full range of accreta risk factors should improve proactive management of this severe condition.<sup>(5)</sup> Advancements in medical imaging, particularly ultra-

sound technology, have made it a crucial component of routine antenatal care for most pregnant women<sup>(8)</sup>. Ultrasonography is now fundamental in assessing the fetus, placenta, umbilical cord, and amniotic fluid. The antenatal diagnosis of placenta accreta is typically made through ultrasound, aiding in management planning<sup>(9)</sup>. It is important to discuss the consequences or results of having placenta accrete spectrum disorders, both for the mother and the fetus, our research aims to investigate the incidence and determine the risk factors of placenta accrete spectrum disorders and evaluate management and outcomes of cases among deliveries.

## METHODS

**Study Setting, Design, and Sampling** This a prospective cohort study conducted during the year 2022 in department of obstetrics and gynaecology in Benghazi Medical Centre (BMC). Our inclusion criteria encompassed all patients prenatally diagnosed with PAS disorders using ultrasound, Doppler, and magnetic resonance imaging (MRI). We excluded patients with impaired liver or renal function, coagulation disorders, spontaneous intraoperative placental separation, other uterine pathologies requiring hysterectomy, and those who declined participation in the study. Our sample was 60 patients after informed consent Patients were followed up till deliveries, all experiments were conducted according to the relevant guidelines and regulations, and the participants were not exposed to any harm or unintended effects. The study adhered to the ethical principles of the Declaration of Helsinki.

## ASSESSMENT MEASURES

### -Review of records for all patients using the structured data collection sheet which include:

The total number of deliveries, caesarean deliveries, maternal and perinatal deaths

### -Pregnant women were asked about the following:

Age, Parity, Previous abortions, history of infertility, uterine surgery or procedures, detection of PAS (weeks of gestational age), Co-morbidities, coexisting placenta Previa and its degree, Antenatal diagnosis (presence of antenatal bleeding or not) and

Placenta description: (Accrete, Increta, Percreta)

**- Outcomes:**

Caesarean delivery Planned (Yes, No), Caesarean delivery (Elective Emergency), Method of placenta removal, Need for blood transfusion (Yes, No), Hysterectomy (Yes, No), Bladder injury: (Yes, No), Hospital stays in days, Critical care admission (Yes, No), Death (Yes, No) early neonatal death (Yes, No).

**ETHICAL CONSIDERATIONS**

Confidentiality of data was assured using anonymous form of data collection. No interventions and no other use for data. Legal access for the data through alleged administrative permission.

**STATISTICAL ANALYSIS**

Data was analyzed using statistical package for social science (SPSS) version 26. Descriptive statistics as frequency and percentage. Inferential statistics were applied when needed Chi-square( $X^2$ ), t test and Student t test (or Mann-Whitney U test for non-normally distributed data) to find the difference in the distribution of the variables between the internal comparison groups, P-value was considered

significant when  $\leq 0.05$ . Data was presented in form of tables.

**RESULTS**

Our study includes 60 patients with placenta accreta, age of patients ranges from (20-44) years, with mean age group was  $35.37 \pm 5.70$ , 38.3% of the studied group with OMA, 31.7% of the studied group with AMA and 30.0 % VAMA (Table 1).

Our results detected that 43.3 % of the studied group were multipara, 88.3% of studied group with previous abortion, 56.7% of them with previous cesarean section three or more times, 71.7% of the studied group with grade III placenta previa, 96.7% no history of infertility, and 13.3% of them with history of Evacuation and curettage (Table 1).

Regarding other related Comorbidities, we found anemia (11.7%), hypertension (8.3%), bronchial asthma (3.3%), diabetes (3.3%) and Thromboembolic disorders.

The majority of women (95.0%) experienced composite complications, 33.3% of them had hysterectomy, 21.7% of them had critical care admission, 20% with bladder injury (Table, 1).

**Table (1):** Demographic data and clinical history of the studied cases:

| Variable                                 |                           | N  | %    |
|--|---------------------------|----|------|
| Age:                                     | OMA*                      | 23 | 38.3 |
|  | AMA*                      | 19 | 31.7 |
|  | VADA*                     | 18 | 30.0 |
| Parity                                   | Multipara                 | 26 | 43.3 |
|  | Not multipara             | 34 | 56.7 |
| History of abortion                      | No history of abortion    | 7  | 11.7 |
|  | History of ab abortion    | 53 | 88.3 |
| Number of CS                             | One                       | 7  | 11.7 |
|  | Two                       | 19 | 31.7 |
|  | Three or more             | 34 | 56.7 |
| History of infertility                   | No history of infertility | 58 | 96.7 |
|  | History of infertility    | 2  | 3.3  |
| Myomectomy                               | -None                     | 1  | 1.7  |
|  | -Myomectomy               | 59 | 98.3 |
| History of Evacuation and curettage      | None                      | 52 | 86.7 |
|  | Once                      | 5  | 8.3  |
|  | Twice                     | 2  | 3.3  |
|  | three                     | 1  | 1.7  |
| Comorbidities and pregnancy complication | Anemia                    | 7  | 11.7 |
|  | Asthma                    | 2  | 3.3  |
|  | Thromboembolic            | 1  | 1.7  |
|  | Diabetes                  | 2  | 3.3  |
|  | Hypertension              | 5  | 8.3  |



| Variable                            |                              | N  | %    |
|-------------------------------------|------------------------------|----|------|
| Obstetric Complication              | -Co-existing Placenta Previa | 57 | 95.0 |
|                                     | -Active Antepartum bleeding  | 13 | 21.7 |
|                                     | -Polyhydramnios              | 2  | 3.3  |
|                                     | -GDM**                       | 3  | 5.0  |
|                                     | -PIH**                       | 1  | 1.7  |
| Grade of Coexisting Placenta Previa | -Grade I                     | 8  | 13.3 |
|                                     | -Grade II                    | 6  | 10.0 |
|                                     | - Grade III                  | 43 | 71.7 |

\*OMA: Optimal maternal age, \*AMA: Advanced maternal age \* VAMA: very advanced maternal age.

\*\*GDM: gestational diabetes, \*\* PIH: pregnancy induced hypertension

Fifty five percent of the studied sample with Elective Cesarean section, most of our studied group

(93.3%) with placenta increta and accrete, 95% with composite maternal complication (Excessive hemorrhage over 1500 ml, relaparotomy, injuries to adjacent viscera and Disseminated Intravascular Coagulation) ,most of sample have no perinatal deaths (85%), only 11.7 % has early neonatal death (Table, 2).

**Table (2):** Delivery data and Outcome of pregnancy of the studied group:

| Variable                           |                               | N  | %    |
|------------------------------------|-------------------------------|----|------|
| Cesarean section                   | Planned                       | 42 | 70   |
|                                    | Unplanned                     | 18 | 30.0 |
| Actual setting of Cesarean section | Elective                      | 33 | 55.0 |
|                                    | Emergency                     | 27 | 45.0 |
| Placenta Accrete spectrum          | Percreta                      | 4  | 6.7  |
|                                    | Other type (increta- Accrete) | 56 | 93.3 |
| Maternal Outcome                   | -Composite Maternal outcome*  | 57 | 95.0 |
|                                    | -Maternal death               | 2  | 3.3  |
|                                    | -Critical care admission      | 13 | 21.7 |
|                                    | -Bladder Injury               | 12 | 20.0 |
|                                    | -Hysterectomy                 | 30 | 33.3 |
|                                    | - Needs for blood transfusion | 57 | 95.0 |
| Perinatal death                    | -No perinatal death           | 51 | 85.0 |
|                                    | -IUFD**                       | 2  | 3.3  |
|                                    | -Early neonatal death         | 7  | 11.7 |

\* Composite Maternal outcome (representing maternal morbidity and/or mortality)

\*\*IUFD: intrauterine fetal death

There is statistical significant association between three or more cesarean section and more hysterectomy (p value =0.002) and after multivariate analysis more than 3 times C.S is considered risk factor for hysterectomy (p value = 0.03) OR (6.12, 95% CI (1.15-32.59) , but there was statistically insignificant relation between advanced age and hysterectomy , in addition there was no relation with (multipara, any abortion, any previous procedures, any Comorbidities, any antepartum bleeding and Grade

III PP) (Table,3).

**Table (3):** Association of Maternal Factors with Hysterectomy

| Factor                      | Hysterectomy |                 |              |                  |
|-----------------------------|--------------|-----------------|--------------|------------------|
|                             | Univariate   |                 | Multivariate |                  |
|                             | P value      | Odd (CI 95%)    | P value      | Odds (CI 95%)    |
| AMA                         | 0.133        | 2.45(0.74-8.05) | -            | -                |
| VAMA                        | 0.55         | 1.42(0.44-4.49) | -            | -                |
| Grand multi                 | 0.01*        | 3.85(1.24-11.9) | 0.44         | 1.23(0.34-4.24)  |
| History of infertility      | 0.31         | 1(0.08-11.7)    | -            | -                |
| Any abortion                | 0.49         | 3.35(0.37-29.9) | -            | -                |
| Any previous procedure      | 0.44         | 1.75(0.41-7.39) | -            | -                |
| Previous three CS plus      | 0.001*       | 7.6(1.93-30.4)  | 0.03*        | 6.12(1.15-32.59) |
| Any comorbidity             | 0.69         | 1.25(0.4-3.93)  | -            | -                |
| Active ante partum bleeding | 0.57         | 0.52(0.12-2.19) | -            | -                |
| Grade III PP                | 0.83         | 0.88(0.27-2.88) | -            | -                |
| Caesarean delivery Planned  | 0.23         | 0.5(0.15-1.57)  | -            | -                |

\*Statistically significant risk factor

Our results showed that, although univariate analysis revealed a significant association between multiparity and urinary bladder injury ( $p = 0.01$ ), this association was not confirmed in the multivariate analysis; therefore, multiparity was not considered

a risk factor for bladder injury. Additionally, no significant associations were found with advanced age, history of infertility, previous abortions, prior procedures, comorbidities, antepartum bleeding, or Grade III placenta previa (Table 4).

**Table (4):** Association of Maternal Factors with Urinary bladder injury

| Factor                      | Urinary bladder injury |                 |              |                  |
|-----------------------------|------------------------|-----------------|--------------|------------------|
|                             | Univariate             |                 | Multivariate |                  |
|                             | P value                | Odd (CI 95%)    | P value      | Odds (CI 95%)    |
| AMA                         | 0.34                   | 2.1(0.51-8.9)   | -            | -                |
| VAMA                        | 0.77                   | 1.21(0.31-4.6)  | -            | -                |
| Grand multi                 | 0.01*                  | 5.47(1.30-22.9) | 0.4          | 1.23(0.34-4.24)  |
| History of infertility      | 1                      | -               | -            | -                |
| Any abortion                | 0.98                   | 1.57(0.17-14.4) | -            | -                |
| Any previous procedure      | 0.99                   | 1.17(0.21-6.52) | -            | -                |
| Previous three CS plus      | 0.006*                 | 11.96(1.43-100) | 0.083        | 2.25(0.78- 7.82) |
| Any comorbidity             | 0.12                   | 2.69(0.73-9.86) | -            | -                |
| Active ante partum bleeding | 0.27                   | 2.16(0.53-8.8)  | -            | -                |
| Grade III PP                | 0.72                   | 0.74(0.19-2.89) | -            | -                |
| Caesarean delivery Planned  | 0.74                   | 0.82(0.21-3.18) | -            | -                |

\*Statistically significant risk factor

Table (5) shows that, based on the multivariate linear regression analysis, there was a statistically significant association between cesarean section (CS)

delivery and length of hospital stay ( $p = 0.005$ ).



**Table (5):** Multivariate linear regression to detect factors related to length of hospital stay

| Factor                      | B       | Wald X <sup>2</sup> | P      |
|-----------------------------|---------|---------------------|--------|
| AMA                         | 21.530  | 2.791               | 0.095  |
| Caesarean delivery Planned  | 22.292  | 8.029               | 0.005* |
| Any previous procedure      | -12.688 | 1.767               | 0.184  |
| Active ante partum bleeding | 15.853  | 3.442               | 0.064  |
| Age                         | -0.846  | 0.593               | 0.441  |
| Intercept**                 | 36.155  | 1.112               | 0.292  |

\*Statistically significant risk factor

\*\*Intercept (pre-existing medical illness, gestational disease like pre-eclampsia and thrombocytopenia)

In addition, there was no obvious risk factors related to composite maternal outcome or perinatal deaths (table, 6)

**Table (6):** Association of Maternal Factors with composite maternal outcome and foetal deaths

| Factor                      | Composite maternal Outcome |                  | Foetal deaths |                  |
|-----------------------------|----------------------------|------------------|---------------|------------------|
|                             | Univariate                 |                  | Univariate    |                  |
|                             | P value                    | Odd (CI 95%)     | P value       | Odds (CI 95%)    |
| AMA                         | 0.55                       | 3.42(0.29- 40.1) | 0.07          | 0.41(0.08-2.07)  |
| VAMA                        | 1.0                        | -                | 0.25          | 0.35(0.03-3.16)  |
| Grand multi                 | 1.0                        | -                | 0.27          | 0.48(0.08- 2.71) |
| History of infertility      | 1.0                        | -                | 0.28          | 8.66(0.47-157.1) |
| Any abortion                | 1.0                        | -                | 1.0           | -                |
| Any previous procedure      | 1.0                        | -                | 1.0           | -                |
| Previous three CS plus      | 0.57                       | 2.75(0.23-32.1)  | 1.0           | -                |
| Any comorbidity             | 1.0                        | -                | 1.0           | -                |
| Active ante partum bleeding | 0.52                       | 0.53(0.04-6.39)  | 1.0           | -                |
| Grade III PP                | 0.19                       | 5.6(0.47-66.3)   | 1.0           | -                |
| Caesarean delivery Planned  | 1.0                        | -                | 0.11          | 0.52(0.10-2.63)  |

## DISCUSSION

Placenta accreta spectrum (PAS) disorders have emerged as a major life-threatening obstetric issue, with its incidence rising from 0.12% to 0.31% over the past 30 years and an associated mortality rate of approximately 7.0%. PAS is also linked to significant maternal morbidity, including the need for massive blood transfusions, urinary tract injuries, hysterectomy, ICU admission, sepsis, and prolonged hospital stays.

Our study includes 60 patients with placenta accreta ,age of patients ranges from (20-44) years mean age group was 35.37±5.70, 38.3% of the studied group with Optimal maternal age, 31.7% of the studied group With Advanced maternal age and 30.0 % advanced maternal age, our results in agreement with El Gelany et al.,<sup>(10)</sup> who found that 32.4±4.2 (23–39) and declared that placenta accreta increase

with age more than 32 years , Several authors have agreed on the findings regarding risk factors for PAS disorders. Fitzpatrick et al. <sup>(11)</sup> identified advanced maternal age as a significant risk factor. Similarly, a 2017 study highlighted that older maternal age, previous cesarean sections, placenta previa, and high parity were independent risk factors for PAS disorders <sup>(12)</sup>. Other researchers have also reported comparable outcomes <sup>(13,14)</sup>.

Our results detected that 43.3 % of the studied group multipara , 88.3% of studied group with previous abortion , 56.7% of them with previous cesarean section three or more times, 71.7% of the studied group with grade III placenta previa , 96.7% no history of infertility, and 13.3% of them with history of Evacuation and curettage , on the same line El Gelany et al.,<sup>(10)</sup> It was found that the risk factors for PAS disorders included having two or more previ-

ous cesarean sections, a parity of three or more, and a prior history of placenta previa. These findings are consistent with those reported by numerous other researchers<sup>(11,13)</sup>.

Numerous previous studies have investigated the risk factors for PAS, primarily focusing on general populations of pregnant women and comparing those with and without the condition. Around half of PAS cases involve a history of one or more cesarean sections and an abnormally positioned placenta, with this combination being identified as a significant risk factor<sup>(11,15,16,17,18)</sup>. These findings have influenced current clinical practice, leading to PAS screening being focused on women with the combination of previous cesarean sections and an abnormally positioned placenta. However, studies have shown that women with PAS differ in characteristics depending on whether they have this combination of risk factors<sup>(18,19)</sup>. Therefore, PAS risk factors may be unique to each subgroup and should be studied separately. It is particularly important to maintain a high level of diagnostic suspicion when placenta previa coexists with a history of cesarean delivery. Silver et al.<sup>(17)</sup> reported that the risk in such cases increases to 40% or more after a third cesarean. In a recent study, one-third of PAS cases involved women with a history of cesarean and placenta previa in the current pregnancy in a study published by Fitzpatrick et al.<sup>(11)</sup>

Regarding other related Comorbidities, we found iron deficiency anemia (11.7%), hypertension (8.3%), bronchial asthma (3.3%), diabetes (3.3%) and Thromboembolic disorders, other studies by Kloka et al.,<sup>(21)</sup> The incidence of "anemia during pregnancy" (90.43% vs. 55.18%;  $p < 0.001$ ), "other forms of anemia" (92.34% vs. 38.0%;  $p < 0.0001$ ), and "anemia due to acute bleeding" (91.93% vs. 35.74%;  $p < 0.001$ ) is significantly higher in women with PAS. Given that PAS is often associated with inadequate iron stores, particularly due to peripartum bleeding, effective iron management during pregnancy is essential<sup>(22)</sup>. National and international Patient Blood Management (PBM) guidelines recommend screening for anemia during the antepar-

tum period and throughout pregnancy whenever anemia is present<sup>(23,24)</sup>.

Majority of women (95.0%) experienced some complication, 33.3% of them do hysterectomy, 21.7% of them had critical care admission, 20% with bladder injury. On the other hand, the study by Birendra et al.,<sup>(25)</sup> declared that hysterectomy was performed in 87.5% of cases, and similarly, in 91.6% of cases in a study conducted at a tertiary center<sup>(26)</sup>. Conservative or expectant management should be reserved for carefully selected PAS patients after thorough counseling about the risks, uncertain benefits, and effectiveness<sup>(27)</sup>. Protocols from the Royal College of Obstetricians and Gynaecologists (RCOG) and the American College of Obstetricians and Gynecologists (ACOG) emphasize the importance of monitoring blood loss, correcting coagulation disorders, and addressing hydro-electrolytic imbalances. Post-operative care in the intensive care unit continues to focus on stabilizing vital signs<sup>(26)</sup>. In another study, a planned cesarean hysterectomy was performed in 67% of prenatally diagnosed PAS cases, which is considered the preferred treatment approach by experts<sup>(28)</sup>.

Our study declared that 11.7% with neonatal death, 3.3% IUFD and 85% no perinatal mortality, other study by Balayla and Bondarenko<sup>(29)</sup> who detected that unfavorable outcomes for neonates, according to a comprehensive evaluation of 34 studies.

There is statistical significant association between three or more cesarean section and more hysterectomy ( $p$  value = 0.002) and after multivariate analysis more than 3 times C.S is considered risk factor for hysterectomy ( $p$  value = 0.03) OR (6.12, 95% CI (1.15-32.59) , but there was statistically insignificant relation between advanced maternal age and hysterectomy , in addition there was no relation with (multipara, any abortion, any previous procedures, any Comorbidities, any antepartum bleeding and Grade III PP. On the same line with other studies which declared that multiple cesarean section increased the risk of PAS approximately five- to six-fold (a OR 5.64, 95% CI 3.01–10.57)<sup>(30)</sup>. Miller et al.'s cohort study demonstrated two to three



times the risk for PAS in multiple cesarean section (adjusted relative risk 2.96, 95% CI 2.23–3.93)<sup>(31)</sup>, which is an important cause of postpartum uterine atony-related hemorrhage that requires critical care and lead to hysterectomy.

Our results detected that after univariate analysis we found significant association between multipara and Urinary bladder injury (p value =0.01) but after multivariate analysis no association so it is not considered as risk factor for bladder injury, in addition there was no relation with (advanced age, history of infertility, any abortion, any previous procedures, any Comorbidities, any antepartum bleeding and Grade III PP).

Regarding length of hospital stay, we found statistically significant relation between CS delivery and Length of hospital stay (P value = 0.004), also after multivariate analysis, there was statistically significant association between CS delivery and length of hospital stay (p value =0.005).

One potential limitation is the lack of histologic confirmation of PAS in cases where hysterectomy was not performed. However, the prospective study design and the use of predefined criteria reduce the risk of false PAS diagnoses. Another limitation is the small sample size of the studied women. Ideally, we would have preferred to compare these risk factors with a control group of women without placenta accreta.

### IN CONCLUSION

Incidence of placenta accreta increases with advanced age, with multipara and with previous three CS plus. Placenta previa was coexisting in 95% of the cases, also associated with antenatal bleeding, outcome of placenta accreta related to some factors as hysterectomy increase among patient with cesarean section more than 3 times. Addressing the growing burden of PAS disorders requires a combination of early detection, appropriate surgical planning,

### RECOMMENDATION

-Early detection and diagnosis through routine Screening for High-Risk Women: Women with known risk factors, such as a history of cesarean sections or placenta previa.

- In need further prospective studied to compare these risk factors with another group without placenta accrete and compare outcome between different grade of placenta accrete.

- It is important to do Histologic confirmation of PAS for the cases without hysterectomies

Conflict of interest:

The authors report no conflicts of interest in this work

### REFERENCES

1. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus, No.7: Placenta Accreta Spectrum. *Obstet. Gynecol.* 2018, 132, e259–e275.
2. Silver RM, Barbour KD. Placenta accreta spectrum: accreta, increta, and percreta. *Obstet Gynecol Clin North Am.* 2015 Jun; 42(2):381–402.
3. Hecht, J.L.; Baergen, R.; Ernst, L.M.; Katzman, P.J.; Jacques, S.M.; Jauniaux, E.; Khong, T.Y.; Metlay, L.A.; Poder, L.; Qureshi, F.; et al. Classification and reporting guidelines for the pathology diagnosis of placenta accreta spectrum (PAS) disorders: Recommendations from an expert panel. *Mod. Pathol.* 2020, 33, 2382–2396.
4. Khong TY. The pathology of placenta accreta, a worldwide epidemic. *J Clin Pathol.* 2008 Dec;61(12):1243–6.
5. Mogos MF, Salemi JL, Ashley M, Whiteman VE, Salihu HM. Recent trends in placenta accreta in the United States and its impact on maternal-fetal morbidity and healthcare-associated costs, 1998-2011. *J Matern Fetal Neonatal Med.* 2016;29(7):1077-82.
6. Silver RM, Abnormal placentation: placenta previa, vasa previa, and placenta accreta. *Obstet Gynecol.* 2015;126(3):654-687.
7. Adler E, Madankumar R, Rosner M, Reznik SE. Increased placental trophoblast inclusions in placenta accreta. *Placenta.* 2014 Dec;35(12):1075-8.
8. Fisher SJ. Why is placentation abnormal in preeclampsia? *Am J Obstet Gynecol.* 2015;213: S115–22.
9. Japaraj RP, Mimin TS, Mukudan K. Antenatal diagnosis of placenta previa accreta in patients with previous cesarean scar. *J Obstet Gynaecol Res.* 2007 Aug; 33(4):431-7.
10. El Gelany SA, Ibrahim EM, Mohammed MM, et al. Management of bleeding from morbidly adherent placenta during elective repeat caesarean section: retrospective -record-based study. *BMC Pregnancy Childbirth.* 2019;19(1): 106.
11. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ,

- Brocklehurst P, et al. Incidence and risk factors for PAS disorders/incrreta/Percreta in the UK: a national case-control study. *PLoS One*. 2012; 7(12):e52893.
12. Farquhar CM, Li Z, Lensen S, et al. Incidence, risk factors and perinatal outcomes for PAS disorders in Australia and New Zealand: a case-control study. *BMJ Open*. 2017;7:e017713.
13. Zhang D, Siqin Y, Yanyan H, Yan S, Haofan S, Wei G. Risk factors, outcome and management survey of PAS disorders in 153 cases: a five-year experience from a hospital of Shanghai, China. *Int J Clin Exp Med*. 2017;10 (8):12509-16.
14. Balayla J, Bondarenko HD. PAS disorders and the risk of adverse maternal and neonatal outcomes. *J Perinat Med*. 2013;41:141-9.
15. Thurn, L. · Lindqvist, P.G. · Jakobsson, M. ...Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries *BJOG*. 2016; 123:1348-1355
16. Miller, D. A., Chollet, J. A. & Goodwin, T. M. Clinical risk factors for placenta previa-placenta accreta. *Am. J. Obstet. Gynecol*. 1997; 177, 210-214.
17. Silver, R. M. et al. Maternal morbidity associated with multiple repeat cesarean deliveries. *Obstet. Gynecol*.2006; 107, 1226-1232.
18. Bowman ZS, Manuck TA, Eller AG, et al. Risk factors for unscheduled delivery in patients with placenta accreta. *Am J Obstet Gynecol* 2014; 210(3): 241.e1-241.e6.
19. Kayem, G. et al. Clinical profiles of placenta accreta spectrum: the PACCRETA population-based study. *BJOG* 128, 1646-1655 (2021)..
20. Hessami, K. et al. Clinical correlates of placenta accreta spectrum disorder depending on the presence or absence of placenta previa: A systematic review and meta-analysis. *Obstet. Gynecol*.2022; 140, 599-606.
21. Kloka JA, Friedrichson B, Jasny T, Blum LV, Choorapoikayil S, Old O, Zacharowski K, Neef V. Anaemia and red blood cell transfusion in women with placenta accreta spectrum: an analysis of 38,060 cases. *Sci Rep*. 2024 Feb 29;14(1):4999.
22. Matalliotakis M, Velegrakis A, Goulielmos GN, Niraki E, Patelarou AE, Matalliotakis I. Association of placenta previa with a history of previous cesarian deliveries and indications for a possible role of a genetic component. *Balkan J Med Genet*. 2017;20:5-10.
23. Muñoz M, Peña-Rosas JP, Robinson S, et al. Patient blood management in obstetrics: Management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. *Transfus Med*. 2018;28(1):22-39.
24. National institute for Health and Care Excellence (NICE). Antenatal Care. <https://www.nice.org.uk/guidance/ng201/resources/antenatal-care-pdf-66143709695941>. (2021).
25. Birendra R, Jigyasa S. A Retrospective Study of Maternal and Neonatal Outcome in Placenta Accreta Spectrum After Planned or Emergency Delivery From a Tertiary Care Centre in North India. *Cureus*. 2023 Sep 5;15(9):e44725.
26. Varlas VN, Bors RG, Birsanu S, Maxim B, Clotea E, Mihailov M. Maternal and fetal outcome in placenta accreta spectrum (PAS) associated with placenta previa: a retrospective analysis from a tertiary center. *J Med Life*. 2021;14:367-375.
27. Horgan R, Abuhamad A. Placenta accreta spectrum: Prenatal diagnosis and management. *Obstet Gynecol Clin North Am*. 2022;49: 423-438.
28. Bluth A, Schindelbauer A, Nitzsche K, Wimberger P, Birdir C. Placenta accreta spectrum disorders-experience of management in a German tertiary perinatal centre. *Arch Gynecol Obstet*. 2021;303:1451-1460.
29. Balayla J, Bondarenko HD. Placenta accreta and the risk of adverse maternal and neonatal outcomes. *J Perinat Med*. 2013;41:141-149.
30. Huanyu Y, Yan W, Rui H, Jinyu G, Lin Z, Yangyu Z. Risk factors for placenta accreta spectrum without prior cesarean section: A case-control study in China. 2024;166 (3) :1092-1099.
31. -Miller HE , Leonard SA , Fox KA , Carusi DA, Lyell DJ. Placenta accreta spectrum among women with twin gestations. *Obstet Gynaeco*.2021; 137(1): 132- 138 .



## Histopathological evaluation of prostate biopsy in-patient with Prostate cancer in Benghazi Medical Center in the period between 2020-2023.

Ghazala A. Alfitorei<sup>1</sup>, Manal F. Yaya<sup>1\*</sup>, Amerna moftah<sup>2</sup>  
Aya farag<sup>2</sup>, Najah abdalsallam<sup>2</sup>, Negeia Rezqallah<sup>2</sup>.

### Original Research Article

#### Abstract

This descriptive, cross-sectional study was conducted at Benghazi Medical Center (BMC), Benghazi, Libya. Data were collected from the medical records of 81 patients diagnosed with prostate cancer who were admitted to the oncology department between January 2020 and December 2023. The aim of this study was to describe the demographic, clinical, and histopathological characteristics of prostate cancer patients.

**Results:** The mean age of the patients was 71.6 years, and 83% of cases occurred among those aged 71–80 years. Overall, 19.8% of patients were smokers. Nine patients (11.1%) had diabetes mellitus, one patient (1.2%) had hypertension, and approximately 84% reported no family history of prostate cancer. Histopathological examination revealed adenocarcinoma in different stages of differentiation, with acinar adenocarcinoma accounting for 95% of cases and ductal adenocarcinoma for 2.5%. Most adenocarcinoma cases presented as Grade I (44.4%), followed by Grades II and IV (17.3% each).

**Conclusion:** The study demonstrated that most cases occurred in older patients and were diagnosed at an early stage. Acinar adenocarcinoma was the predominant histopathological type, and the low rate of metastasis suggests a favorable prognosis.

**Keywords:** prostate cancer, adenocarcinoma, PSA, Libyan males, Benghazi, histopathology.

<sup>1</sup>.Department of Histology, Faculty of Medicine, University of Benghazi.

<sup>2</sup>.Department of Cytotechnology, Faculty of biomedical science, University of Benghazi.

\*Corresponding author: Manal F. Yaya, Email: [manal.yaya@uob.edu.ly](mailto:manal.yaya@uob.edu.ly).

## INTRODUCTION

Prostate cancer is one of the most common malignancies among men, particularly those older than 50 years, and remains a leading cause of cancer-related mortality in industrialized countries (1). Its incidence and outcomes are influenced by a combination of hereditary, environmental, and sociocultural factors, which contribute to the variations observed across populations (2). Genetic predisposition is among the most important determinants of risk, with family history consistently identified as a significant predictor. Evidence from epidemiologic and twin studies confirms the substantial contribution of inherited traits to prostate cancer susceptibility (3). Mutational alterations in genes involved in androgen synthesis and metabolism further support the critical biological role of androgens in carcinogenesis (4,5).

Although some prostate tumors remain latent for years, progression to advanced or metastatic disease significantly increases morbidity and mortality. Understanding the molecular mechanisms underlying this transition is therefore crucial for guiding treatment and improving survival rates. Spondin 3 (RSPO3), previously associated with colorectal and lung cancers, has been proposed as a potential yet underexplored biomarker in prostate cancer (6).

The diagnostic process typically begins with abnormal prostate-specific antigen (PSA) results or suspicious findings on digital rectal examination, followed by histopathological confirmation through biopsy. Management strategies vary according to stage and may include active surveillance, surgery, radiotherapy, or hormonal therapy. In recurrent or advanced cases, androgen deprivation therapy (ADT), chemotherapy, and targeted agents are widely used, with combination regimens often achieving better outcomes (7).

Histologically, prostate adenocarcinoma is the most common type of malignancy, with acinar adenocarcinoma being the predominant subtype. Ductal adenocarcinoma, although less common, is more aggressive. Other rare forms include urothelial carcinoma of prostatic origin and squamous cell car-

cinoma, both associated with poorer prognoses (8). Accurate histological classification is essential for guiding treatment decisions. Staging relies on several prognostic indicators—including the Gleason grading system, TNM classification, PSA levels, and the Grade Group system—all of which play key roles in determining disease severity and therapeutic strategies (9). This study was aimed to describe the demographic, clinical, and histopathological characteristics of prostate cancer patients.

## MATERIALS AND METHODS


This descriptive, cross-sectional study was conducted at Benghazi Medical Center (BMC), Benghazi, Libya. Data were collected from the medical records of 81 patients diagnosed with prostate cancer who were admitted to the oncology department between January 2020 and December 2023. The variables extracted included socio-demographic characteristics, medical history, smoking status, histopathological type, and prostate-specific antigen (PSA) levels.

## STATISTICAL ANALYSIS

Data were analyzed using the Statistical Package for the Social Sciences (SPSS). Frequencies, percentages, and mean  $\pm$  standard deviation (SD) were calculated. Fisher's exact test was used to assess statistical associations. A p-value  $< 0.05$  was considered statistically significant. Figures were generated using Microsoft Excel 2010

## RESULTS

During the study period, a total number of 81 cases of prostate cancer were found, patients' age was between 52 to 92 and the mean age was 71.6 years and the majority were between 71 and 80 years as shown in figure 1.




**Figure 1.** Distribution of patients according to age

As shown in Table 1, the majority of cases (n = 52, 64.2%) were from Benghazi, while 29 patients (35.8%) were from outside the city.

**Table 1:** Distribution of patients according to place of residence

| Address          | No. | %    |
|------------------|-----|------|
| Benghazi         | 52  | 64.2 |
| Outside Benghazi | 29  | 35.8 |
| Total            | 81  | 100  |

Figure 2 shows that most prostate cancer patients were nonsmokers (n = 62, 80.2%). Among the patients, 11.1% had diabetes mellitus, 1.2% had hypertension, and 66.7% had both conditions. Additionally, 84% of the cases had no family history of prostate cancer.



**Figure 2.** Distribution patients according to smoking status(A), medical history(B), and family history of prostate cancer(C)




Table 2 shows that the majority of prostate cancer cases were acinar adenocarcinoma (n = 77, 95%), followed by ductal adenocarcinoma (n = 2, 2.5%). Another 2 cases (2.5%) had no recorded histopathological type.

**Table 2.** Distribution of patients according to the histopathological pattern of prostate cancer

| Type of the tumor     | No. | %   |
|-----------------------|-----|-----|
| Acinar Adenocarcinoma | 77  | 95  |
| Ductal Adenocarcinoma | 2   | 2.5 |
| Not recorded          | 2   | 2.5 |
| Total                 | 81  | 100 |


Figure 3 illustrates the PSA levels at the time of initial presentation. Elevated PSA levels were observed in 29.6% of patients, while 23.5% had normal levels. In approximately 46.9% of the cases, PSA levels were not recorded.



**Figure 3.** Distribution of patients according to PSA level


According to Gleason Score Grades, figure 4 shows that 36 patients (44.4%) had Grade I disease. Equal

proportions of patients (17.3% each) were classified as Grade II and Grade IV, while 14.8% had Grade V.



**Figure 4.** Distribution of patients according to the grade of the prostatic cancer

Figure 5 indicates that only 7 patients had metastatic disease.



**Figure 5:** Distribution of the patients according to the disease metastasis.

## DISCUSSION

Prostatic diseases—including inflammation, benign prostatic hyperplasia, and carcinoma—are major contributors to male morbidity and mortality. Both benign prostatic hyperplasia and prostate cancer become increasingly common with advancing age (10).

In the present study, 81 patients were included, with ages ranging from 52 to 92 years and a mean age of 71.6 years. Most patients were between 71 and 80 years old. This finding is consistent with a previous study in Benghazi (10), which reported a mean age of  $73.1 \pm 9.4$  years (range 48–90 years), in another

study in Benghazi most of the cases were aged 61–70 years (11). This reinforces age as non-modifiable risk factor within our population.

Geographical, environmental, and lifestyle factors play important roles in cancer development (12,13). In this study, most cases originated from Benghazi (64.2%). Although tobacco smoking is widely recognized as a significant risk factor—heavy smokers having a 24–30% higher risk of prostate cancer mortality than nonsmokers (14) 80.2% of the patients in this study were nonsmokers, contrasting with much of the existing literatures. The limited number of patients reporting smoking in our dataset may indicate inaccurate documentation or underreporting rather than the absence of an association.

Family history is another well-established risk factor (15). In this study, only 16% of patients reported a positive family history. The prevalence of diabetes and hypertension among the patients was consistent with previous study (16), which reported similar frequency.

Histopathological evaluation showed that acinar adenocarcinoma was the predominant subtype, in agreement with international classification systems that identify it as the most common prostate cancer subtype (8), followed by ductal adenocarcinoma. Gleason grading revealed that Grade I was the most



common, followed by Grades II and IV. This is in agreement with a study from Pakistan (17), which also reported Grade I as the most frequent grade, but contrasts with previous findings from Benghazi (10), where Grade IV predominated. These differences may reflect variations in screening practices, patient presentation, or biopsy sampling. Notably, recent recommendations advocate adopting the Grade Group system proposed by Epstein et al. (2016) for improved prognostic accuracy, suggesting a need for standardized grading in future local research (9).

Elevated PSA levels typically reflect the disruption of normal prostate architecture (10), and levels above 20 ng/mL have been strongly correlated with adenocarcinoma (17,18). In this study, 29.6% of patients had elevated PSA values, although incomplete data limited a comprehensive interpretation. PSA is well established as an important diagnostic marker (18). Although PSA screening aims to reduce mortality through early detection, its long-term effect on death rates remains uncertain (19).

Metastasis at presentation occurred in only 8% of cases—significantly lower than the rate reported in other study (20). This comparatively low percentage may indicate improved screening strategies and more timely clinical management in this population.

### CONCLUSION

This study found that prostate cancer is predominantly diagnosed among older men in Benghazi, with most cases identified at an early stage of the disease. Acinar adenocarcinoma was the most common histological subtype. The relatively low proportion of metastatic cases at presentation suggests favorable prognostic characteristics within this population.

### RECOMMENDATIONS

To improve clinical outcomes, we recommend implementing structured prostate cancer screening programs in Libya, with particular emphasis on high-risk groups. Early detection and timely intervention could substantially reduce disease-related morbidity and mortality.

Multi-center research with standardized methodol-

ogies is recommended to establish a more accurate national representation of prostate cancer epidemiology and outcomes.

### ACKNOWLEDGMENTS

We express our sincere appreciation to all individuals who supported the completion of this research. We also extend our gratitude to Benghazi Medical Centre for providing access to the necessary data.

**Ethical Statement:** This retrospective study was conducted using anonymized patient records from Benghazi Medical Center. No interventions were performed, and confidentiality was strictly maintained in accordance with institutional and international ethical guidelines.

### CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest related to this study.

### REFERENCES

- Chen J, Zhang D, Yan W, Yang D, Shen B. Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. *BioMed Res Int*. 2013;2013:901578. doi:10.1155/2013/901578.
- Hjelmborg, J. B., Scheike, T., Holst, K., Skytthe, A., Penney, K. L., Graff, R. E., Pukkala, E., Christensen, K., Adami, H. O., Holm, N. V., Nuttall, E., Hansen, S., Hartman, M., Czene, K., Harris, J. R., Kaprio, J., & Mucci, L. A. (2014). The heritability of prostate cancer in the Nordic Twin Study of Cancer. *Cancer Epidemiology, Biomarkers & Prevention*, 23(11), 2303–2310. <https://doi.org/10.1158/1055-9965.EPI-13-0568>
- Termini D, Hartogh DJD, Jaglanian A, Tsiani E. Curcumin against prostate cancer: current evidence. *Biomolecules*. 2020;10(11):1536. doi:10.3390/biom10111536.
- Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C. Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer. *Am J Pathol*. 2015;185(2):293-301. doi:10.1016/j.ajpath.2014.10.012.
- Cittadini A, Isidori AM, Salzano A. Testosterone therapy and cardiovascular diseases. *Cardiovasc Res*. 2021;118(8):2039-2057. doi:10.1093/cvr/



cvab241.

6.Mesci, A., Lucien, F., Huang, X., Wang, E. H., Shin, D., Meringer, M., Hoey, C., Ray, J., Boutros, P. C., Leong, H. S., & Liu, S. K. (2019). RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer. *Journal of translational medicine*, 17(1), 125. <https://doi.org/10.1186/s12967-019-1878-3>

7.Descotes JL. Diagnosis of prostate cancer. *Asian J Urol*. 2019;6(2):129-136. doi:10.1016/j.ajur.2018.11.007

8.Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs Part B: prostate and bladder tumours. *Eur Urol*. 2016;70(1):106-119. doi:10.1016/j.euro.2016.02.028.

9.Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. *Eur Urol*. 2016;69(3):428-435. doi:10.1016/j.euro.2015.06.046.

10.Garalla HM, Darraz KMA, Essa MMA. A retroprospective clinicopathological study of prostatic lesions in surgical specimens. *Libyan Int Med Univ J*. 2022;7:51-56.

11.Elhony A, El Darat T, Elkawafi R, Ramse W, Alzaghad AI, Sheriff DS. Gross hematuria and prostatic cancer in Libyan patients. *J Adv Med Pharm Sci*. 2019;21(2):1-5. doi:10.9734/JAMPS/2019/v21i230141.

12.Alhdiri MA, Samat NA, Mohamed Z. Mapping Libya's prostate cancer based on the SMR method: a geographical analysis. *Geografia Online TM Malaysian J Soc Space*. 2016;12(9):118-125.

13.Malak S. Natural human factors play in the incidence of malignant tumors in the north-west of Libya [dissertation]. Tripoli, Libya: University of Tripoli; 2013. [Arabic].

14.Huncharek M, Haddock S, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: meta-analysis of 24 prospective cohort studies. *Am J Public Health*. 2010;100(4):693-701. doi:10.2105/

AJPH.2009.185256.

15.Kwabi-Addo, B., Wang, S., Chung, W., Jelinek, J., Patierno, S. R., Wang, B. D., Andrawis, R., Lee, N. H., Apprey, V., Issa, J. P., & Ittmann, M. (2010). Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 16(14), 3539–3547. <https://doi.org/10.1158/1078-0432.CCR-09-3342>

16.Raphael JE, Ekeke N. Hypertension and type 2 diabetes mellitus as risk factors for prostate cancer patients in Southern Nigerians. *Saudi J Biomed Res*. 2022;7(2):101-106.

17.Hameed S, Malik A, Bilal S, Dogar SR, Aslam A. Pattern of prostatic disease: a histopathological survey. *Prof Med J*. 2010;17(4):573-577.

18.Issac A, Varughese A, Raghuvver C, Asha SPK, Abdul Majeed N, Rajan J. A clinicopathological analysis of 120 cases of prostate biopsies and their correlation with prostate specific antigen levels. *Ann Pathol Lab Med*. 2018;5(11):A882-A887. doi:10.21276/apalm.2237.

19.Martin, R. M., Turner, E. L., Young, G. J., Metcalfe, C., Walsh, E. I., Lane, J. A., Sterne, J. A. C., Noble, S., Holding, P., Ben-Shlomo, Y., Williams, N. J., Pashayan, N., Bui, M. N., Albertsen, P. C., Seibert, T. M., Zietman, A. L., Oxley, J., Adolfsen, J., Mason, M. D., Davey Smith, G., ... CAP Trial Group (2024). Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. *JAMA*, 331(17), 1460–1470. <https://doi.org/10.1001/jama.2024.4011>

20.Daher, M., Telvizian, T., Dagher, C., Abdul-Sater, Z., Massih, S. A., Chediak, A. E., Charafeddine, M., Shahait, M., Alameddine, R., Temraz, S., Geara, F., Youssef, B., El Hajj, A., Nasr, R., Wazzan, W., Bulbul, M., Khauli, R., Shamseddine, A., & Mukherji, D. (2021). High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center. *Urology annals*, 13(4), 418–423. [https://doi.org/10.4103/UA.UA\\_47\\_20](https://doi.org/10.4103/UA.UA_47_20).



## Prevalence of Skin Findings among Libyan Diabetic Patients.

Ghada. A. Albarghathi <sup>1\*</sup>, Antisar. A. Najm <sup>2</sup>, Aisha. B. Trapolsi <sup>1</sup>, Shadia. J. Awad <sup>3</sup>.

### Original Research Article

#### Abstract

**Background:** Diabetes mellitus (DM) is the most common endocrine disorder. Almost one-third of diabetic patients are affected by cutaneous manifestations during their disease. Cutaneous manifestations of diabetes are caused by either diabetes-induced metabolic changes in the skin or by associated complications like vasculopathy and neuropathy.

**Objectives:** To estimate the prevalence of skin diseases among patients with diabetes mellitus.

**Method:** One hundred eighty known adult diabetic patients of either sex attending the outpatient clinic of the diabetic center (Diabetic Center / Benghazi / Libya) for treatment and follow-up of diabetes were randomly selected for the study. Detailed case history of each patient with special attention to cutaneous lesions were taken. A dermatologist performed a detailed dermatological examination.

**Results:** In this study, most diabetes patients ranged from 41 to 60 years for females, while for males, they were over 60 years. The majority of patients in the current study were females. The most common dermatosis associated with DM was acanthosis nigricans; seen in (69.4%) of patients, skin tag was the second most common dermatosis, accounting for (56.7%) of patients, xerosis was seen in (54.4%), pruritus seen in (37.2%), fungal skin infections found in (25.6%). Diabetic dermopathy was seen in (17.7%), and prayer signs were found in (10.6%). Fifteen (8.3%) diabetic patients had nail changes, and eight (4.4%) diabetic patients had foot ulcers. Diabetic bullae were found in (2.2%); as well as viral infections were seen in (2.2%). Two (1.1%) diabetic patients have bacterial infections.

**Conclusion:** The prevalence of certain dermatoses was increased among diabetic patients. So, diabetic patients are considered to be at risk of developing certain skin diseases.

**Keywords:** Diabetes mellitus (DM), Acanthosis nigricans, Skin tag, Xerosis; Pruritus.

1.Dermatology Department, Faculty of Medicine, University of Benghazi, Benghazi-Libya.

2.Dermatology Department, Aljomhoryia Hospital, Benghazi-Libya.

3.Dermatology Department, Faculty of Medicine, Ajdabiya University, Ajdabiya- Libya.

\*Corresponding author: Ghada. A. Albarghathi, Email: [ghadataeib@yahoo.com](mailto:ghadataeib@yahoo.com).

## INTRODUCTION

The skin is almost invariably affected by DM; the cutaneous findings of DM are numerous and different studies have reported a different frequency. Most of the patients affected by DM develop skin manifestations eventually (1). Skin findings among patients with DM are attributed to abnormal carbohydrate metabolism, atherosclerosis, microangiopathy, neuron degeneration, impaired host responses, and some other yet undetermined mechanism (2). Various skin disorders associated with diabetes include: acanthosis nigricans, skin tags, diabetic dermopathy, diabetic bullae, diabetic thick skin, yellow skin, eruptive xanthomas, necrobiosis lipoidica, disseminated granuloma annulare, yellow nails, scleroderma, diabetic rubeosis, lichen planus and vitiligo (3). Controlling the metabolism of the body may prevent some of these manifestations and also support the treatment (4). Increasing the awareness about skin diseases commonly seen among patients with DM can be associated with a better prognosis of disease through early management (5).

## OBJECTIVES


To determine the prevalence of skin diseases among patients with diabetes mellitus.

## METHODS

A cross-sectional study was conducted on 180 known adult diabetic patients of either sex attending the outpatient clinic of the diabetic center (Diabetic Center / Benghazi / Libya) for treatment and diabetes follow-up who were randomly selected during the period from January 2022 to March 2022. Non-Libyans, patients with other endocrinal disorders, and pregnant women were excluded from the study group. We also excluded any patients who were not willing to participate. Verbal informed consent was obtained from all participants. Detailed case history of each patient with special attention to cutaneous lesions was taken and dermatologist performed detailed dermatological examination. The data were analyzed by using the statistical package for social sciences program version 18 (SPSS), with a P-value of <0.05 considered statistically significant.

## RESULTS

A total of 180 diabetic patients, 43 (23.9%) males and 137 (76.1%) females (Figure 1).



**Figure 1.** Distribution of patients according to sex. The most of diabetes patients age group was those over 60 years old followed by 41- 60 years old for males, for females the age group was 41- 60 years followed by those over 60 years old (Table 1).

**Table 1.** Distribution of patients according to age.

| Age group | Female No(%) | Male No(%) | P value |
|-----------|--------------|------------|---------|
| <= 20     | 1(0.7%)      | 0(0%)      | 0.2     |
| 40-21     | 3(2.2%)      | 2(4.7%)    |         |
| 60-41     | 72(52.6%)    | 16(37.2%)  |         |
| =>61      | 61(44.5%)    | 25(58.1%)  |         |
| Total     | 137(100%)    | 43(100%)   |         |

Differences between males and females regarding age groups were not significant (P value = 0.2). The distribution of diabetic patients according to cutaneous findings is shown in Table 2. Acanthosis nigricans was observed in 125 (69.4%) patients; 44% were males and 77.4% were females. The commonest site involved was the neck.

**Table 2.** Distribution of diabetic patients according to cutaneous findings.

| Cutaneous findings   | Female No (%) | Male No (%) | Total No (%) |
|----------------------|---------------|-------------|--------------|
| Acanthosis nigricans | 106 (77.4%)   | 19 (44.2%)  | 125 (69.4%)  |
| Skin tag             | 86 (62.8%)    | 16 (37.2%)  | 102 (56.7%)  |
| Xerosis              | 70 (51.1%)    | 28 (65.1%)  | 98 (54.4%)   |
| Pruritus             | 42 (30.7%)    | 25 (58.1%)  | 67 (37.2%)   |
| Fungal infections    | 46 (33.6%)    | 0 (0%)      | 46 (25.6%)   |
| Diabetic dermopathy  | 24 (17.5%)    | 8 (18.6%)   | 32 (17.7%)   |
| Prayer sign          | 18 (13.1%)    | 1 (2.3%)    | 19 (10.6%)   |
| Nail changes         | 8 (5.8%)      | 7 (16.3%)   | 15 (8.3%)    |
| Foot ulcer           | 5 (3.6%)      | 3 (7%)      | 8 (4.4%)     |
| Diabetic bullae      | 3 (2.2%)      | 1 (2.3%)    | 4 (2.2%)     |
| Viral infections     | 4 (2.9%)      | 0 (0%)      | 4 (2.2%)     |
| Bacterial infections | 0 (0%)        | 2 (4.7%)    | 2 (1.1%)     |

In 80 (52.3%) of cases (Figure 2), the axilla was involved in 60 (39.2%), while the groin was involved in 13 (8.5%). Among 102 (56.7%) patients having skin tags; (37.2%) were males and (62.8%) were females.



**Figure 2:** Acanthosis nigricans involving the neck. The neck alone was involved in 50 (49%) (Figure 3), the neck along with the chest was involved in 42 (41.2%), and the axilla was involved in 10 (9.8%). Xerosis was seen in 98 (54.4%) patients; (65.1%) were males and (51.1%) were females. Hands were involved in 60 (61.2%) patients (Figure

4), and bodies were involved in 38 (38.8%).



**Figure 3.** Skin tags involving the neck.



**Figure 4.** Hand xerosis.

Pruritus was seen in 67 (37.2%); about (58.1%) was observed in males and (30.7%) was seen in females. Forty-six (25.6%) patients had fungal infections all cases were females (33.6%). Tinea pedis affected about 30 (16.7%) patients (Figure 5), 16 (8.9%) patients had candidiasis, 10 (62.5%) had vaginal candidiasis, and 6 (37.5%) had it under the breast.



**Figure 5:** Tinea pedis

Diabetic dermopathy was seen in 32 (17.7%) patients; 18.6% were males and 17.5% were females. Nineteen (10.6%) of diabetic patients had prayer sign; (2.3%) of males and (13.1%) of females (Figure 6).



**Figure 6:** Prayer sign

Among 15 (8.3%) diabetic patients having nail changes; (16.3%) of males and (5.8%) of females. Ten (66.7%) patients have yellow nails, and 5 (33.3%) patients have thick nails (Figure 7).



**Figure 7:** Nail changes showing thick nail palate.

Eight (4.4%) of diabetic patients had foot ulcers (7% of males and (3.6%) of females. Diabetic bullae seen in 4 (2.2%) patients (2.3%) of males and (2.2%) of females. Among 4 (2.2%) diabetic patients having viral infections, all were females (2.9%). Two (1.1%) patients have planter warts, and 2 (1.1%) patients have herpes zoster. Two (1.1%) patients had bacterial infections all were males (4.7%). One (0.55%) patient had carbuncle (Figure 8), and 1 (0.55%) patient had ecthyma.



**Figure 8:** Carbuncle on the back.

## DISCUSSION

In the current study, most of the diabetes patients age group was 41-60 years for females, while males were those over 60 years old, these observations were consistent with a regional study from El-Beida city (6). The majority of patients enrolled in the present study were females. Skin findings were seen more commonly in females in the current study, as the higher number of females presenting to the OPD indicates greater health awareness among females; this result appears to be similar to the study of Niaz, F, et al. (7). In this study, the most common five skin disorders observed associated with diabetes are: acanthosis nigricans (69.4%), skin tag

(56.7%), xerosis (54.4%), pruritus (37.2%), and fungal infections (25.6%), this comes in accordance with studies in Libya (6), Saudi Arabia (8), and Turkey (9). In the present study, the most common dermatosis associated with DM was acanthosis nigricans, seen in (44.2%) of males and (77.4%) of females, followed by skin tags, which accounted for (37.2%) of males and (62.8%) of females. Thappa et al. (10) concluded that skin tags may serve as a marker for diabetes mellitus.

Xerosis was seen in 65.1% of males and 51.1% of females, consistent with a study from El-Beida City (6). The high prevalence of xerosis in our diabetic patients is most likely because most of the patients don't drink an adequate amount of water per day, especially in the winter season, or due to the normal xerotic process of the elderly. Pruritus was also seen in 58.1% of males and 30.7% of females. Pruritus is well known to have an association with diabetes mellitus as reported in the past literature (11, 12). Al-Mutairi et al. who reported pruritus in (47%) of their patients (13); this is nearly similar in frequency when compared to our patients (37.2%). In the present study, 25.6% of the enrolled patients had fungal skin infections; all were females (33.6%). The most common disease was tinea pedis, which was seen in (16.7%) of patients. Tinea pedis can act as a portal of entry for secondary bacterial invasion. Candidiasis, which may be an early indicator of undiagnosed diabetes, was also seen in 8.9% of our patients. Diabetic dermopathy was seen in 17.7% of our patients (18.6% of males and 17.5% of females); this is in contrast to the results obtained by Niaz, F, et al., where diabetic dermopathy frequency was 9% in their patients (7).

In this study, 10.6% of the enrolled patients had prayer sign (2.3% of males and 13.1% of females), which is inconsistent with Ezejioko ROI, who reported that prayer sign was seen in only 4% of patients (14). Fifteen (8.3%) diabetic patients had nail changes (16.3%) of males and (5.8%) of females, lower than that reported by Niaz, F, et al., where nail changes were seen in (16%) of their patients (7). In the current study, 8 (4.4%) diabetic patients had

foot ulcers (7%) of males and (3.6%) of females. It is usually related to different mechanisms like impaired immunity, neuropathy, peripheral arterial disease, venous insufficiency, and lymphedema. It has been reported with a variable frequency in different studies ranging between 10 and 50% (11, 15, 16). Consistent with current study, Niaz, F, et al have reported foot abnormalities were more common in female diabetics (7), while study done by Mansour et al. have reported foot abnormalities were common in male diabetics (17). Diabetic bullae were found in 2.2% of our patients (2.3% of males and 2.2% of females); this is in agreement with the results obtained by Bhat et al. (18). Viral infections were seen in (2.2%) of the patients; all of them were females (2.9%), this is in agreement with other regional studies (6). In this study, 2 (1.1%) diabetic patients had bacterial infections (4.7%); all of them were males. One (0.55%) patient had a carbuncle, and one (0.55%) patient had ecthyma; these findings are in contrast to the frequency of bacterial infections that was reported to be higher by a study from El-Beida city (6).

### CONCLUSION

The prevalence of certain dermatoses was high among diabetic patients. So, diabetic patients are considered to be at risk of developing certain skin diseases.

### RECOMMENDATION

General practitioners should be aware of the diagnosis and management of skin diseases that are commonly seen among diabetic patients, and difficult cases should be referred to specialists for early management to minimize complications and morbidities associated with diabetes mellitus.

### REFERENCES

1. Rangunatha S, Anitha B, Inamadar AC, Palit A, Devamani SS. Cutaneous disorders in 500 diabetic patients attending diabetic clinic. *Indian journal of dermatology*. 2011;56(2):160.
2. Muhammad B et al. Frequency and association of dermatological manifestations of type 2 diabetes mellitus with body mass index and HbA1c levels. *Journal of Pakistan Association of Dermatologists*.

2018;28(2):199-206.

3. Perez MI, Kohn SR. Cutaneous manifestations of diabetes mellitus. *J Am Acad Dermatol*. 1994;30:519-31.
4. KRR Schons. Cutaneous manifestations in diabetes mellitus. In *Dermatology in Public Health Environments: A Comprehensive Textbook*, edited by RR Bonamigo, SIT Dornelles. Springer International Publishing, Cham, 2018;719-738.
5. B Murphy-Chutorian, G Han, and SR Cohen. Dermatologic manifestations of diabetes mellitus. a review. *Endocrinology and Metabolism Clinics of North America*. 2013;42(4):869-898.
6. Altubouli SS, & Ali MS. Skin Manifestation of Diabetes Mellitus in El-Beida City. *Journal of Dental and Medical Sciences*. 2019;18(10):68-71.
7. Niaz F, Bashir F, Shams N, Shaikh Z, & Ahmed I. Cutaneous manifestations of diabetes mellitus type 2: prevalence and association with glycemic control. *Journal of Pakistan Association of Dermatologists*. 2016;26(1):4-11.
8. Shahzad M, Al Robaee A, Al Shobaili HA, Alzolibani AA, Al Marshood AA, & Al Moteri B. Skin manifestations in diabetic patients attending a diabetic clinic in the Qassim region, Saudi Arabia. *Medical Principles and Practice*. 2011;20(2):137-141.
9. Ozlu E, Uzuncakmak T, Takir M, Akdeniz N, & KARADAĞ A. Comparison of cutaneous manifestations in diabetic and nondiabetic obese patients: A prospective, controlled study. *Northern Clinics of Istanbul*. 2018;5(2).
10. DM Thappa. Skin tags as markers of diabetes mellitus: an epidemiological study in India. *The Journal of dermatology*. 1995;22:729-731.
11. Ahmed K, Muhammad Z, & Qayum I. Prevalence of cutaneous manifestations of diabetes mellitus. *J Ayub Med Coll Abbottabad*. 2009;21(2):76-9.
12. Elhaj NA, Ali HS, Abu-Agla H, Alfaraouk KO, Elbadaw RA, Aljarbou AN, ... & Bashir AH. The Prevalence of Pruritis among Sudanese Patients with Diabetes Mellitus. *Am j Dermatol*. 2019;8(5):73-83.
13. Al-Mutairi N, Zaki A, Sharma AK, & Al-Sheltawi M. Cutaneous manifestations of di-



abetes mellitus. Medical Principles and Practice. 2006;15(6):427- 430.

14. Ezejiolor OI, et al. Pattern of dermatological disorders among diabetics. Egyptian Dermatology Online Journal. 2013;9(2):1.

15. Vahora R, Thakkar S, & Marfatia Y. Skin, a mirror reflecting diabetes mellitus: A longitudinal study in a tertiary care hospital in Gujarat. Indian journal of endocrinology and metabolism. 2013;17(4):659.

16. Majeed M, Iqbal F, & Mehboob A. Cutaneous manifestations in type-1 and type-2 diabetes mellitus (A study profile of 200 patients). Proc Shaikh Zayed Postgrad Med Inst. 2004;18:638.

17. Mansour AA, & Imran HJ. Foot abnormalities in diabetics: Prevalence and predictors in Basrah, Iraq. Pakistan Journal of Medical Sciences. 2006;22(3):229.

18. Bhat YJ, Gupta V, & Kudyar RP. Cutaneous manifestations of diabetes mellitus. Int J Diab Dev Ctries. 2006;26(4):153

## The Prevalence of Amoebiasis in Children Admitted to Gastro Department at Children's Hospital of Benghazi.

Abdusalam A. Abdusalam <sup>1\*</sup>, Abdulsalam F. Alawaaj <sup>2</sup>  
Zahoor H. Almabrouk <sup>3</sup>.

### Original Research Article

#### Abstract

**Background:** Amoebiasis, caused by the protozoan parasite *Entamoeba histolytica*, remains a major public health concern, particularly in less developed and developing regions where sanitation standards are inadequate.

**Aim:** To investigate the role of *E. histolytica* as a primary cause of gastroenteritis and to assess infection rates among children admitted to the Gastroenteritis Department at Benghazi Children's Hospital over a one-year period.

**Method:** A cross-sectional study was conducted by using records from the Parasitology Department between January and December 2023. A total of 1,443 stool samples were examined microscopically and categorized into four age groups: 1–3, 4–6, 7–9, and 10–14 years.

**Results:** The overall prevalence of *E. histolytica*/dispar was 35.3%. *Giardia lamblia* infections accounted for 2.8%, while other microbial infections—including fungal organisms such as *Candida* spp.—represented 1.2%. The highest infection rate was recorded in the Gastroenteritis Department (59.0%), compared to 30.1% in the Outpatient Department. Seasonal trends showed a peak prevalence of 5.5% in August and the lowest rate of 1.3% in April.

**Conclusion:** The study highlights the substantial burden of *E. histolytica* infections among children in Benghazi, emphasizing the urgent need for improved sanitation, enhanced public health strategies, and continuous monitoring to reduce infection rates.

**Keywords:** Parasites, Amebiasis, *Entamoeba histolytica*, Gastroenteritis.

1. Department of Nutrition Therapeutic, College of Medical Technology-Ajdabiya, Libya.

2. Department of Public Health, College of Medical Technology-Benghazi, Libya.

3. Department of Medical Laboratories, College of Medical Technology-Ajdabiya, Libya.

\*Corresponding author: Abdusalam A. Abdusalam, Email: [abdussalamaboubaker@gmail.com](mailto:abdussalamaboubaker@gmail.com).



## INTRODUCTION

Amoebiasis, caused by the protozoan parasite *Entamoeba histolytica*, constitutes a major human intestinal disease with significant public health implications, particularly in regions with inadequate sanitation. As a primary contributor to severe diarrheal illness, amoebiasis is responsible for an estimated 40,000–100,000 deaths annually worldwide [1]. The clinical presentation varies widely, encompassing asymptomatic carriage, mild gastrointestinal disturbances, and severe outcomes such as amoebic colitis and amoebic liver abscess (ALA), which can progress to invasive extra-intestinal disease [2]. The public health importance of amoebiasis is further magnified by its role in childhood diarrhea and its classification as a reportable disease in systems like Libya's National Notifiable Disease Reporting System (NNDRS) [3].

Transmission occurs primarily through the fecal-oral route via the ingestion of contaminated food or water containing resilient *Entamoeba* cysts (10–18  $\mu\text{m}$ ), which are resistant to standard chlorination [4]. Upon ingestion, these cysts undergo excystation in the small intestine, releasing motile trophozoites that colonize the large intestine and penetrate the intestinal mucosa, leading to the formation of characteristic flask-shaped ulcers [5]. Given its low infectious dose and environmental stability, *E. histolytica* is classified as a Category B priority biodefense pathogen by the NIAID [5]. Clinically, amoebic colitis typically presents with symptoms such as colicky abdominal pain, frequent bowel movements, and diarrhea often containing visible blood and mucus [1].

Globally, the prevalence of *E. histolytica* infection is highly disparate, with reported rates in Africa reaching 12.4% in South Africa and 58.3% in Kenya [6]. High regional prevalence is often attributed to risk factors such as inadequate sanitation and poor hygiene [6].

International studies have confirmed seasonal patterns in *E. histolytica* infections; for instance, 65.5% of documented cases in China occurred between May and October, peaking in June [7]. Additionally,

a large-scale study in northern Jordan, examining 21,906 patients, found the highest prevalence of both *G. lamblia* and *E. histolytica* during the summer months [8].

Local epidemiological data from Libya highlight significant gaps in understanding the prevalence and impact of *E. histolytica* infections. A study conducted in Sebha and Mourzak reported an overall intestinal parasite infection rate of 16.0% in children, with *E. histolytica/dispar* (12.8%) being significantly more prevalent than *Giardia lamblia* (3.2%) ( $p=0.004$ ) [9]. This study also noted a non-significant trend toward higher infection rates in males (18.6%) compared to females (12.9%) ( $p=0.401$ ), while identifying a significant association between prevalence and seasonal variation ( $p=0.027$ ), with peaks observed in March [9].

Supporting these findings, a separate survey in Zella City reported an overall parasitic prevalence of 87%, with *E. histolytica* dominating at 65%, particularly during the autumn and spring seasons [10]. These results underscore the persistent challenge of intestinal parasitic infections in Libya, despite improvements in cultural and social awareness.

Given these local and regional insights, the current study aims to address knowledge gaps regarding *E. histolytica* infections among children in Libya. Specifically, this study sought to determine the prevalence and seasonal trends of *E. histolytica* among children admitted to the Gastroenteritis Department at Benghazi Children's Hospital over one year. Furthermore, it aimed to investigate associations with age, gender, and the hospital department, thereby contributing valuable data to enhance understanding and management of amoebiasis in the local context.

## METHOD

### Study Setting

This cross-sectional study was carried out at Benghazi Children's Hospital in Benghazi, Libya, following formal approval from the hospital administration. Data was collected over a 12-month period, from January to December 2023. Cases of *Entamoeba histolytica* infection were identified through the examination of records obtained from

the medical laboratories of the hospital's Parasitology Department.

### Study Subjects

The study comprised stool samples primarily referred from the gastroenteritis department, while samples from other hospital departments were also included for comprehensiveness. Training in parasite detection, laboratory diagnosis, information collection, sample acquisition procedures, and necessary precautions was provided under the supervision of parasitology specialists. This included observation within the hospital's gastrointestinal tract department. Suspected cases of parasitic infection were categorized into four age groups for analysis: 1-3 years, 4-6 years, 7-9 years, and 10-14 years.

### Stool Examination

Parasitological examination was conducted using direct wet mount microscopy on all referred samples, processed immediately after collection. A small fecal aliquot was mixed with iodine solution and examined under low ( $\times 10$ ) and high ( $\times 40$ ) power magnification to identify *E. histolytica*. Positive cases were defined by the presence of trophozoites or cysts, but microscopy cannot differentiate between *E. histolytica* and *E. dispar*. To enhance diagnostic accuracy, normal saline wet mounts were prepared, and concentration techniques were employed. Multiple slides were examined by trained technicians in a blinded manner to minimize bias, with inter-observer agreement assessed to ensure consistency. These considerations are crucial for accurately diagnosing *E. histolytica* infections and understanding the limitations of the microscopy techniques used.

### Limitations of the Study

Several limitations were encountered in this study. Some cases were excluded due to missing or unrecorded patient age and gender data, along with ambiguous documentation of parasitic infections. Operational challenges arose during technician training, impacting consistency in sample processing. Additionally, logistical constraints in collaboration between the gastrointestinal department and the laboratory affected research activities. There

was also insufficient information regarding patient residence, whether local to Benghazi or from external areas. It is important to note that the samples collected were from patients admitted to the hospital or attendees of the departments during their illness, which explains the difficulties in obtaining comprehensive information. These factors highlight the constraints imposed by the available data from Benghazi Children's Hospital.

### Statistical Analysis

Collected data were coded, tabulated, and analyzed using the Statistical Package for the Social Sciences (SPSS 25) software. Descriptive statistics, employing counts and percentages, were used to summarize quantitative data. Analytical statistics involved the application of the Chi-square test to compare groups based on qualitative variables.

### RESULTS

Analysis of 1,443 stool samples from children admitted to the gastroenteritis department revealed the following age distribution among participants (aged 1-14 years): the 1-3-year age group comprised 395 cases (27.4%), the 4-6-year group had 589 cases (40.8%), the 7-9-year group included 441 cases (30.6%), and the 10-14-year group accounted for 18 cases (1.2%) The results are presented in Table (1).



**Table 1.** Distribution of participating according to age.

| Age in years | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------|-----------|---------|---------------|--------------------|
| 1-3          | 395       | 27.4    | 27.4          | 27.4               |
| 4-6          | 589       | 40.8    | 40.8          | 68.2               |
| 7-9          | 441       | 30.6    | 30.6          | 98.8               |
| 10-14        | 18        | 1.2     | 1.2           | 100.0              |
| Total        | 1443      | 100.0   | 100.0         |                    |

Table 2 detail gender distribution, identifying 804 males (55.7%) and 639 females (44.3%). Table shows the age group between 4-6 years had the highest participation rate, where the percentage of boys was (22.5%) and girls (18.4%), followed by

the age group between 7-9 years that was (18.2%) for boys and (12.3%) for girls While the lowest participation rate was in the age groups of 10-14 years and was (1.2%).

**Table 2.** Frequency and percentage of participating according to gender.

| Gender | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------|-----------|---------|---------------|--------------------|
| Boy    | 804       | 55.7    | 55.7          | 55.7               |
| Girl   | 639       | 44.3    | 42.9          | 100.0              |
| Total  | 1443      | 100.0   | 100.0         |                    |

**Table 3.** Distribution of participating according to age and gender.

| Age group | Boy   | Gender |      | Total |
|-----------|-------|--------|------|-------|
|           |       | Girl   |      |       |
| 1-3       | Count | 210    | 185  | 395   |
|           | Total | 14.6   | 12.8 | 27.4  |
| 4-6       | Count | 324    | 265  | 589   |
|           | Total | 22.5   | 18.4 | 40.8  |
| 7-9       | Count | 263    | 178  | 441   |
|           | Total | 18.2   | 12.3 | 30.6  |
| 10-14     | Count | 7      | 11   | 18    |
|           | Total | 0.5%   | 0.8% | 1.2   |
| Total     | Count | 804    | 639  | 1443  |
|           | Total | 55.7   | 44.3 | 100.0 |

No significant difference was identified between both groups ( $p > 0.05$ )

Pathogen distribution is shown in Table 4. Entamoeba histolytica/dispar was detected in 35.3% of

samples, while Giardia spp. was found in 2.8%. Other microbial infections (including Candida spp.) accounted for 1.2%, with 60.7% of samples negative for the targeted parasites.

**Table 4.** Distribution of participating according to type of parasites.

| Type of parasite & other microbial. | Frequency | Percent | Valid Percent | Cumulative Percent |
|-------------------------------------|-----------|---------|---------------|--------------------|
| Candida spp.                        | 17        | 1.2     | 1.2           | 1.2                |
| E. histolytica/dispar               | 510       | 35.3    | 35.3          | 36.5               |
| Giardia lamblia                     | 40        | 2.8     | 2.8           | 39.3               |
| Nil                                 | 876       | 60.7    | 60.7          | 100.0              |
| Total                               | 1443      | 100.0   | 100.0         |                    |

Table 5 illustrate the distribution across hospital departments. The gastroenteritis department contributed the majority of samples (59.0%), followed by

the Outpatient Department (OPD) (30.1%), Medical Unit (MU) (6.2%), Intensive Care Unit (ICU) (3.0%), and Hematology (0.4%)

**Table 5.** Distribution of participating according to department.

| Department      | Frequency | Percent | Valid Percent | Cumulative Percent |
|-----------------|-----------|---------|---------------|--------------------|
| Gastroenteritis | 852       | 59.0    | 59.0          | 59.0               |
| Hematology      | 6         | .4      | .4            | 59.5               |
| ICU             | 44        | 3.0     | 3.0           | 62.5               |
| MU              | 90        | 6.2     | 6.2           | 68.7               |
| Nephron         | 16        | 1.1     | 1.1           | 69.9               |
| OPD             | 435       | 30.1    | 30.1          | 100.0              |
| Total           | 1443      | 100.0   | 100.0         |                    |

Seasonal variation in case presentation is displayed in Table 6. August recorded the highest caseload

(14.3%), followed by October (10.9%). The lowest incidence was observed equally in March and April (5.5%).

**Table 6.** Distribution of participating according to months of years.

| Months of the year | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------------|-----------|---------|---------------|--------------------|
| January            | 125       | 8.7     | 8.7           | 44.8               |
| February           | 98        | 6.8     | 6.8           | 36.1               |
| March              | 80        | 5.5     | 5.5           | 62.5               |
| April              | 80        | 5.5     | 5.5           | 5.5                |
| May                | 123       | 8.5     | 8.5           | 71.0               |
| June               | 94        | 6.5     | 6.5           | 57.0               |
| July               | 82        | 5.7     | 5.7           | 50.5               |
| August             | 207       | 14.3    | 14.3          | 19.9               |
| September          | 126       | 8.7     | 8.7           | 100.0              |
| October            | 157       | 10.9    | 10.9          | 91.3               |
| November           | 135       | 9.4     | 9.4           | 80.4               |
| December           | 136       | 9.4     | 9.4           | 29.3               |
| Total              | 1443      | 100.0   | 100.0         |                    |



The relationship between age and parasite infection is presented in Table 7. The 4–6-year age group exhibited the highest *E. histolytica*/dispar infection rate (15.0%), followed by the 7–9-year group

(10.6%). The 10-14-year group had the lowest rate (0.6%). The overall *Giardia* infection rate remained 2.8%.

**Table 7.** Distribution of participating according to relationship between age groups and types of parasites.

| Age group and Type Cross-tabulation |       |                               |                     |     |      |       |
|-------------------------------------|-------|-------------------------------|---------------------|-----|------|-------|
| Age group Candida spp.              |       | Type                          |                     |     |      | Total |
|                                     |       | <i>E. histolytica</i> /dispar | <i>Giardia</i> spp. | Nil |      |       |
| 1-3                                 | Count | 5                             | 131                 | 12  | 247  | 395   |
|                                     | Total | 0.3                           | 9.1                 | 0.8 | 17.1 | 27.4  |
| 4-6                                 | Count | 2                             | 217                 | 15  | 355  | 589   |
|                                     | Total | 0.1                           | 15.0                | 1.0 | 24.6 | 40.8  |
| 7-9                                 | Count | 10                            | 153                 | 13  | 265  | 441   |
|                                     | Total | 0.7                           | 10.6                | 0.9 | 18.4 | 30.6  |
| 10-14                               | Count | 0                             | 9                   | 0   | 9    | 18    |
|                                     | Total | 0.0                           | 0.6                 | 0.0 | 0.6  | 1.2   |
| Total                               | Count | 17                            | 510                 | 40  | 876  | 1443  |
|                                     | Total | 1.2                           | 35.3                | 2.8 | 60.7 | 100.0 |

No significant difference was identified between both groups.  $P=0.236$  ( $p > 0.05$ )

Table 8 describe the association between gender and department. Males had higher admission rates to the gastroenteritis department (33.0% vs. 26.1%

for females). Similarly, OPD presentation was higher in males (17.3%) compared to females (12.9%), potentially reflecting behavioral differences.

**Table 8.** Participating according to relationship between gender and department.

| Department and Gender Cross-tabulation |            |        |       |      |       |       |
|--|------------|--------|-------|------|-------|-------|
|  |            | Gender |       |      | Total |       |
|  |            | boy    | Girl  |      |       |       |
| Department                             | Gastro     | Count  | 476   | 376  | 852   |       |
|  |            | Total  | 33.0  | 26.1 | 59.0  |       |
|  | Hematology | Count  | 4     | 2    | 6     |       |
|  |            | Total  | 0.3   | 0.1  | 0.4   |       |
|  | ICU        | Count  | 21    | 23   | 44    |       |
|  |            | Total  | 1.5   | 1.6  | 3.0   |       |
|  | MU         | Count  | 47    | 43   | 90    |       |
|  |            | Total  | 3.3   | 3.0  | 6.2   |       |
|  | Nephron    | Count  | 7     | 9    | 16    |       |
|  |            | Total  | 0.5   | 0.6  | 1.1   |       |
|  | OPD        | Count  | 249   | 186  | 435   |       |
|  |            | Total  | 17.3  | 12.9 | 30.1  |       |
|  | Total      |        | Count | 804  | 639   | 1443  |
|  |            |        | Total | 55.7 | 44.3  | 100.0 |

No significant difference was identified between both groups.  $P=.666$  ( $p > 0.05$ )

Table 9 represent the relationship between age groups and department. Children aged (4-6) years recorded the highest percentage of admission to the gastrointestinal ward with a percentage (24.5%). While the percentage was close in the same ward in the age groups (7-9, 1-3) the percentage was

(17.7%, 16.2. respectively). As for the OPD, the age group (4-6) had the highest percentage was (12.0%). While the nephron department has the lowest admission rate among the age groups (1.1%). There is statistically significant difference was identified between groups ( $P \leq 0.05$ ).

**Table (9).** Distribution of participating according to relationship between age group and department.

| Department<br>1-3 |       | Age group |      |       |      | Total |
|-------------------|-------|-----------|------|-------|------|-------|
|                   |       | 4-6       | 7-9  | 10-14 |      |       |
| Gastro            | Count | 234       | 353  | 255   | 10   | 852   |
|                   | Total | 16.2      | 24.5 | 17.7  | 0.7  | 59    |
| Hematology        | Count | 0         | 2    | 3     | 1    | 6     |
|                   | Total | 0.0       | 0.1  | 0.2   | 0.1% | 0.4   |
| ICU               | Count | 23        | 11   | 8     | 2    | 44    |
|                   | Total | 1.6       | 0.8  | 0.6   | 0.1  | 3.0   |
| MU                | Count | 20        | 47   | 23    | 0    | 90    |
|                   | Total | 1.4       | 3.3  | 1.6   | 0.0  | 6.2   |
| Nephron           | Count | 4         | 3    | 9     | 0    | 16    |
|                   | Total | 0.3       | 0.2  | 0.6   | 0.0  | 1.1   |
| OPD               | Count | 114       | 173  | 143   | 5    | 435   |
|                   | Total | 7.9       | 12.0 | 9.9   | 0.3  | 30.1  |
| Total             | Count | 395       | 589  | 441   | 18   | 1443  |
|                   | Total | 27.4      | 40.8 | 30.6  | 1.2  | 100   |

Finally, Table10 demonstrate the seasonality of E. histolytica/dispar infections. The peak infection rate occurred in August (5.5%), followed by September

(4.2%), with the lowest rate in April (1.3%). The cumulative prevalence of E. histolytica/dispar infection over the study period was 35.3%.



**Table (10).** Distribution of participating according to relationship between months and *E. histolytica/dispar*.

| Months    | <i>E. histolytica/dispar</i> Frequency (%) |
|-----------|--|
| January   | 35 (2.4)                                   |
| February  | 30 (2.1)                                   |
| March     | 29 (2.0)                                   |
| April     | 19 (1.3)                                   |
| May       | 45 (3.1)                                   |
| June      | 31 (2.1)                                   |
| July      | 44 (3.0)                                   |
| August    | 79 (5.5)                                   |
| September | 60 (4.2)                                   |
| October   | 54 (3.7)                                   |
| November  | 45 (3.1)                                   |
| December  | 39 (2.7)                                   |
| Total     | 510 (35.3)                                 |

There is statistically significant difference was identified between months ( $P \leq 0.05$ ).

describe the association between gender and department. Males had higher admission rates to the gastroenteritis department (33.0% vs. 26.1% for females). Similarly, OPD presentation was higher in males (17.3%) compared to females (12.9%), potentially reflecting behavioral differences.

## DISCUSSION

The findings of this study provide critical insights into the demographic, seasonal, and clinical patterns of parasitic infections, particularly *E. histolytica/dispar* and *Giardia lamblia*, among children admitted to Benghazi Children's Hospital. The results underscore significant associations between age, gender, seasonal factors, and healthcare utilization, which align with broader epidemiological trends while highlighting region-specific risk factors.

Compared to recent international studies, the prevalence of *Entamoeba histolytica/dispar* in our cohort of children at Benghazi Children's Hospital (35.3%) is substantially greater than the 13.0% infection rate documented by Uchejeso et al in Nigeria, where differences are attributed to sanitation standards and sample characteristics [11]. In Kabul, Afghanistan, Mamozai et al described a lower infection preva-

lence in young children, emphasizing disparities linked to urban health resources and public health infrastructure [12]. Methodologically, our work utilized retrospective microscopy of stool samples throughout one year, whereas other studies applied more advanced molecular diagnostics, such as PCR and ELISA, offering greater sensitivity and species differentiation [13]. Seasonal variation found in our dataset aligns with Ethiopian findings, where peaks in amoebiasis prevalence have been connected to climate influences on transmission [14]. Overall, these international comparisons reinforce the significance of local sanitation conditions, diagnostic approaches, and healthcare systems in shaping regional prevalence rates and highlight the need for targeted public health interventions.

## Demographic and Gender Disparities

The age distribution of cases revealed a pronounced vulnerability among children aged 4–6 years, who constituted the largest proportion of infections (40.8%) and exhibited the highest prevalence of *E. histolytica/dispar* (15.0%). This aligns with global evidence indicating heightened exposure to fecal-oral pathogens in early childhood due to exploratory behaviors, inadequate hygiene practices, and increased environmental interaction. Notably, the sharp decline in cases among older children (10–14 years: 1.2%) may reflect improved immunity or reduced exposure as children age. Gender disparities were evident, with boys (55.7%) disproportionately affected, particularly in high-risk departments like gastroenterology (33.0% boys vs. 26.1% girls). This aligns with the hypothesis that boys' outdoor activities in unsanitary environments elevate their exposure to contaminated water or soil, a phenomenon documented in low-resource settings with limited public health infrastructure.

## Infection Patterns and Seasonal Trends

The dominance of *E. histolytica/dispar* (35.3%) over *Giardia lamblia* (2.8%) underscores the endemicity of amoebiasis in the region, likely exacerbated by socioeconomic factors such as contaminated water sources, overcrowded housing, and poor hygiene practices. The high proportion of negative

results (60.7%) suggests potential underdiagnosis, non-parasitic etiologies, or the influence of unmeasured variables like viral or bacterial pathogens. Seasonal variation in infections, peaking in August (14.3%) and October (10.9%), correlates with warmer temperatures and potential fluctuations in water quality or increased outdoor activity during summer months. The low April prevalence (1.3%) may reflect cooler weather reducing pathogen survival or seasonal hygiene campaigns, though further investigation is warranted.

### Clinical and Public Health Implications

The predominance of gastroenteritis admissions (59.0%) highlights the burden of diarrheal diseases in this population, consistent with global data linking poverty and inadequate sanitation to gastrointestinal infections. The statistically significant age-department association ( $p \leq 0.05$ ), particularly the high gastroenterology admissions among 4–6-year-olds (24.5%), reinforces the need for targeted interventions in this age group. Conversely, the minimal hematology involvement (0.4%) suggests parasitic infections in this cohort primarily manifest as acute gastrointestinal illness rather than systemic complications.

### Limitations and Future Directions

While this study offers valuable insights, its hospital-based design limits generalizability to community settings, where asymptomatic or mild cases may go undetected. The reliance on hospital records may introduce selection bias, and the lack of granular socioeconomic data (e.g., household income, water source details) restricts the ability to fully elucidate risk factors. Future research should incorporate community-based longitudinal studies to capture broader epidemiological trends and evaluate interventions such as water purification programs, hygiene education, and routine deworming. Additionally, molecular diagnostics could clarify the prevalence of *E. histolytica* versus non-pathogenic *Entamoeba* dispar and *Giardia lamblia*, refining clinical management. Potential contributing factors to the high prevalence (e.g., socioeconomic conditions, water source quality, hygiene practices) were noted.

### CONCLUSIONS

This study underscores the interplay of demographic, environmental, and seasonal factors in shaping the burden of parasitic infections among children in Benghazi. Addressing these challenges requires multisectoral efforts to improve sanitation infrastructure, promote hygiene education, and strengthen healthcare capacity for early diagnosis and treatment. Prioritizing high-risk groups—particularly young children and boys—could mitigate morbidity and reduce the strain on pediatric healthcare services.

From the present study, it could be concluded that amoebiasis remains one of the most significant enteropathogenesis worldwide. Most of the cases that were admitted to the gastroenteritis department, at the Benghazi Children's Hospital accounted for (35.3%) of the disease rate in this department.

### RECOMMENDATIONS

The relatively uncomplicated lifecycle of *Entamoeba* species facilitates efficient transmission between human hosts, thereby ensuring their continued persistence as commensal-like organisms. Despite ongoing research, no effective vaccine is currently available, and treatment options remain limited to a single major class of drugs. These constraints make prevention particularly difficult and emphasize the urgent need for greater public health awareness, as well as the development of innovative therapeutic and preventive measures to control amoebic infections. Amoebiasis constitutes a health problem among children in Benghazi city. Therefore, the study recommended the following:

It has become clear to us from the current study and previous studies in Libya that the *Entamoeba* parasite is widespread, so we recommend combating the parasite in cooperation with the Ministry of Health. Efforts should be made to raise clinicians' awareness of this parasitic diseases.

Technicians must be trained on how to detect parasites in multiple ways and not limited to the routine method.

Personal hygiene should be promoted in the region through campaigns by the government.



There is a need for continuous stool examination of children suffering from diarrhea in hospital and treatment given as infection rate was high to control the disease.

Illegal immigrants and expatriate workers may be one of the reasons for the spread of the disease, and we recommend conducting routine examinations to avoid the transmission of any diseases.

Avoid eating street foods especially in public places. Parasitology is neglected in many laboratories, so we recommend that it be in the first ranks and that cooperation with the Ministry of Health be done in this so that parasitic diseases do not spread.

#### REFERENCES

- Ngobeni R, Abhyankar MM, Jiang NM, et al. Entamoeba histolytica-encoded homolog of macrophage migration inhibitory factor contributes to mucosal inflammation during amebic colitis. *J Infect Dis.* 2017;215(8):1294–1302. doi:10.1093/infdis/jix083.
- Carrero JC, Reyes-Lopez M, Serrano-Luna J, Shibayama M, Unzueta J, Leon-Sicairo N, et al. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. *Int J Med Microbiol.* 2020;310(1):151358. doi: 10.1016/j.ijmm.2019.151358.
- National Centre for Disease Control for Libya. 2015. Available from: <https://ncdc.org.ly>.
- Schaap P, Schilde C. Encystation: The most prevalent and under investigated differentiation pathway of eukaryotes. *J Microbiol.* 2018;164(5):727–739. doi:10.1099/mic.0.000631.
- Shirley DA, Moonah S. Fulminant amebic colitis after corticosteroid therapy: a systematic review. *PLoS Negl Trop Dis.* 2016;10(7): e0004879. doi: 10.1371/journal.pntd.0004879.
- Nasrallah J, Akhouni M, Haouchine M, et al. Updates on the worldwide burden of amoebiasis: A case series and literature review. *J Infect Public Health.* 2022; 15:1134–1141. doi: 10.1016/j.jiph.2022.09.010.
- Huang J, Chen Y, Sun J, et al. Amoebic dysentery — China, 2005–2019. *China CDC Weekly.* 2019;2(42):803–doi:10.46234/ccdcw2020.092.
- Jaran AS. Prevalence and seasonal variation of human intestinal parasites in patients attending hospital with abdominal symptoms in northern Jordan. *East Mediterr Health J.* 2017;22(10):756–760. doi:10.26719/2016.22.10.756.
- Hasan MS, Ibrahim AH, et al. Prevalence of Entamoeba histolytica/Entamoeba dispar and Giardia lamblia infections among children in Sebha and Mourzak cities, Libya. *J Pure Appl Sci.* 2018;17(1). Mohamed KS. Prevalence of intestinal parasites among patients attending Zella Central Laboratory, Zella City, Libya. *J Pure Appl Sci.* 2021;20(2).
- Uchejeso O, et al. Prevalence of Amoebiasis and Other Intestinal Parasites among Children Attending Plateau State Specialist Hospital Jos, Nigeria. *EC Gastroenterology and Digestive System.* 2022;9(3):01-07. doi:10.31080/ecgds.2022.09.00331.
- Mamozai K, et al. Prevalence of Amoebiasis in Children Aged 1-5 Years at Bayazid Rokhan Teaching Hospital, Kabul, Afghanistan. *FMHR Journal.* 2025;3(3). Halila, S. A. (2023). Study of the prevalence of the parasite Entamoeba histolytica in Zawia – Libya. *Libyan Journal of Medical Research,* 17(1), 156–170.
- Nath J, et al. PCR-based detection of Entamoeba histolytica in stool samples from a North East Indian population. *PLoS One.* 2015;10(12):e0143493. doi: 10.1371/journal.pone.0143493.
- Roro GB, et al. Prevalence and associated risk factors of Entamoeba histolytica infection in school children in Ethiopia. *Parasite Epidemiol Control.* 2022;18: e00223.

## The Role of Multi Detector Computerized Tomography in Evaluation of Maxillofacial Fractures.

Kamla M. Muftah<sup>1\*</sup>, Ali A. Beheh<sup>1</sup>, Gebril Hewadi<sup>1</sup>, Arwi B. Elfseie<sup>1</sup>.

### Original Research Article

#### Abstract

**Objective:** The current study's goals are to assess the effectiveness of Multi Detector Computerized Tomography (MDCT) in treating patients who have experienced maxillofacial trauma, describe demographic variations, describe the frequency and types of fractures that were subjected to CT scans in the Benghazi region of Libya, and compare the results with those of comparable studies carried out elsewhere in the world.

**Materials and Methods:** We collected information from the radiology department of the al-Jala teaching hospital in Benghazi to conduct a descriptive, cross-sectional hospital-based study Between 2010 and 2013, 417 patients' medical records who underwent head and face CT scans after suffering maxillofacial trauma were examined for the study (4 years).

**Results:** The peak frequency, which occurred in the age group of 21 to 30, covered a range of ages from 2 to 85 years. The median age, measured by mean and standard deviation, was 29.9 +/- 12.2 years. There were six men for every woman. Road traffic accidents (RTAs) were the leading cause of fractures (75%), followed by assault (7.67%), and we found no association between gender and the cause of fracture ( $p = 0.537$ ). While the orbital walls (61%) were the most frequently broken bone in simple maxillofacial fractures, the zygomaticomaxillary complex (ZMC), which makes up 22.2% of the midface, was the most vulnerable area in complex facial fractures. There was no connection between gender and the location of the fracture.

**Conclusion:** Maxillofacial trauma can occasionally occur with serious cosmetic and functional repercussions. MDCT is required for the identification and classification of maxillofacial fractures and provides an accurate diagnosis for the design of treatment plans. Early surgical intervention is crucial for the successful management of these fractures.

**Keywords:** Fracture, Midface, Benghazi, Image.

<sup>1</sup>.Department of radiology, Faculty of Medicine, University of Benghazi.

\*Corresponding author: Kamla M. Muftah, Email: [syalo.osen@yahoo.com](mailto:syalo.osen@yahoo.com).



## INTRODUCTION

Facial fractures can be detected using The Multi-Detector Computerized Tomography (MDCT) as it's considered to be the golden standard method due to its non-invasive technique, accessibility, speed of acquisition, and exceptional accuracy in detecting even minute fractures. Additionally, acute intracranial pathology, which might be more urgent, is assessed concurrently. [1,2] Blunt or penetrating trauma that uses moderate-to-strong force is the most common cause of facial fractures. These fractures may result from a gunshot wound, a fall, a physical assault, or a motorcycle accident. The MDCT can promptly spot any related facial buttresses and soft tissue injuries that might require surgery. When a complicated fracture develops, many issues could arise, such as lefort fractures, are kind of midfacial fractures which damage the pterygoid plates in their entirety and can separate the maxilla from the skull in whole or in part like in Lefort III type, increasing the risk of intracranial infections, or like type II involving the medial part of midface, and Lefort I in which the palate is separated from the dentition Hemorrhage and cerebrospinal fluid leakage rise when a frontal sinus fracture extends through the posterior sinus wall. Other types of complex fractures include the zygomaticomaxillary complex, which disrupts all four zygomatic sutures and may result in enophthalmos due to increased orbital volume because of the angulation of the lateral orbital wall, and the naso-orbito-ethmoid complex fractures, which frequently involve the medial orbital wall, the nasal bone, the ethmoid sinuses, and the location where the medial canthal tendon attaches. [1,3] While it is the radiologist's obligation to recognize and accurately diagnose facial fractures on imaging, it is equally important to simply and clearly state the findings in the radiology report. An excellent report should show understanding of the clinically significant factors that might influence management. The craniofacial anatomy includes a complex section known as the midface. It consists of numerous distinct bone components that interact with one another, communication. The mid-

face merits special consideration when it comes to evaluation and management because, in addition to its structural characteristics, it serves functional purposes related to breathing, speech, swallowing, mastication, olfaction, and vision.

Therefore, any injury or deformity in this area can have a significant impact on a person's quality of life. Due to the complexity of the midface anatomy, specialized imaging techniques like CT scans are often required to accurately diagnose. The posterior boundary is made up of the frontal bone superiorly and the sphenoid inferiorly, while the lateral boundary is the temporal bone. Midface structure has thin bone parts supported by a hard frame of buttresses. structural pillars of the mid-face are canines, zygomatic, and pterygoid buttresses [4]

The midface is made up of several bony structures including two maxillae, zygomatic bones, zygomatic processes of temporal bones, lacrimal, palatine, and nasal bones, the vomer bone, the ethmoid, with the connected conchae, two inferior conchae, and the pterygoid plates of the sphenoid bone [5].

## MATERIAL AND METHOD

Data were collected from the Radiology Department at Al-Jala Teaching Hospital in Benghazi to conduct a descriptive, cross-sectional, hospital-based study. Between 2010 and 2013, the medical records of 417 patients who underwent head and facial CT scans following maxillofacial trauma were reviewed. The study utilized a General Electric (GE) 128-slice helical CT scanner. CT scans of the face were performed with the patient in a supine position, and axial slices were acquired at 0.625 mm collimation, with a field of view extending from the top of the frontal sinuses to the chin. Supine axial imaging was selected to ensure rapid acquisition and patient comfort, with a total exposure time of approximately 16 seconds. Coronal and sagittal reconstructions were generated, and 3D volume-rendered images were also obtained.

### Imaging modality:

Computed tomography (CT) scans, which offered fine-grained visualisation of fracture patterns, were used to evaluate all fractures. Two primary catego-

ries were used to classify fractures: Simple fractures: affecting the mandible, orbital walls, nasal bone, isolated zygomatic arch, frontal sinus, and maxillary sinus. Complex fractures include naso-orbito-ethmoidal (NOE) fractures, LeFort I, II, and III fractures, and zygomaticomaxillary complex (ZMC) fractures. Descriptive statistics were used to summarise clinical and demographic features in the statistical analysis, which was carried out using SPSS version 23 for Windows. Associations between variables were examined using chi-square tests or other suitable statistical techniques; a p-value of less than 0.05 was deemed statistically significant.

The study received approval from the Head of the Radiology Department as well as ethical approval from the hospital's Research and Ethics Committee.

**RESULTS**


**Age and gender distribution:**

The age of the patients was ranged from 2 to 85 years at the time of the injury, with a mean age (SD) of 29.9 years. The age group from 21 to 30 years had ranked the highest incidence of maxillofacial trauma (n = 180; 43.2%). Up until the third decade, the age-specific distribution of patients showed an upward trend, after which the incidence fell with each succeeding decade. Injuries happened 21 times (5%) in the first decade, 51 times (12.2%) in the second, 180 times (43.2%) in the third, 104 times (24.9%) in the fourth, 35 times (8.4%) in the fifth, 18 times (4.3%) in the sixth, 05 times (1.2%) in the seventh, and three times (0.7%) in the eighth. Pediatric (less than 18 years of age) fracture accounted for 12.7% (n = 53) of patients, and 2.87% (n=12) was more than 60 years of age table 1. Men were mostly affected than women in all age groups table 1.

**Table 1:** Distribution of the Study Sample by their age group and sex.

| Age group | Male | Female | Total | Percent% | Mean ± SD | P value |
|-----------|------|--------|-------|----------|-----------|---------|
| (1-10)    | 17   | 4      | 21    | 5%       | 29 ± 12.2 | P=0.008 |
| (11-20)   | 40   | 11     | 51    | 12.2%    |           |         |
| (21-30)   | 165  | 15     | 180   | 43.2%    |           |         |
| (31-40)   | 91   | 13     | 104   | 24.9%    |           |         |
| (41-50)   | 27   | 8      | 35    | 8.4%     |           |         |
| (51-60)   | 12   | 6      | 18    | 4.3%     |           |         |
| (61-70)   | 4    | 1      | 5     | 1.2%     |           |         |
| >70       | 3    | 0      | 3     | 0.7%     |           |         |
| Total     | 359  | 58     | 417   | 100      |           |         |

The male to female ratio was 6:1. Figure 1 shows the distribution of the patients according to their sex.



**Figure 1:** Distribution of the patients according to their sex.


**ETIOLOGY**

The most common reason for maxillofacial trauma were maxillofacial trauma (n = 314; 75.29%), followed by physical assault (n = 32; 7.67%), gunshot wound (n = 29; 6.95%), and unintentional falls (n = 29; 6.95%). Sports-related injuries occurred in 13 cases (3.1%) of the remaining

fractures, which were caused by a variety of factors. Injury etiologies are displayed in Table 2 and Figure 2. Regarding the etiologies of trauma, our findings showed a statistically significant difference between genders (p = 0.032).

**Table 2:** Distribution of the patients by their gender and cause of maxillofacial trauma

| Etiology of Trauma | Road Traffic Accident | Fall from Height | Physical Assault | Sport Injuries | Bump Explosive | Gun Shot   | Total     | P value |
|--------------------|-----------------------|------------------|------------------|----------------|----------------|------------|-----------|---------|
| Male               | 261 (62.5%)           | 25 (5.9%)        | 32 (7.67%)       | 2 (0.47)       | 11 (2.63%)     | 28 (6.71%) | 359 (86%) | 0.032   |
| Female             | 53 (12.7%)            | 4 (0.95%)        | 0 (0)            | 0 (0)          | 0 (0)          | 0 (0.23%)  | 58 (14%)  |         |
| Total              | 314 (75.29%)          | 29 (6.95%)       | 32 (7.67%)       | 2 (0.47%)      | 11 (2.63%)     | 29 (6.95%) | 417 (100) |         |



**Figure 2:** Etiologies of Maxillofacial Trauma.

#### Fracture site:


Among the simple maxillofacial fractures, the orbital walls were the bone that fractured most frequently. There were 254 cases overall (or 60.9%) where the orbital wall fracture was present. The second most affected area of maxillofacial trauma was the

maxillary sinus wall (n = 216; 51.8%), followed by the nasal bone (n = 180; 43.2%), the isolated zygomatic arch (n = 132; 32%), the mandible fracture (n = 105; 25.2%), and the frontal sinus fracture (n = 80; 19.2%), Table 3 and figure 3.



**Table3:** Distribution of patients by their gender and the site of the simple Maxillofacial Fracture.

| Computed Tomography Finding (CT) | Male | Female | Number (no) | Percent% |
|----------------------------------|------|--------|-------------|----------|
| Orbital Wall Fracture            | 229  | 25     | 254         | 61.0%    |
| Maxillary Sinus Fracture         | 195  | 21     | 216         | 52.0%    |
| Nasal Bone Fracture              | 152  | 28     | 180         | 43.2%    |
| Isolated Zygomatic Arch Fracture | 117  | 15     | 132         | 32.0%    |
| Mandible Fracture                | 90   | 15     | 105         | 25.2%    |
| Frontal Sinus Fracture           | 72   | 8      | 80          | 19.2%    |




**Figure 3:** Distribution of the patients by the site of Simple Maxillofacial Fractures According to the MDCT Findings.

The most common complex maxillofacial fractures overall (n= 94; 22.5%) were zygomatic maxillary complex fractures, followed by naso-orbito-ethmoid complex fractures (n=31; 7.4%), maxillary

fracture le fort III with total number of 26 and percentage 6.2% and le fort II (n=23; 5.5%), and le fort I (n=9; 2.2%), table 4 and figure 4.

**Table 4.** Distribution of patients by their gender and the site of the complex Maxillofacial Fracture.

| Computed Tomography Finding (CT)       | Male | Female | Number (n) | Precent % |
|--|------|--------|------------|-----------|
| Zygomatic-Maxillary Complex Fracture   | 48   | 46     | 94         | 22.5%     |
| Naso-Orbital-Ethmoidal Complex Fractur | 28   | 3      | 31         | 7.4%      |
| Le Fort Type III Fracture              | 23   | 3      | 26         | 6.5%      |
| Le Fort type II Fracture               | 21   | 2      | 23         | 5.5%      |
| Le Fort type I Fracture                | 8    | 1      | 9          | 2.2%      |



**Figure 5:** Distribution of patients according to the site of the complex Maxillofacial Fracture.

Regarding the distribution of fractures by age group, ZMC, lefort I, and II fractures were observed in all age groups with the exception of children aged 0 to 10 years. Patients between the ages of 21 and 30 made up the majority of mid facial fracture cases (43.2%), with orbital wall fractures making up the most common simple fracture pattern in this group and Zygomaticomaxillary complex the most common complex fracture pattern. It is also noteworthy that isolated orbital fractures were most common in the youngest age group (0 to 10), and maxillary si-

nus wall fractures were most prevalent in the oldest group (60+), table 5.



**Table 5.** Distribution of the patients according to the site of the fractures and age Group Category.

| Age Group | Orbital Wall Fracture | Maxillary sinus wall Fracture | Nasal Bone Fracture | Isolated zygomatic arch fracture | Mandible fracture | Frontal sinus | ZMC | NOE | Le Fort I | Le Fort II | Le Fort III |
|-----------|-----------------------|-------------------------------|---------------------|----------------------------------|-------------------|---------------|-----|-----|-----------|------------|-------------|
| (1-10)    | 14                    | 3                             | 3                   | 2                                | 5                 | 3             | 0   | 2   | 0         | 0          | 2           |
| (11-20)   | 28                    | 21                            | 25                  | 16                               | 8                 | 10            | 12  | 4   | 1         | 1          | 3           |
| (21-30)   | 111                   | 87                            | 80                  | 55                               | 45                | 38            | 42  | 13  | 3         | 9          | 8           |
| (31-40)   | 61                    | 68                            | 51                  | 34                               | 34                | 22            | 23  | 8   | 1         | 7          | 9           |
| (41-50)   | 22                    | 18                            | 12                  | 11                               | 6                 | 6             | 8   | 2   | 2         | 1          | 2           |
| (51-60)   | 13                    | 12                            | 4                   | 11                               | 6                 | 1             | 8   | 0   | 1         | 3          | 2           |
| (61-70)   | 3                     | 4                             | 3                   | 2                                | 0                 | 0             | 0   | 0   | 1         | 1          | 0           |
| >70       | 2                     | 3                             | 2                   | 1                                | 1                 | 0             | 1   | 2   | 0         | 1          | 0           |
| Total     | 254                   | 216                           | 180                 | 213                              | 105               | 80            | 94  | 31  | 9         | 23         | 26          |

The ZMC fracture was the most prevalent complex bone fracture in both sexes; however, in men, the most common fracture pattern was an isolated orbital wall fracture. A solitary fracture of the nasal bone was the most frequent simple bone fracture in females, Fisher's exact test was utilized to investigate the relationship between gender and fracture site, Fisher's exact test ( $p = 0.812$ ) found no association between gender and fracture site.

### DISCUSSION

The most frequent cause of maxillofacial fractures, according to this study, was traffic accidents, the occurrence of maxillofacial trauma in developing nations is influenced by a lack of traffic laws, along with inadequate road infrastructure, older cars lacking safety standards, and cell phone use while driving [6]

Previous research has revealed that in affluent countries, violence is more common than traffic accidents as a reason for maxillofacial fractures [7]

In this study, the ratio of male to female patients in maxillofacial fractures was 6:1.

An additional study also came to a similar conclusion which done by [8,9] Men typically became the family's breadwinner and tend to spend more time outside, which increases their risk of trauma, whereas women are more frequently at home and have fewer trauma risk factors.

a MDCT scanner and a modern workstation are now essential diagnostic tools for any emergency room,

to provide the best acute therapy of the midfacial trauma, the surgeon must fully understand the morphology and severity of the fractures [10].

there are considerable geographical disparities in the frequency of midfacial fractures, the majority of research reported in the literature indicates that mandibular fractures occur more frequently than mid-facial fractures [11,12, 13].

In this study, 61% of all facial bone fractures involved the orbital bone coinciding with other studies [14,15,16] the second most typical type of fractured bone was the maxillary sinus wall, which made up 52% of all fractured bones; the third most often fractured isolated bone was the nasal bone, with an average incidence of 43.2%. Separate fractures of the zygomatic arch made up about 32% of the fractures, mandibular fractures made up 25.2%, and frontal sinus fractures made up 19.2%.

Zygomatoco-maxillary complex fractures are the most prevalent type of complicated facial fractures, accounting for 22.5% of occurrences, similar to sizable studies [17,18,19]. followed by the naso-orbital-ethmoidal complex fracture at 7.4%. Le Forte III contributed 6.5%, Le Forte II 5.5%, and Le Forte I 2.2% to the total.

We proved that the CT scan is an effective diagnostic tool for assessing face fractures. Because it makes 3-D investigation and high-resolution multi-planar reconstructions possible.

## CONCLUSION

In Benghazi, one of the major health problems is maxillofacial trauma. Maxillofacial fractures can become an aesthetic and functional issue if they are not promptly and effectively treated. Trauma affects a person's psychological well-being and has a detrimental socioeconomic effect on society, in people between the ages of 21 and 30 have the highest maxillofacial fractures (43.2%), according to our study. In the current study, 75% of the causes were related to road accidents. The zygomaticomaxillary complex (22.5%) was the most broken area of the midface, according to our study, which also found that ocular wall fractures predominated among people with simple maxillofacial trauma (61%). The findings of our investigation showed that car accidents were the main cause of maxillofacial injuries in Benghazi.

## RECOMMENDATION

Public awareness campaigns are needed to educate the population—particularly drivers—about the importance of adhering to driving regulations and using safety equipment. These findings also highlight the need for authorities to strictly enforce existing traffic laws to reduce reckless, high-speed driving on highways.

## REFERENCES

1. Bither S, Mahindra U, Halli R, Kini Y, Kharkar V, Rudagi BM. Incidence and pattern of mandibular fractures in rural population: a review of 324 patients at a tertiary hospital in Loni, Maharashtra, India. *Dent Traumatol*. 2008 Oct;24(5):468-70.
2. Olusanya AA, Adeleye AO, Aladelusi TO. Updates on the epidemiology and pattern of traumatic maxillofacial injuries in a Nigerian University Teaching Hospital: A 12-month prospective cohort in-hospital outcome study. *Craniofacial Trauma Reconstr*. 2015 Mar;8(1):50-8.
3. Tugaineyo E, Odhiambo WA, Akama MK, Macigo FG, Chindia ML. Aetiology, pattern and management of oral and maxillofacial injuries at Mulago national referral hospital. *East Afr Med J*. 2012 Oct;89(10):351-8.
4. Adi M, Ogden GR, Chisholm DM. An analysis of mandibular fractures in Dundee, Scotland (1977 to 1985). *Br J Oral Maxillofac Surg*. 1990 Jun;28(3):194-9.
5. Thapliyal G, Rajan H. Management of midfacial fractures: An overview. *J Postgrad Med Educ*. 2014;48(2):68-74.
6. Salzman JA. Fractures of the middle third of the facial skeleton. *Am J Orthod*. 1978 Oct;74(4):469.
- Subhashraj K, Nandakumar N, Ravindran C. Review of maxillofacial injuries in Chennai, India: a study of 2748 cases. *Br J Oral Maxillofac Surg*. 2007 Dec;45(8):637-9.
7. Bataineh AB. Etiology and incidence of maxillofacial fractures in the north of Jordan. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1998 Jul;86(1):31-5.
8. Al Ahmed HE, Jaber MA, Abu Fanas SH, Karas M. The pattern of maxillofacial fractures in Sharjah, United Arab Emirates: a review of 230 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2004 Aug;98(2):166-70.
9. Iida S, Kogo M, Sugiura T, Mima T, Matsuya T. Retrospective analysis of 1502 patients with facial fractures. *Int J Oral Maxillofac Surg*. 2001 Aug;30(4):286-90.
10. Liu FC, Le TT, Oleck NC, Halsey JN, Hoppe IC, Lee ES, et al. Pediatric Pedestrian Facial Fracture Patterns and Management Following Motor Vehicle Collisions. *J Craniofac Surg*. 2020 Jan-Feb;31(1):265-8.
11. Le TT, Oleck NC, Liu FC, Halsey JN, Hoppe IC, Lee ES, et al. Motor Vehicle Collision Injuries: An Analysis of Facial Fractures in the Urban Pediatric Population. *J Craniofac Surg*. 2020 Oct;31(7):1910-3.
12. Deepak Y, Amit J, Sadhan M, Shashank T, Ravish M. Role of Computed Tomography in The Evaluation of Patients with Maxillofacial Trauma. *Mod App Dent Oral Health*. 2019;4(1):1-5.
13. Hogg NJ, Stewart TC, Armstrong JE, Girotti MJ. Epidemiology of maxillofacial injuries at trauma hospitals in Ontario, Canada, between 1992 and 1997. *J Trauma*. 2000 Sep;49(3):425-32.



14. Bataineh AB. Etiology and incidence of maxillofacial fractures in the north of Jordan. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1998 Jul;86(1):31-5.
15. Schuknecht B, Graetz K. Radiologic assessment of maxillofacial, mandibular, and skull base trauma. *Eur Radiol.* 2005 Mar;15(3):560-8.
16. dos Santos DT, Costa e Silva AP, Vannier MW, Cavalcanti MG. Validity of multislice computerized tomography for diagnosis of maxillofacial fractures using an independent workstation. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2004 Dec;98(6):715-20.
17. Boffano P, Roccia F, Zattero E, Dediol E, Uglešić V, Kovačić Ž, et al. European Maxillofacial Trauma (EURMAT) project: A multicentre and prospective study. *J Craniomaxillofac Surg.* 2015 Jan;43(1):62-70
18. Zaleckas, L., Pečiuliene, V., Gendviliene, I., Puriene, A. & Rimkuviene, J. 2015. Prevalence and etiology of midfacial fractures: A study of 799 cases. *Medicina (Lithuania).* 51(4):222–227. DOI: 10.1016/j.medic.2015.06.005.



## Thyroid disorders in patients with polycystic ovarian syndrome in Benghazi.

Omar Alfalah <sup>1\*</sup>, Fathia Ehmouda <sup>2</sup>.

### Original Research Article

#### Abstract

**Background:** Recent studies have highlighted a higher occurrence of thyroid abnormalities in women diagnosed with polycystic ovary syndrome (PCOS), although the underlying mechanisms linking the two conditions remain uncertain.

**Aim and Objectives:** To determine the prevalence of thyroid dysfunction among patients with PCOS.

**Methods:** A retrospective review of medical records was conducted for 116 patients attending the endocrine clinic in Benghazi medical center during the period from the first of September to the end of October 2020.

**Results:** The mean age was (35.5±9.8 years), the mean body mass index for the study group was 31.8±6.5kg/m<sup>2</sup>. Among studied group; 81% of participants had oligomenorrhea, 97.4% had hirsutism, and 84% had ultrasound features of polycystic ovaries; Overall, the prevalence of thyroid disorders among patients with PCOS was 31%, the main thyroid disorder was autoimmune thyroiditis which represented 13.8% followed by subclinical hypothyroidism which found in 9.5% of all participants.

**Conclusion:** More than one third of the studied group had thyroid disorders. Autoimmune thyroiditis represented the main disorder.

**Keywords:** PCOS, thyroid, thyroiditis, hypothyroidism, hyperthyroidism, goiter, autoimmune, subclinical.

<sup>1</sup>.Department of Internal Medicine, Faculty of Medicine, University of Benghazi and Benghazi Medical Center, Benghazi, Libya.

<sup>2</sup>. Department of Internal Medicine, Faculty of Medicine, University of Benghazi and 7th October hospital, Benghazi, Libya.

\*Corresponding author: Omar Alfalah, Email: [omar.alfallah@uob.edu.ly](mailto:omar.alfallah@uob.edu.ly).

DOI: [10.37376/benunivmedj.v2i2](https://doi.org/10.37376/benunivmedj.v2i2)



## INTRODUCTION

Polycystic ovary syndrome (PCOS) is recognized as one of the most prevalent endocrine conditions in women, typically defined by irregular ovulation, androgen excess, and the presence of polycystic ovaries. It affects 15–20% of women of reproductive age (1). Evidence suggests an association between PCOS and thyroid disorders, particularly autoimmune thyroiditis and nodular goiter (2). Rates of subclinical hypothyroidism (SCH) and autoimmune thyroiditis have been reported to be more common in women with PCOS compared to the general population (3). The Rotterdam Consensus (2003) established the diagnostic framework for PCOS, requiring the presence of at least two of the following: (1) menstrual irregularities such as amenorrhea (absence of menstruation for  $\geq 6$  months), oligomenorrhea (cycle length  $>35$  days), or prolonged cycles; clinical or biochemical signs of hyperandrogenism; and ultrasound findings of polycystic ovaries, defined as  $\geq 12$  follicles measuring 2–9 mm in diameter and/or an ovarian volume  $>10$  mL (4). Subclinical hypothyroidism affects approximately 4–8% of women of reproductive age (5). Although often asymptomatic, it may present with subtle manifestations including dyslipidemia, hyperglycemia, insulin resistance, menstrual dysfunction, obesity, and infertility—symptoms that may overlap with PCOS (2,6). In primary hypothyroidism, elevated thyroid-stimulating hormone (TSH) and prolactin levels can influence ovarian physiology. Prolactin interferes with ovulation by altering the follicle-stimulating hormone (FSH) to luteinizing hormone (LH) ratio and increasing adrenal androgen secretion. Additionally, TSH may interact with FSH receptors, while prolonged hypothyroidism can lead to collagen accumulation in the ovaries, further aggravating cystic morphology. The degree of ovarian changes often depends on both the duration and severity of the thyroid dysfunction. Recent research has highlighted elevated markers of autoimmunity in women with PCOS, reinforcing the possible link between PCOS and autoimmune thyroid disease (2). In fact, one study showed that

the prevalence of PCOS was significantly higher in adolescents (13–18 years) with hypothyroidism and positive thyroid peroxidase antibodies (anti-TPO Ab), compared with controls (46.8% vs. 4.3%) (7). The study aimed to estimate the frequency of thyroid disorders among patients with PCOS at Benghazi medical center.

## PATIENTS AND METHODS

This study was conducted at the Benghazi Medical Center at the endocrine clinic during the period from the first of September to the end of October 2020, a retrospective study of patients' files. The total number of files was 1083, among them 116 patients were diagnosed with polycystic ovarian syndrome.

The questionnaire was adapted from an article (Thyroid profile in polycystic ovarian syndrome) (8).

The questionnaire was divided into three main sections: section A involving personal data (age, marital status, body mass index), section B involving features of polycystic ovarian syndrome (amenorrhea, oligomenorrhea or prolonged cycles, evidence of hyperandrogenism, ultrasonography features of PCOS), and section C involving the type of thyroid dysfunction.

Data analyzed using SPSS version 20. Variables were summarized as frequencies, percentages, means, and standard deviations.

## RESULTS

### I. General characteristics of PCOS patients

The mean age for the study group was 35.5 years with a standard deviation of 9.8 years ( $35.5 \pm 9.8$  years), 45.7% were in the age group between 26 to 35 years and most of them were single (66.4%). The mean BMI for the study group was  $31.8 \pm 6.5$  kg/m<sup>2</sup>.

The result showed most of the patients with polycystic ovarian syndrome were classified as obese class I and overweight, with percentages (29.3%, 26.7% respectively) as shown in Table 1.

**Table 1:** Body mass index distribution.

| Classification | No. | %    |
|----------------|-----|------|
| Normal         | 17  | 14.7 |
| Over Weight    | 31  | 26.7 |
| Obesity I      | 34  | 29.3 |
| Obesity II     | 22  | 19.0 |
| Obesity III    | 12  | 10.3 |
| Total          | 116 | 100% |

## II. polycystic ovarian syndrome

### 1. Hyperandrogenism signs

The clinical signs of hyperandrogenism found in the patients who underwent the study were hirsutism, acanthosis nigricans, and acne. Hirsutism was almost found in all patients, with a percentage of 97.4%. And in some patients, there was more than one sign. While acanthosis nigricans and acne were less frequent with percentages of (18.1%, 7.8% respectively) as shown in Table 2.

**Table 2:** Hyperandrogenism signs distribution.

| Sign                 | Yes | No  | %    |
|----------------------|-----|-----|------|
| Hirsutism            | 113 | 3   | 97.4 |
| Acanthosis nigricans | 21  | 95  | 18.1 |
| Acne                 | 9   | 107 | 7.8  |

### 2. Menstrual cycle

Most patients (81%) presented with oligomenorrhea. Amenorrhea and menorrhagia represented 9.5% for each.


### 3. Pelvis ultrasound

Most patients had ovarian cysts by pelvic ultrasound, with a percentage of 84%.

## III. Thyroid disorders among the studied group

Overall, the prevalence of thyroid disease in polycystic ovarian syndrome was 31% of all participants.

The highest percentage of the studied group (69%) had normal thyroid function, while autoimmune thyroiditis and subclinical hypothyroidism represented (13.8%, 9.5% respectively) Hypothyroid patients represented 1.7% due to either post-surgical hypothyroidism or post-radioactive iodine hypothyroidism. Figure 1



**Figure 1:** Distribution according to thyroid disorders.

## DISCUSSION

The present study found that polycystic ovary syndrome (PCOS) was most frequently observed in women aged 26–35 years, while its prevalence decreased notably during puberty. It was predominantly a condition of reproductive age, with high rates among women of marriageable age in arabic muslim communities. Consequently, many women presented to outpatient clinics with infertility or menstrual abnormalities.

A significant relationship was observed between obesity and thyroid dysfunction. In the present study obesity affected more than a half which was near to that reported by Najem et al. (9) where obesity reported in 57% of their study participants. Thyroid function appeared to influence BMI like diabetes and physical activity (10). While the prevalence of overweight in adolescents with PCOS was 33.3% in Rahmanpour et al which was near to the present study (11).

Among the clinical manifestations of hyperandrogenism, hirsutism was the most common. Similar results were reported by Najem et al. (9) where hirsutism was reported in 90.8% of patients. Acanthosis nigricans and acne in Najem et al study were similar to our study, 15.8%, and 12% respectively. In contrast, Amato et al. (12) documented a lower



prevalence of hirsutism (57.7%).

Menstrual disturbances were also prevalent; oligomenorrhea was observed in 81% of patients in this study. Comparable results were reported by Najem et al. (9), who found oligomenorrhea in 85.8% of PCOS patients. Ultrasound evaluation revealed features consistent with PCOS was lower than that reported in studies using transvaginal ultrasound (96.7%), likely due to the lower sensitivity and higher operator dependency of transabdominal ultrasound (13,14). Thyroid disorders identified among third of the participants, autoimmune hypothyroidism was the most prevalent. According to prior reports, anti-thyroid antibodies and elevated TSH presented in 27% and 11% of PCOS patients, respectively (15). The prevalence of autoimmune hypothyroidism was 22.1% in Arduc et al. study (16), which was higher than our study. Sinha et al. (17) compared 80 women with PCOS to 80 controls and observed a significantly higher prevalence of goiter (27.5% vs. 7.5%) and subclinical hypothyroidism (22.5% vs. 8.75%) among the PCOS group. As compared to Lubecka et al. (18) the prevalence of subclinical hypothyroidism ranged from 11.3% to 30.3% (mean, 20.3%) among patients with PCOS. Also, in Raj et al. (19) they found that subclinical hypothyroidism more prevalent in participant with PCOS compared to participants without PCOS (43.5% vs. 20.5%).

### CONCLUSION

Overall, the prevalence of thyroid disorders among patients with PCOS was 31%; the main thyroid disorder was autoimmune thyroiditis.

### LIMITATIONS

A retrospective study from a patients' files and some data might be missing.

### RECOMMENDATION

It is recommended that all patients with PCOS undergo routine screening for thyroid function and thyroid-specific autoantibodies, even if clinical signs of thyroid disease are absent.

### REFERENCES

1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Hum Reprod.* 2010;25(2):544-551. doi:10.1093/humrep/dep399
2. Duran C, Basaran M, Kutlu O, Kucukaydin Z, Bakdik S, et al. Frequency of nodular goiter and autoimmune thyroid disease in patients with polycystic ovary syndrome. *Endocrine.* 2015;49(2):464-469. doi:10.1007/s12020-014-0504-7
3. Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact. *Trends Endocrinol Metab.* 2015;26(3):136-143. doi:10.1016/j.tem.2014.12.003
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril.* 2004;81(1):19-25.
5. Abalovich M, Mitelberg L, Allami C, Gutierrez S, Alcaraz G, et al. Subclinical hypothyroidism and thyroid autoimmunity in women with infertility. *Gynecol Endocrinol.* 2007;23(5):279-283.
6. Diaz A, Lipman Diaz EG. Hypothyroidism. *Pediatr Rev.* 2014;35(8):336-347. doi:10.1542/pir.35-8-336
7. Ganie MA, Marwaha RK, Aggarwal R, Singh S. High prevalence of polycystic ovary syndrome characteristics in girls with euthyroid chronic lymphocytic thyroiditis: a case-control study. *Eur J Endocrinol.* 2010;162(6):1117-1122.
8. Nanda SS, Dash S, Behera A, Mishra B. Thyroid profile in polycystic ovarian syndrome. *J Evol Med Dent Sci.* 2014;3(37):9594-600. doi:10.14260/jemds/2014/3242.
9. Najem FI, Elmehdawi RR, Swalem AM. Clinical and biochemical characteristics of polycystic ovary syndrome in Benghazi-Libya: a retrospective study. *Libyan J Med.* 2008;3:71-4. doi:10.3402/ljm.v3i2.4761.
10. Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, et al. Small differences in thyroid function may be important for body mass index and the



**Genetic Neuromuscular Diseases in Libya.**Heba Abdelrazik El-Zawawi<sup>1\*</sup>.**Letter to Editor***Dear Editor:*

Whereas in previous decades the landscape for certain disorders such as cancer and genetic diseases, in particular neuromuscular, was bleak, a glimmer of hope has now arisen. This glimmer is growing fast into a beam that promises to shine light over the coming decades. Genetic therapy has finally arrived.

I wish to shed light on the prospects in our location here in Libya: what has been done so far and what remains to be done. Our experience over the last 4 years will also be outlined. The reader will find that we have much to be proud of, and yet the challenges have been sometimes seemingly insurmountable.

The scientific committee for genetic neuromuscular diseases (NMDs) was instituted in Libya four years ago. (1) Members include adult and pediatric neurologists' representatives from most of the main cities of Libya as well as legal, pharmacist, and administrative members. It is part of the Libyan Program for Neuromuscular Diseases, which includes the Patient Neuromuscular Society. Thus, Libya has made considerable progress in the promotion of patient advocacy for these conditions. The neurologist members of the scientific committee are the heads of subcommittees formed in the city or city location to which they belong. Thus, a network covering all of Libya has been formed. The main concept overriding this organization is teamwork. Patients attend the subcommittee clinics to be assessed, tested genetically, counselled, treated, and followed up. Accurate statistics can be obtained regarding these diseases' incidence and prevalence in Libya. A national patient database is now the next aim.

---


1. Consultant Neurologist at Benghazi Medical Centre, Professor Medical Neurology at Benghazi University.

\*Email: [elzawawiheba@gmail.com](mailto:elzawawiheba@gmail.com)

## GENETIC TESTING

Around 1052 patients had genetic testing, and from the results we found spinal muscle atrophy (SMA),

Duchenne muscle dystrophy (DMD), and other NMDs, with limb girdle muscle dystrophy being the most prevalent (Figure 1). (1)



**Figure 1:** Genetic neuromuscular diseases in Libya 2022-2024.

## Libya's Epidemiology for Genetic Neuromuscular Diseases:

We calculated the prevalence of SMA and DMD as 3.02/100,000 population and 7.06/100,000 males, respectively. (1)

With regard to SMA in particular, this was considered to be high as compared to the rest of the world and may be the result of consanguineous marriages in our location for this autosomal recessive disorder. This highlights the importance of prenatal genetic testing, neonatal screening, and family counselling and planning, especially in families with a history of genetic diseases. It is our hope to participate in a national program and campaign for genetic diseases, which would address all these aspects of diagnosis, prevention, and treatment where possible.

## GENETIC THERAPIES:

The field of treatments for various genetic diseases is rapidly expanding; the mechanistic approaches include those for SMA. Nusinersen is an antisense oligonucleotide given intrathecally, and Risdiplam is a small DNA splicing protein that is given oral-

ly and is now freely available for SMA patients in Libya (around 150 patients). Gene therapy with Onasemnogene aberparovvec is given early to patients before age 2 years who weigh less than 21 kg and corrects the gene defect. An adenovirus vector carries a new gene into the patient's DNA to form the missing SMN protein. (2) It is a highly specialized treatment for which so far Libyan children have been sent to Egypt (18 patients) and, following that, to the United Arab Emirates (6 patients so far), where they received the therapy at specialized centers for genetic diseases. The treatment is now available to be given intrathecally for ages above 2 as well and higher weights. (3) The challenge for most health services will be meeting the cost of the expensive treatments.

Genetic therapies for Duchenne Muscle Dystrophies: include exon-skipping therapies with antisense oligonucleotides; 103 patients with appropriate gene mutations received their first doses of these intravenous therapies. (4) Ataluren was given to 40 patients with nonsense mutations but has been



stopped pending FDA decision, as in a study it was found not to be sufficiently effective. (5) Luckily, givinostat, a histone deacetylase inhibitor, which has also been used in hematological conditions, (6) will soon become available for all patients with DMD who do not receive exon-skipping medications, around 200 patients. (7) Steroids are provided to all patients.

The plan is now to make gene therapy delandistrogene moxeparvec-rokl available inside Libya for mobile patients with DMD. This therapy is with an adenovirus vector carrying a micro-dystrophin gene, which will be incorporated in the patient's DNA to form a functioning micro-dystrophin protein. It is approved for ambulatory individuals at least 4 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene. (8) The therapy will require intensive care and other specialized facilities as well as training of staff. We aim to collaborate with teams in the region who have experience in giving this therapy with success.

**Vaccinations and Vaccination Campaigns:**

The Scientific Committee provides guidelines and supervises programs that aim to cover all aspects of the genetic neuromuscular patients' daily life. Recently a national influenza vaccination program was organized.

#### **The Multidisciplinary Team Concept:**

This concept, although new in our health service, was readily adopted by the Scientific Committee, and although the challenge was and remains to provide such multiple specialty teams to all the major cities in Libya, the fact that treating physicians are now aware that patients must be approached holistically has been a great advancement in their care.

#### **Social coverage and patient advocacy:**

The plight of patients with neuromuscular disease in a developing country environment clearly reached all concerned, including the authorities and the Libyan public. A very close relationship exists between the patients, their families, and the Scientific Committee through the Libyan Neuromuscular Patient Group, which is a main stakeholder in the Libyan Program for Genetic Neuromuscular Diseases. Pa-

tients in Libya voice their concerns and state their individual as well as community requirements loudly, and they are heard. The Scientific Committee liaises with the government-funded departments concerned, including the Social Security Services, to ensure their needs are met. This is aimed at providing where needed BiPAP machines, cough assist devices, and electronic wheelchairs, as well as home adaptations and other necessities for the daily life of these patients.

#### **Physiotherapy and rehabilitation:**

The challenge was to provide specialized physiotherapy and rehabilitation services to all patients with these conditions all over Libya. Therefore, several training courses were arranged for physiotherapists locally and abroad, as well as a resident visiting specialist team from Slovakia. The visiting team provides both treatment for patients and training of local physiotherapists.

**Surgery for Scoliosis:** It is recognized that scoliosis is a debilitating complication of neuromuscular diseases, which, having been brought to the attention of our authorities, led to several visits by specialized surgical teams to perform corrective surgery in Libya and train Libyan surgeons to perform this surgery in the future. This surgery is performed under neurophysiological and radiological control, and therefore training in these specialties is also required.

**Genetic treatment in Libya: The Future:** The future aims to keep Libya in the mainstream of the rapidly advancing field of genetic discoveries, whether in testing and diagnosis or the development of effective new therapies. Adenovirus vector gene replacement is not the only mechanistic approach. CRISPR-Cas9-based therapies are also being considered and are in the pipeline. (9) We are likely to get therapies for other forms of genetic neuromuscular diseases such as limb girdle muscle dystrophies. In order to keep up, Libya must upgrade the health service, train specialists in genetics, and provide genetic laboratories and newborn screening, as well as genetic clinics where counselling can be given. We must also provide and equip multidisciplinary teams working in specialized centers and also promote and



fundresearch.

#### CONCLUSION:

Libya is now considered a model state in North Africa for addressing the needs of patients with genetic neuromuscular diseases and funding genetic therapies for its patients. We have come a long way since these diseases were considered hopeless for patients, but there is still much more to be done.

Acknowledgements:

We wish to thank the patients and their families as well as all the medical and administrative staff who are the backbone of the Scientific Committee and the Subcommittees.

#### REFERENCES:

- 1- El-Zawawi, H. A. (2025, November 10–11). Diagnosis and management of genetic neuromuscular diseases in Libya: The role of the scientific committee and our experience and future aims [Unpublished presentation]. DMD Peer-to-Peer Exchange Program, Sidra Hospital, Qatar. Available upon request from the author.
- 2-Blair HA. Onasemnogene Apeparovvec: A Review in Spinal Muscular Atrophy. *CNS Drugs*. 2022 Sep;36(9):995-1005. doi: 10.1007/s40263-022-00941-1. Epub 2022 Aug 12. PMID: 35960489.
- 3-FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy, FDA Release November 24, 2025
- 4-Takeda S, Clemens PR, Hoffiman EP. Exon-Skipping in Duchenne Muscular Dystrophy. *J Neuromuscul Dis*. 2021;8(s2):S343-S358. doi: 10.3233/JND-210682. PMID: 34180420; PMCID: PMC8673534.
- 5-PTC Therapeutics announces FDA acceptance of Translarna NDA resubmission. News release. PTC Therapeutics. October 30, 2024. Accessed November 5, 2024. <https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-fda-acceptance-translarnatm-nda>
- 6-Vannucchi AM, Guglielmelli P, Pieri L, Antonoli E, Bosi A (February 2009). "Treatment options for essential thrombocythemia and polycythemia vera". *Expert Review of Hematology*. 2 (1): 41- 55. doi:10.1586/17474086.2.1.41. PMID 21082994. S2CID 28311699. Archived from the original on 1 July 2015. Retrieved 18 September 2010.

7- "New treatment against Duchenne muscular dystrophy". European Medicines Agency (EMA). 25 April 2025. Retrieved 2 May 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

8-FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy. FDA Release, June 20, 2024

9- Happi Mbakam C, Lamothe G, Tremblay G, Tremblay JP. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy. *Neurotherapeutics*. 2022 Apr;19(3):931-941. doi: 10.1007/s13311-022-01197-9. Epub 2022 Feb 14. PMID: 35165856; PMCID: PMC9294086.